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Abstract: 
 Nucleic acid delivery to human cells holds huge potential in treating disease by directly manipulating 
gene expression via the delivery of coding nucleic acids that lead to protein production (DNA, mRNA) or 
non-coding RNAs that lead to gene downregulation (siRNA, miRNA). The structure of nucleic acids makes 
them particularly difficult to functionally deliver to the cytosol of living cells, as nucleic acids are high 
molecular weight, strongly negatively charged due to their phosphate backbone and susceptible to many 
nucleases present in the extracellular fluid that lead to enzyme mediated degradation. These challenges can be 
overcome via the use of delivery vectors that complex nucleic acids into condensed nanoparticle formulations 
that facilitate cellular uptake, endosomal escape and cytosolic release of nucleic acids to target cells. To date, 
however, chemical delivery methods for nucleic acids have suffered from low efficacy preventing clinical 
translation. This thesis sought to engineer materials to yield more effective delivery of nucleic acids to 
mammalian cells as well as design assays to better understand the barriers to effective delivery and how those 
barriers might be overcome.  
 Chapter one provides an overview of the guiding aims of the thesis and summary of academic 
contributions towards its completion. In chapter two, I first provide an overview of the state of gene delivery 
via polymeric vectors followed by a review of the state of gene delivery for therapeutic cancer applications. 
Chapter three details my efforts to engineer a more effective fluorescent ratio based sensor of pH for 
investigation of endosomal pH following nanoparticle internalization. In chapter four, I describe efforts to 
adapt hydrodynamic flow focusing to form poly(beta-amino ester) (PBAE) nanoparticles and improve 
lyophilization techniques. Chapter five details optimization of assembly parameters of PBAE nanoparticles 
including mixing ratio, assembly time and buffer system. Chapter six is an interesting study where I worked 
with Donald Zack’s lab to deliver plasmid DNA to pluripotent stem cell derived post-mitotic retinal pigment 
epithelial cells by creating a large library of PBAE structures. Chapter seven details the creation of branched 
PBAE structures and their assessment relative to their linear counterparts using a tri-acrylate molecule. 
Chapter eight details the utilization of a canonical linear, end-capped PBAE to improve cytosolic delivery of 
STING agonist cyclic dinucleotides for improved cancer therapy at low therapeutic doses. Finally, chapter 9 
provides a brief perspective on where I believe the field is headed and what are the most exciting advances I 
have seen in the past few years. 
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Chapter 1. Introduction to the Thesis 
1.1 Objectives 
 The primary objectives associated with this thesis were to advance the study of non-viral delivery 
technologies toward clinical utilization for gene therapies. The work in this thesis was accomplished broadly 
via the high level aims and sub-aims as follows: 
1. Develop polymeric materials that enable nuclear delivery of nucleic acids to mammalian cells at high 
levels of efficacy. 
a. Develop assays to explore intracellular trafficking and endosomal escape of polymeric 
nanoparticles. 
b. Engineer polymer chemistries that explore influence of polymer structure on transfection 
efficacy 
c. Develop high throughput methods enabling semi-automated synthesis and testing of large 
polymeric nanoparticle libraries to identify trends in transfection efficacy and enable rapid 
screening in hard-to-transfect cell populations. 
2. Evaluate efficacy of polymeric nanoparticles in vitro to clinically relevant cell populations and design 
mechanisms for clinical level scale up of polymeric nanoparticles. 
a. Develop methods for PBAE nanoparticles scale-up, clinical utilization and standardization 
of transfection 
b. Apply high-throughput synthesis and screening methods to identify polymeric nanoparticles 
formulations enabling delivery of nucleic acids in vitro 
3. Test the efficacy of developed polymeric nanoparticle formulations to deliver nucleic acids in vivo for 
functional gene therapies. 
a. Assess ability of PBAE nanoparticles to deliver cyclic dinucleotides as adjuvants for cancer 
immunotherapy to immune cells in vitro and in vivo leading to robust prevention of tumor 
growth 
b. Apply PBAE nanoparticles for delivery of nucleic acids in vivo to therapeutically transfect 
cancer cells 
  
1.2 Summary of Contributions 
Chapter 2: A background in polymeric gene delivery 
• Review article - Kim J, Wilson DR, Zamboni CG, Green JJ. Targeted polymeric nanoparticles for 





• Book chapter - Kim J*, Kozielski KL*, Wilson DR*, Green JJ Biodegradable Polymeric 
Nanoparticles for Gene Delivery. Perspectives in Micro and Nanotechnology for Biomedical 
Applications. Imperial College Press. (2015). *These authors contributed equally to this work. 
Chapter 3: A Triple-Fluorophore Labeled Nucleic Acid pH Nanosensor to Investigate Non-Viral 
Gene Delivery 
• Research article - Wilson DR, Routkevitch D, Rui Y, Quinones-Hinojosa A, Zack DJ, Green JJ. A 
Triple-Fluorophore Labeled Nucleic Acid pH Nanosensor to Investigate Non-Viral Gene Delivery. 
Molecular Therapy. 25(7):1-13. (2017). 
• Research talk - Wilson DR, Routkevitch D, Mosenia A, Wahlin KJ, Zack DJ, Quinones-Hinojosa A, 
Green JJ. Development of a pH sensor to probe endosomal buffering of polymeric nanoparticles 
effective for gene delivery. American Society for Gene and Cell Therapy (ASGCT) National 
Conference. Washington, D.C. 2016. *Awarded meritorious abstract travel award. 
• Poster presentation - Wilson DR, Mosenia A, Quinones-Hinojosa A, Green JJ. The Role of 
Endosomal Buffering in Poly(Beta-amino ester) Nanoparticle Mediated Transfection. BMES 
National Conference. Tampa, FL. 2015. 
• Poster presentation - Wilson DR, Mosenia A, Quinones-Hinojosa A, Green JJ. The Effect of 
Poly(Beta-amino ester) Structure on Endosomal Buffering and Escape. MedImmune Science Day. 
Gaithersburg, MD. 2015. 
Chapter 4: Continuous Microfluidic Assembly of Biodegradable Poly(beta-amino ester)/DNA 
Nanoparticles for Enhanced Gene Delivery 
• Research article - Wilson DR, Mosenia A, Suprenant MP, Upadhya R, Routkevitch D, Meyer RA, 
Quinones-Hinojosa A, Green JJ. Continuous Microfluidic Assembly of Biodegradable Poly(beta-
amino ester)/DNA Nanoparticles for Enhanced Gene Delivery. Journal of Biomedical Materials Research 
Part A. 105:1813–1825. (2017). 
• Research poster - Wilson DR, Mosenia A, Suprenant MP, Upadhya R, Routkevitch D, Meyer RA, 
Green JJ. Microfluidic Formation of Self-Assembled Poly(beta-amino ester)/DNA Nanoparticles for 
Enhanced Transfection Efficacy. NanoDDS. Baltimore, MD. 2016. 
Chapter 5: The Role of Assembly Parameters on Polyplex Poly(Beta-Amino Ester) Nanoparticle 
Transfections 
• Research article - Wilson DR, Suprenant MP, Michel JH, Wang EB, Tzeng SY, Green JJ. The Role 
of Assembly Parameters on Polyplex Poly(Beta-Amino Ester) Nanoparticle Transfections. 






Chapter 6: A Combinatorial Library of Biodegradable Polyesters Enables Non-viral Gene Delivery to 
Post-mitotic Human Stem Cell-derived Polarized RPE Monolayers 
• Research article - Misha B*, Wilson DR*, Sripathi SR, Suprenant MP, Rui Y, Wahlin KJ, Berlinicke 
CA, Green JJ, Zack DJ. A combinatorial library of biodegradable polyesters enables non-viral gene 
delivery to post-mitotic human stem cell-derived polarized RPE monolayers. Regenerative 
Engineering and Translational Medicine.  1–13. (2019). *These authors contributed equally. 
• Wilson DR, Mishra B, Sripathi SR, Suprenant MP, Rui Y, Berlinicke C, Zack DJ, Green JJ. 
Nanoparticle Engineering for Non-Viral Gene Delivery to the Retina. Institute for 
NanoBioTechnology Student Research Forum. Baltimore, MD. 2018. 2nd place. 
• Research Talk - Wilson DR, Mishra B, Rui Y, Sripathi SR, Suprenant MP, Hansen BS, Cheng J, 
Mitchell KL, Berlinicke C, Zack DJ, Green JJ. Combinatorial Library of Polymers Enables 
Transfection of Post-Mitotic Differentiated Retinal Cells. Biomedical Engineering Society National 
conference. Phoenix, AZ. 2017. 
• Research Talk - Wilson DR, Mishra B, Rui Y, Sripathi SR, Suprenant MP, Hansen BS, Cheng J, 
Mitchell KL, Berlinicke C, Zack DJ, Green JJ. A High-Throughput Screening Platform to Identify 
Nanoparticle Formulations for Transfection of Primary and Post-mitotic Differentiated Cells. 
ASGCT National conference. Washington, D.C. 2017. 
Chapter 7: Differentially Branched Ester Amine Quadpolymers with Amphiphilic and pH Sensitive 
Properties for Efficient Plasmid DNA Delivery 
• Research article - Wilson DR, Rui Y, Siddiq K, Routkevitch D, Green JJ. Differentially Branched 
Ester Amine Quadpolymers with Amphiphilic and pH Sensitive Properties for Efficient Plasmid 
DNA Delivery. Molecular Pharmaceutics. 16 (2) 655-668. (2019). 
• Research Talk - Wilson DR, Tzeng SY, Shen J, Mishra B, Kim J, Rui Y, Berlinicke CA, Zack DJ, 
Campochiaro PA, Green JJ. Structure-Function Relationships of Branched Ester-Amine 
Quadpolymers for Non-Viral Retinal Gene Therapy. ASGCT National Conference. Washington, 
D.C. 2019. *Awarded meritorious abstract travel award. 
• Research Talk - Wilson DR, Rui Y, Siddiq K, Routkevitch D, Tzeng SY, Shen J, Campochiaro PA, 
Green JJ. Differentially Branched Ester Amine Quadpolymers with Amphiphilic and pH Sensitive 
Properties for Efficient Nucleic Acid Delivery. Society for Biomaterials National Conference. Seattle, 
WA. 2019. 





• Research article -  Wilson DR, Sen R, Sunshine JS, Pardoll DM, Green JJ, Kim Y. Biodegradable 
STING agonist nanoparticles for enhanced cancer immunotherapy. Nanomedicine: Nanotechnology, Biol, 
Med. 14, 237-246 (2018). Featured as Cover Article 
• Research Talk - Wilson DR, Sen R, Sunshine JC, Pardoll DM, Kim YJ, Green JJ. Biodegradable 
STING agonist nanoparticles for enhanced cancer immunotherapy. SAPA-DC Scientific Symposium 
& 3rd NIH-CSSA Annual Research Symposium. Rockville, MD. 2018. 1st place. 
• Research Talk - Wilson DR, Sen R, Sunshine JC, Pardoll DM, Kim YJ, Green JJ. Biodegradable 
STING agonist nanoparticles for enhanced cancer immunotherapy. Mid-Atlantic Biomaterials Day. 
Baltimore, MD. 2018. 
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Increasingly scientists and clinicians are discovering the genetic basis of diseases, ranging from 
monogenic disorders to multigenic diseases such as various cancers. Moreover, human diseases are 
increasingly being understood on the molecular level, rather than as a phenotype, which is moving treatments 
towards stratified and personalized medicine. Gene therapy holds the promise of a technology that could 
address this growing need for genetic medicine as it can potentially tune individual cell gene expression on or 
off in a targeted and precise manner. This technology also could, theoretically, be applied to almost any 
human disease. The central challenge is that in practice, safe and effective delivery of desired nucleic acids to 
targeted human cells is very difficult. This chapter outlines these challenges in gene delivery and then 
discusses state-of-the art approaches at overcoming these obstacles and obtaining successful gene delivery in 
in vitro and in vivo systems through the use of biodegradable polymers. Biodegradable gene delivery polymers, 
or plastics that are designed to safely deliver a biological cargo inside cells and then degrade, have certain 
advantages over other materials as well as over viruses for the delivery of genes. This chapter elucidates the 
diverse types of biodegradable polymers used for gene delivery, the related nanoparticulate systems they form 






 The delivery of nucleic acids to manipulate gene regulation can be both a therapeutic and a scientific 
tool. Diseases caused by missing or defective genes could potentially be cured by replacing these genes, such 
as upregulating tumor suppressor genes in cancer.1-3 The immune system can be modulated by the 
introduction of DNA-based vaccines,4,5 or by introducing genes that would allow the immune system to 
better recognize or fight cancer.6,7 Additionally, suicide genes can be introduced to kill cancer cells.8 Ex vivo, 
gene therapy can be used to manipulate stem cells for targeted differentiation,9 or to reprogram induced 
pluripotent stem cells from differentiated cells.10 Turning off or down regulating genes could treat diseases 
caused by gene overexpression.11,12 Technology to selectively turn genes off is also a valuable biological tool 
to elucidate the function of genes within a cell and in the context of a disease.13 
 Viral gene delivery vectors, although effective, come with risks such as tumorigenicity and 
immunogenicity.14 Adenovirus-mediated gene delivery studies have found that dosage repeatability and 
concentrations can be limited by toxicity and humoral immune response.15 Although non-viral nucleic acid 
delivery can avoid these issues, it is typically less effective.16 
 Lipid-based and inorganic delivery vehicles have previously been examined for their potential to 
deliver nucleic acids. Lipid-based delivery is well-characterized,17-19 and commercially-available lipid-based 
delivery vehicles are available for in vitro delivery of DNA20,21 and siRNA.22 Lipid-based nanoparticles can 
potentially generate off-target and immunogenic effects,20 but there are strategies to attenuate these unwanted 
interactions such as the introduction of poly(ethylene glyocol) (PEG) shielding.23,24 Calcium phosphate 
crystals,25-27 gold nanoparticles, quantum-dots and other inorganic materials have also been employed for 
non-viral gene delivery. Gold is advantageous because it’s biocompatible, easy to functionalize, and has 
malleable physical properties.28-32 Quantum dots are useful for fluorescent imaging as they are brighter and 
less prone to photobleaching than typical fluorophores.33,34 Several lipid-based and inorganic nanoparticle 
systems have also been combined with polymeric materials for enhanced gene delivery, particularly through 
the incorporation of PEG coatings24,35,36 for nanoparticulate shielding or polyamines for improved interaction 
with DNA and intracellular delivery.37,38  
Biodegradable polymeric gene delivery systems are a relatively newer class of materials for non-viral 
gene therapy.  They are promising due to key features such as safety mediated by their biodegradability, 
design flexibility due to their tunable structure, large cargo capacity, and relative ease in manufacture.  This 
chapter will focus on biodegradable polymeric nanoparticles for gene delivery.  They will be discussed in the 
context of systemic and intracellular barriers to gene delivery and how polymer design can be utilized to 
overcome these barriers. New developments in the field of biodegradable polymeric gene delivery and an 







Obstacles to Gene Delivery 
The central limitation of non-viral vectors for gene delivery is inefficient gene transfection arising 
from the natural mechanisms of the human body to protect itself against foreign substances.39 These barriers 
to biomaterial-mediated gene transfection span a spectrum from the systemic level to the cellular level (Figure 
2-1).40 Different biomaterial properties and modifications to gene carriers are important for each step of the 
delivery process leading to successful expression of exogenous delivered nucleic acid. We will discuss seven 
major biological barriers to gene transfer using non-viral vectors and strategies to overcome each of these 
barriers. It is also important to note that the design properties seemingly optimal for one of the delivery 
obstacles could pose a challenge to other obstacles; hence further effort is needed to globally optimize 







Figure 2-1. Major barriers to nucleic acid delivery using nanoparticles include stable particle formation, systemic 
circulation, tissue and cell targeting, cellular uptake, endosomal escape, and release of nucleic acid. Reprinted 
by permission from Macmillan Publishers Ltd: Nature reviews. Genetics 2014, 15, 541-55, copyright 2014.40 
 
Nucleic acid binding / encapsulation 
An efficient gene delivery vector must condense or encapsulate the nucleic acid to prevent enzymatic 





the field of non-viral gene delivery focused on the use of naturally occurring biological materials with 
significant positive charge that could electrostatically bind to the DNA. In this manner, DNA could be 
condensed into a smaller size, be made more resistant to potential enzymatic degradation, and have improved 
ability to enter cells. Polycation poly(L-lysine) (PLL) was observed to bind to nucleohistones,42,43 and was 
later investigated as one of the earliest polymers to form nanocomplexes with DNA.44-46 PLL is capable of 
complexing with DNA to form nanoparticles that successfully undergo cellular uptake but fail to escape from 
the endosome.47 To overcome this challenge, PLL has been used in combination with other materials that aid 
in endosomal escape including other peptide molecules and pH sensitive moieties that make use of the 
proton sponge effect.48-50 To improve delivery in comparison to PLL, alternative gene delivery materials 
needed to be discovered. An off-the-shelf commercially produced polymer with very high charge density, 
polyethylenimine (PEI), was first reported for use in transfection in 1995 by Boussif et al., who attributed its 
high transfection efficiency to its ability to undergo endosomal escape via the proton sponge effect.51 
Unfortunately, while transfection efficacy is correlated with the molecular weight of PEI, cytotoxicity is 
similarly correlated, making unmodified high MW PEI largely unsuitable for in vivo applications. PEI is a non-
biodegradable polycation that requires excess polymer to effectively transfect cells and can lead to 
accumulation upon repeated administration.52,53 To overcome this first obstacle to non-viral gene delivery, 
other biomaterials can encapsulate nucleic acids into particulates. Amphiphilic lipids, such as N-[1-(2,3-
dioleyloxy)propyl-N,N,N-trimethylammonium chloride (DOTMA), and relatively hydrophobic polymers, 
including poly(lactide-co-glycolide) polymer (PLG), form DNA-encapsulated nanoparticles by either phase 
separation alone or in combination with electrostatic interaction.54,55 
 Polymeric vectors are able to deliver different types of nucleic acids. For DNA, standard double-
stranded plasmids as well as minicircles, which are plasmids that have had prokaryote sequences such as the 
CpG islands removed, are widely used to introduce exogenous genes that encode for proteins of interest.56 
Because of the large size of DNA molecules, they are able to bind to cationic polymers such as PEI and 
poly(β-amino ester)s (PBAE) and form stable nanoparticles.57,58 Small interfering RNA (siRNA), through the 
RNA interference pathway, causes mRNA to be broken down and inhibits translation.59 As an siRNA 
molecule is dramatically shorter (~20 bp vs. > 1,000 bp) and stiffer than a plasmid DNA molecule, stable 
particle formulation through electrostatic interactions with cationic polymers is more difficult.60,61 Therefore, 
siRNA-delivering nanoparticles can require more complex engineering solutions to form effective particles, 
such as making siRNA more multivalent by introducing short complementary overhangs62 or multimerizing 
siRNA molecules with cleavable disulfide linkages.63 More recently, an enzymatic RNA polymerization 
technique has been used to condense RNA structures into self-assembled RNAi-microsponges.64 While 
siRNA binding and encapsulation can be challenging, siRNA delivery overall is not necessarily more difficult 









 Both viral-based and non-viral based vectors face the problem of rapid clearance from the systemic 
circulation on the order of minutes.66,67 While viruses often suffer from specific antibody-mediated immune 
response, non-viral platforms are quickly cleared by several non-specific mechanisms. Most polymeric gene 
delivery materials are positively charged as electrostatic interaction is the prevalent driving force in forming 
many types of nanoparticles for gene delivery. The resulting positive surface charge of nanoparticles provides 
colloidal stability in aqueous solutions and facilitates interaction with cellular membrane. However, it also 
attracts anionic counter ions in physiological salt and serum proteins that cause opsonization and aggregation, 
leading to increased clearance by the mononuclear phagocyte system (MPS) and the reticuloendothelial 
system (RES).68-70 
Several strategies have been employed to minimize clearance from the systemic circulation, including 
charge shielding and shape control. One common “stealth” technology involves coating nanoparticles with 
PEG, which provides a relatively inert surface due to its neutral and hydrophilic structure.71,72 Conjugation of 
PEG or “PEGylation” to gene delivery particles composed of cationic polymers,73,74 lipids,75,76 dextran-
spermine,77 and other materials have been reported demonstrating beneficial effects.  An alternative approach 
is the neutralization of excess positive surface charge of particles through coatings with anionic 
biomacromolecules such as negatively charged polypeptides.78 More recently, engineering of particle shape 
has also been shown to be an important parameter to extend circulation time.  Nanoparticles for drug 
delivery with higher aspect ratios had longer circulation half-lives than spherical particles,79 and this strategy 
has begun to be utilized for gene delivery nanoparticles.80 
 
Tissue and cell targeting 
 Tissue targeting can be accomplished through design of a targeted systemically administered 
nanoparticle, through a tissue-specific promoter, or through a local injection. Nanoparticles can be injected 
into anatomically accessible sites to enhance delivery in the local region of interest while reducing non-
specific transfection at other sites. For example, intracerebroventricular delivery grants direct access to the 
brain, retrograde intrabiliary infusion to the liver, and intratumoral injection to tumors.81-83  
 Nanoparticles that are administered intravenously must have mechanisms to exit the circulation at 
the target tissue. The application of nanoparticles to solid tumors is often benefited by passive targeting. The 
formation of new blood vessels near rapidly growing solid tumors allows nanoparticles with diameters of 400 





prolonging systemic circulation by the aforementioned strategies, such as PEGylation, can increase the 
accumulation of nanoparticles at a tumor site, and this enhanced permeability and retention (EPR) effect has 
become an important tool in nanoparticle-mediated gene delivery for cancer therapy.84 On the other hand, 
molecular ligands and chemical moieties that bind specifically to overexpressed receptors on the vascular 
endothelial cells’ surface near a solid tumor have been conjugated to various nanoparticles as an active 
targeting mechanism. For example, arginine-glycine-aspartic acid (RGD) peptide sequence and other chemical 
antagonists to various integrin isoforms have been covalently conjugated or electrostatically bound via 
negatively charged polypeptides to biomaterials target tumor vasculature.85-89 Another emerging method of 
conferring tissue-specificity to nanoparticles utilizes aptamers as targeting ligands.90   
 Nanoparticles with targeting ligands can be used to target many additional cell types as well.  This is 
important as, when cell-specific RNA interference or therapeutic exogenous DNA expression is critical, 
nucleic acid delivery nanoparticles with cell-specific targeting can increase efficacy and reduce potential off-
target side effects. Overexpressed receptors on the surface of specific cell types of interest are good 
candidates to target with ligands. The gene delivery and nanomedicine literature show that modification of 
nanoparticles ligands of many different types can be effective including: galactosylated PEI targeting 
hepatocytes, antibodies specific to the insulin receptor to target cancer cells in brain, synthetic peptides that 
bind to integrin α5β1 on neuroblastoma cells, small molecules targeting CD40 on ovarian cancer cells, and 
leukocyte function-associated antigen-1 to bind to melanoma cells.91-95  
Other methods for cell-specific gene delivery are also possible.  Following a polymer library 
approach, a recent study by Guerrero-Cázares et al. showed that the specific chemical structure of a polymer 
that comprises a polymer/DNA gene delivery nanoparticle can confer cell specificity to one type of cell over 
another such as primary brain tumor initiating cells over healthy neural progenitor cells.96 Similar results have 
also been shown for polymeric nanoparticles that can target liver cancer cells97 and endothelial cells.98,99  A 
final approach is including a cell type-specific promoter in the plasmid to promote targeting of specific cells 
such as cancer cells.100  In this manner, even if some of the polymeric nanoparticles are delivered to off-target 
cells, there is only successful expression of the exogenous gene in the targeted cells where the specific 




 Once nanoparticles reach the cells of interest, they must overcome several barriers at the cellular level 
before successful transfection is achieved. First, gene carriers need to cross the cellular membrane, for which 
exist both non-specific and specific mechanisms. Macropinocytosis is a non-specific cellular uptake 





entered via macropinocytosis result in poor transfection efficacy due to high rate of recycling.102 Also, the 
positive surface charge on nanoparticles formulated with cationic polymers or lipids promotes electrostatic 
interaction with the negatively charged cell surface, which in turn triggers another non-specific pathway, 
adsorptive endocytosis.103 It should be noted that positive surface charge is shielded by approaches designed 
to increases systemic circulation time such as PEGylation.  These coatings minimize electrostatic interactions 
between nanoparticles and cellular membranes.  
On the other hand, specific uptake mechanisms are mediated by receptors on the cellular membrane, 
which can recognize various molecular ligands as well as chemical moieties of a nanoparticle. In the case of 
PEGylated nanoparticles, ligands can be conjugated to the terminal ends of the PEG chain, and chemical 
moieties can be exposed upon environment-stimulated PEG cleavage.104,105 There are two major specific 
uptake routes for gene carriers. Clathrin-mediated endocytosis is initiated with clathrin-coated pits of 
approximately 100 – 150 nm in size that pinch off from the plasma membrane to form endosomes.106 
Nanoparticles modified with MC1SP-peptide and transferrin that target the melanocortin receptor-1 and the 
transferrin receptor respectively, and unmodified lipoplexes and liposomes are found to be endocytosed via 
this pathway.107-109 In comparison, caveolae-mediated endocytosis is characterized by flask-shaped 
invaginations of about 50 – 100 nm in diameter.110 Folic acid ligands that bind with folate receptors as well as 
unmodified polymeric nanoparticles can be directed to caveolae-mediated uptake.109,111   
 Different uptake pathways lead to different intracellular fate, which underscores the importance of 
the cellular uptake on successful transfection.112 For example, the major route of uptake for PBAE 
nanoparticles does not necessarily lead to high transfection efficiency.113 The surfaces of nanoparticles can be 
modified to direct their uptake pathway , improve the intracellular fate of the plasmids that they contain, and 







 Once endocytosed, nanoparticles must escape the endosomal compartment and reach the cytoplasm. 
One mechanism of endosomal escape for polymeric nanoparticles is through the proton sponge effect.114 
Reversibly protonated biomaterial vector can act as a buffer as the endosome gradually become acidic, 
thereby protecting the cargo. Subsequently, chloride ions enter the endosomes to neutralize the charge, 
creating osmotic pressure that eventually leads to endosomal burst and cargo release. PLL, owing to its 
primary amines that are easily protonated at pH 7, is unable to provide strong buffering capacity at 
endosomal pH. In order to neutralize the acidic pH, researchers have either co-delivered PLL with 
amphipathic amines, such as chloroquine, or substituted its lysine residues with histidine or arginine residues 
that have titratable amines. 48,115 PEI and PBAE, on the other hand, have weakly basic tertiary amines in their 
structure that allows for the proton sponge effect.51,116 Although the proton sponge hypothesis is a widely 
believed mechanism of endosomal escape, it has been challenged and remains to be clearly elucidated.117 
 Nanoparticles can also escape the endosome by destabilizing endosomal membranes. For example, 
amphiphatic, fusogenic peptides, such as GALA (repeats of Glu-Ala-Leu-Ala) and KALA (repeats of Lys-
Ala-Leu-Ala), have been utilized as the primary component of non-viral vectors and have also been associated 
non-covalently with nanoparticles.118,119 These fusogenic peptides are able to form alpha-helical structures at 
endosomal pH that can destabilize the endosomal membranes. Other amphiphatic lipids, such as 
dioleoylphosphatidylethanolamine (DOPE), that assume non-bilayer structure, can also facilitate endosomal 
membrane destabilization when associated with liposomes.120,121   
 
Release of nucleic acid and nuclear transport of DNA 
 
Although strong binding or encapsulation of nucleic acid is necessary to form stable particles, nucleic 
acids must be able to be released from the particles once the particles have entered the cytoplasm. This 
release typically occurs due to thermodynamics-driven disassociation of the anionic DNA from cationic 
polymers or due to degradation of the particle.  Release is necessary in order to enable the nucleic acid to 
have a biological effect, as DNA that isn’t released from its carrier is unable to be transcribed as 
efficiently.122,123 This was illustrated by a recent study showing that the binding constant between polycations 
and DNA is biphasic with the transfection efficiency.124 Additionally, polymer degradability imparts decreased 
cytotoxicity, as polymer molecular weight has been shown to positively correlate with toxicity.125 Lack of 
degradability contributes to the toxicity of conventional polymers such as 25 kDa branched PEI.126,127 Below, 





them to degrade (Figure 2-2), in addition to the design of polymers with degradable moieties inherent in their 
chemical structure.  
 
Figure 2-2. Chemical moieties that can enable the degradation of polymeric nanoparticles. Chemicals listed 
above the reaction scheme arrow indicate those necessary for the reaction, while chemicals listed below 
indicate reaction catalysts. 
 
Hydrolysis 
The release of nanoparticle cargo can be achieved through polymer hydrolysis via the cleavage of 
ester, urethane, imine, and orthoester linkages. Poly[alpha-(4 aminobutyl)-L-glycolic acid] (PAGA) is a 
hydrolysable analog of PLL in which the amides linking conventional PLL monomers are replaced with ester 
linkages. PAGA based DNA delivery has been shown to lead to higher transfection efficacy and lower 
toxicity versus conventional PLL.128 Hydrolytically cleavable PEI can be synthesized by linking shorter PEI 
polymers together with ester-containing crosslinkers. Diacrylate monomers used to crosslink 800 Da PEI 































































while achieving 16-fold enhancement to transfection efficacy with no measureable toxicity.129 PBAE polymers 
are formed via Michael addition of amine-containing monomers with diacrylate monomers and therefore 
contain esters within the polymer backbone.130 Combining various amine and acrylate monomers enables the 
creation of libraries of PBAEs with various chemical properties,131 and whose binding constants are affected 
by polymer molecular weight.124 Other poly(amino ester)s can be synthesized to have a similar chemical 
structure and transfection efficacy as 25 kDa PEI but with reduced toxicity (Figure 2-4).132 Poly(lactic-co-
glycolic) acid (PLGA)-based nanoparticles can encapsulate nucleic acids, particularly using a double emulsion 
method and polyamines, and successfully deliver nucleic acids.133 PLGA chemically modified with amine-
containing molecules grafted onto their polymer backbone has also been shown to effectively deliver DNA 
and siRNA.134,135 Other hydrolytically cleavable polymer linkages have been explored for biodegradable 
polymer design. Amine containing polyurethanes can be designed to deliver DNA.136 Polyimines, which 
specifically allow for acid-labile hydrolysis, can be used to link short chain PEI.137 Additionally, polyorthoester 




Polymer bioreducibility via the inclusion of disulfide bonds enables cargo release targeted to the 
cytoplasm. Cytosolic reduction is due to the presence of reducing agents such as glutathione, a molecule 
present in concentrations roughly 1000 times higher in the cytosol versus extracellular space.140 This cellular 
compartment-specific degradation and release makes bioreducible polymers particularly useful for delivery of 
siRNA, mRNA, and miRNA whose site of action is within the cytosol. In contrast, DNA delivery via 
disulfide-containing polymers has sometimes been found to be less-effective.141 As with hydrolytic linkages, 
reducible linkages can improve delivery efficacy and reduce cytotoxicity of conventional polymers. PLL linked 
with disulfides has shown improved nucleic acid delivery.142 Methods to crosslink PLL with disulfides, either 
by incorporating cysteines into the polypeptide backbone,143 or by chemically modifying the lysine side chains 
to contain thiols,144,145 has led to improved siRNA and DNA delivery. Linear PEI linked with disulfides also 
showed improved siRNA delivery with lower toxicity than 25 kDa PEI.146 The KALA fusogenic peptide has 
also been modified with cysteines to allow for crosslinking.147  
Polymer bioreducibility can be imparted by synthesizing polymers from disulfide-containing 
monomers. Poly(amido amine)s (PAAs) are synthesized with diacrylamide and amine-containing monomers, 
and are therefore not biodegradable. However, disulfide-containing diacrylamides can also form PAAs and 
impart targeted cargo release to the cytoplasm. Disulfide-containing PAAs have been extensively studied for 
both DNA and siRNA delivery. 146,148-151 PBAEs can also be bioreducible, either by end-capping with 





polymer backbone.153 Bioreducible PBAEs have been shown to be successful as siRNA delivery vehicles, 





Other modes of degradability can enable targeted release of polymeric nanoparticles through 
triggered release. This release can be tissue or environment-specific.  As an example, enzyme-cleavable 
linkages, specifically matrix-metalloproteinase (MMP)-cleavable groups, can allow for release within tumor 
space.155 Polymers can be degraded by enzymes or polymeric nanoparticles can become deshielded in the 
presence of specific enzymes.  Nanoparticle degradation and nucleic acid release can also be triggered by an 
external source.  For example,  light-induced degradation could allow for user-controlled release and spatially 




Lastly, the final potential delivery step following delivery of nucleic acids to the cytoplasm is their 
transport into a specific organelle, such as the nucleus.  Unlike siRNA, DNA plasmids have to be transported 
to the nuclear membrane and enter the nucleus for their biological effects to occur. Following nuclear import, 
exogenous DNA expression requires transcription and translation.  The simian virus 40 large T antigen 
nuclear localization signal (NLS), which is a peptide sequence rich of lysine amino acid, is known to facilitate 
nuclear transport.157 Many vectors, including cationic peptides and lipids, as well as DNA plasmids, have been 





































Figure 2-3. Characteristic chemical structures of polymers used for non-viral gene delivery   
Peptides 
Poly(L-lysine) 
While poly(L-lysine) (PLL), shown in Figure 2-3A, generally has low efficacy for gene delivery by 
itself, multicomponent nanoparticles that incorporate PLL as a polycation to bind nucleic acids have been 
more successful. In one example, PEG-PLL-DMMAn-Mel nanoparticles have shown potential improvement 
for PLL-based siRNA delivery.  In this system, Meyer et al created PEG-modified PLL nanoparticles that 
utilized the lytic peptide melittin (Mel) shielded by pH cleavable dimethylmaleic anhydride (DMMAn) to only 
expose the lytic peptides for endosomal escape once a pH of 5.50 In addition to the pH sensitive lytic peptide 
exposure, siRNA release was achieved via disulfide cleavage between the siRNA and polymer.50 These PEG-
PLL-DMMAn-Mel nanoparticles were shown to achieve 90% knockdown in vitro, with a caveat being 
potential cytotoxicity (70% metabolic activity as measured by an MTT assay).50 While results of this 
nanoparticle formulation were promising for siRNA delivery in vitro, in vivo testing revealed a high level of 
toxicity in healthy mice and tumor bearing mice alike requiring sacrifice of the animals shortly after 
application.50  This study highlights the potential role of biomaterial-induced toxicity in synthetic gene 
delivery systems.   
Other uses of PLL for nucleic acid delivery have included pH cleavable PEGylated PLL-cholic acid 
nanoparticles shown to have a nine-fold reduction in gene expression in vitro with cell viability over 90%.161 In 
vivo results of PEGylated PLL-cholic acid nanoparticle delivery of VEFG siRNA achieved a tumor size 
reduction of 41% with a measured 70% qPCR knockdown of VEGF mRNA without a significant weight 
reduction in treated mice.161 Another PLL nanoparticle formulation utilizing dendritic PLL for the 
knockdown of Apolipoprotein B to reduce serum low-density lipoprotein levels was shown to achieve 
significant knockdown in vivo leading to a 40% reduction in serum LDL.162 PLL has been shown to be an 
effective polycation when modified to enable endosomal escape and cellular targeting, but its current use is 
limited as it lacks the versatility of many other polycations for the delivery of nucleic acids. 
Cell-penetrating peptides 
Peptides have been incorporated in many other nanoparticle designs as both the backbone structure 
and as surface molecules. Amphipathic endosomal escape peptides such as GALA and KALA, as mentioned 
previously, are well documented for improving transfection among various cell types and with different 
nanoparticle formulations.118,163 Other CPPs have been used in the creation of nanoparticles for the delivery 
of siRNA with lysine residues often being used to increase the cationic nature of the peptides.164 Peptides 
have also been incorporated into nanoparticles for the purposes of endosomal release. For example, sHGP, a 
15 amino acid oligopeptide from HIV gp41, has been shown to improve endosomal release.165 Peptide 





endosomal escape and has been shown to improve efficacy of transfection with siRNA.166 Control over the 
enzymatic degradation rate of peptide-based nanoparticles has also been achieved by Chu et al. who designed 
nanoparticles utilizing both D and L amino acids for controlled cleavage by Cathepsin B.167 In this way, a 
stereospecific enzymatic degradation strategy was shown to offer excellent stability extracellularly with a 
controlled rate of intracellular degradation to release nucleic acids.167 
CPP based nanoparticles termed PF6 for the delivery of siRNA were created by Andaloussi et al. and 
demonstrated to be able to knockdown a reporter gene up to 90% in serum containing media with minimal 
cytotoxicity and inflammatory effects.164 Importantly, PF6 nanoparticles were shown to be stable over a span 
of weeks in water as well as being stable over a short term in serum containing media.  These nanoparticles 
has a diameter between 125-200 nm and a zeta potential of approximately -10 mV.164 Intravenous 
administration of PF6 with luc-siRNA to transgenic mice with bioluminescent liver cells showed effective 
knockdown peaking on day 5 at a 75% reduction.164 PF6 knockdown of the functional protein HPRT1 was 
observed to be greatest in the liver and in addition there was silencing of greater than 60% in the kidneys.164  
Synthetic polymers 
Polyethylenimine 
High molecular weight 25 kDa Polyethylenimine (PEI), shown in Figure 2-3B, has previously been 
shown to condense DNA to form nanoparticles, undergo endosomal escape, and successfully deliver 
DNA.51,168 Unfortunately while transfection efficacy is correlated with the molecular weight of PEI, 
cytotoxicity is likewise correlated making unmodified 25 kDa PEI largely unsuitable for in vivo applications.168 
Related to issues of immediate cytotoxicity, PEI is a non-biodegradable polycation that requires excess 
polymer to effectively transfect cells that can lead to accumulation upon repeated administration.52,53 PEI of 
approximately 25 kDa molecular weight was shown to have higher transfection efficiency than higher 
molecular weight versions, such as 50 kDa and 800 kDa, but still suffered from cytotoxicity in vivo in 
mice.51,169 To further minimize the cytotoxicity of non-biodegradable PEI, lower molecular weight versions of 
linear and branched PEI have been investigated, as have partially biodegradable cross-linked PEI and 
hyperbranched oligoethyleneimine.170-173 Biodegradable linkages between low molecular weight PEI segments 
have primarily included bioreducible disulfides and hydrolysable esters, both of which have been shown to 
improve transfection efficacy as well as decrease cytotoxicity compared to 25 kDa PEI.129,172 In 2003, Forrest 
et al. created hydrolysable PEI polymers from 800 Da PEI and diol-diacrylate monomers that improved 
transfection efficiency and reduced cytotoxicity.129 Using disulfide cross-linked 1.8 kDa low molecular weight 
PEI, Liu et al. were able to achieve greater than 60% transfection with 90% cell viability in serum containing 
media in 2010.174  
These improvements to polymer structure have made PEI much less toxic in vitro but do not fully 





PEI-based nanoparticle formulations have been investigated in human clinical trials.  One example is a Phase 
I clinical trial for the delivery of a plasmid encoding interleukin-12, which was administered to thirteen 
patients with recurrent ovarian cancer and indicated favorable safety results.175 The nanoparticle was 
composed of a lipopolymer, PEG-PEI-cholesterol, and was administered in a series of four increasing doses 
every 4 weeks intrapleurally.175 
 
Poly(beta-amino ester)s  
The development of poly(beta-amino ester)s (PBAEs), shown in Figure 2-3C, as a material for 
transfection has been greatly advanced by high throughput screening of PBAE polymer libraries in which 
monomers that make up the backbones, side chains, and end capping groups have been systematically 
varied.131,176-178 This rapid screening technique has allowed for a large variety of PBAEs to be tested and 
patterns in transfection to be determined. Transfection by PBAEs has been shown in some cases to be cell 
type specific, with cellular uptake and transfection differences between healthy cells and tumor cells due to 
variation in polymer structure.96,97,179 Using polymer libraries and high throughput screening, PBAE 
nanoparticle formulations for the delivery of siRNA and DNA to human glioblastoma cells have been 
achieved up to 85% and 90% respectively in vitro, significantly greater than Lipofectamine 2000 and other 
commercial transfection reagents (Figure 2-4).153 While most PBAE nanoparticles for the delivery of nucleic 
acids have used linear PBAEs for rapid intracellular degradation and release of DNA polyplexes, cross-linked 
PBAEs formed by Michael addition using triacrylate monomers and N,N-dimethylethylenediamine have also 
been created to reduce the rate of degradation and DNA release.180 
In vivo results of PBAE nanoparticle-mediated delivery of DNA in mice have demonstrated 
functional transfection for treating diseases such as ovarian cancer.181 Transfection of brain tumor-initiating 
cells (BTICs) in 3D oncospheres with pDNA has been accomplished with PBAE nanoparticles at up to 76% 
transfection in vitro.96 In this work, PBAE nanoparticle specificity of transfection for BTICs over fetal neural 
progenitor cells (fNPCs) has been demonstrated both in vitro and in vivo, supporting the notion that in vitro 
monolayer culture screening of PBAE nanoparticles has relevance for in vivo efficacy. Transfection of ovarian 
tumor bearing mice via intratumoral injection of PBAE nanoparticles containing a plasmid encoding 
diphtheria toxin showed a mean tumor load reduction greater than that of administration with dual 
chemotherapeutics.181 The intrapleural injection route used in this study mirrors the current injection route of 
chemotherapeutics for advanced ovarian cancer, supporting the clinical relevance of the work.181 Of 
importance to clinical relevance, PBAE/DNA nanoparticles, although readily hydrolysable, have been 






PBAEs have also been used as a cationic polymer to supplement other materials in the creation of 
nanoparticles for the in vivo delivery of siRNA. Cohen et al. have created acetalated-dextran nanoparticles with 
10 wt% PBAE that showed pH sensitive degradation and release of DNA.182 PBAE has been used as a 
cationic polymer for binding DNA in conjunction with PLGA to form microspheres capable of transfecting 
macrophages to express a tumor specific antigen and induce an adaptive immune response in mice.183 
For localized delivery of DNA and siRNA amenable to tissue engineering applications, PBAEs have 
been used in the development of multilayer polyelectrolyte films shown to enable contact dependent 
transfection.184 Multilayered films, such as those developed in the lab of David Lynn, rely on charge 
association between layers of polycations, in this case cationic PBAEs and anionic DNA, to respond in a pH 
and temperature dependent manner for localized transfection.185 DNA release was shown to be largely 
dependent on multilayer film degradation and released DNA in a relaxed conformation compared to the 
typical supercoiled conformation resulting from nanoparticle delivery.184 Multilayered polyelectrolyte films 
have been further developed for localized delivery of siRNA with release due in large part to diffusion out of 
the film rather than film degradation186 Notably, the multilayer film design allowed for sustained release of 
DNA for 30 hours, while siRNA was released in a burst manner.184,186 The Hammond and Irvine groups have 
developed PBAE-based layer-by-layer coatings of microneedles that can be used for DNA vaccination and 
delivery of immunostimulatory RNA through the skin.187 Using this approach, the authors found potent 








Figure 2-4. Poly(beta-amino ester)s (PBAE)s for gene delivery to brain cancer (A) Libraries of PBAEs can be 
synthesized by reacting different acrylate and amine-containing monomers. (B) DNA-containing 
nanoparticles can be lyophilized and stored prior to in vivo administration. (C) Intracranially administered 





tissue in a mouse model. Reprinted with permission from ACS Nano. 2014, 8, 5141-5153, copyright 2014 
American Chemical Society.96   
 
Poly(amido amine)s 
Dendrimers are symmetrically branched polymer structures that have been used as base units to 
encapsulate and deliver various materials through charge interactions or conjugation. Many dendrimers, 
including poly(amidoamine) (PAA or PAMAM) shown in Figure 2-3D, are synthesized by a series of Michael 
addition reactions, allowing for great specificity of size and nitrogen content for complexation with nucleic 
acids by a fine-tuned N:P ratio. The exterior surface of dendrimer molecules can also be modified with 
hydrophilic groups to allow for improved solubility in water or with targeting ligands for attempted improved 
active cellular uptake. The most frequently used dendrimer for nucleic acid delivery to date has been 
PAMAM, although peptide dendrimers have also been utilized with some success.188 Bioreducible PAMAM 
nanoparticles for the delivery of DNA have been created with very high cell viability and transfection 
efficiency up to 200 times that of branched PEI.189 The degree to which the structure of these hyperbranched 
PAMAM particles were able to be reduced was able to be finely tuned by the changing the monomer molar 
ratios used in the Michael addition reactions used to create the polymer.189  Beyond PAMAM, Barnard et al. 
developed an ester hydrolysable dendrimer with surface amine groups capable transfection of in vitro up to 10 
times more efficiently than PEI.190 
 
Poly(lactide-co-glycolide) and poly(caprolactone) 
PLGA microparticles containing 25 wt% PBAE were used to transfect macrophages with reporter 
gene DNA both in vitro and in vivo.183 In vivo results showed that these microparticles containing a plasmid for 
the expression of a tumor antigen were able to induce rejection of the transplanted tumor matching the 
antigen.183 The resulting adaptive immune response was sufficient to cause a reduction in measured tumor 
growth by day 11 following transfection.183 In another nanoparticle formulation, copolymer hybrid poly(ester 
amine) nanoparticle formulations of polycaprolactone and PEI have been formulated with improved 
transfection over 25 kDa PEI for a number of cell lines.191  Thus, biodegradable polymer blends are an 




Chitosan, a natural linear polysaccharide derived from chitin and shown in Figure 2-3E, has been 
used in the delivery of pDNA and siRNA.192 Chitosan varies by the degree of deacetylation from chitin 





chitosan has been used more frequently for nucleic acid delivery due to its greater cationic nature and 
corresponding ability to complex with the negatively charged backbone of DNA or RNA. Mao et al. created 
PEGylated chitosan DNA nanoparticles with the targeting molecule transferrin capable of transfection.194 
Chitosan-DNA nanoparticles were also found to transfect intestinal epithelium in vivo, generate immunologic 
protection, and reduce allergen-induced anaphylaxis when administered orally to mice.195  For siRNA delivery, 
chitosan thiamine pyrophosphate nanoparticles have been shown to achieve knockdown up to 70% with cell 
viability above 90% in vitro for hepatocarcinoma cells, notably greater than Lipofectamine.196 Trimethyl 
chitosan has also been used in conjunction with the polysaccharide polysialic acid (PSA) for the delivery of 
transcription factor decoy oligonucleotides resulting in a reduction of inflammation measured by excreted 
cytokines in vitro.197 
 
Hyaluronic acid 
Hyaluronic acid (HA), shown in Figure 2-3F, has been utilized in nanoparticles for the delivery of 
nucleic acids as well as a targeting molecule for the CD44 cell receptor often overexpressed on the surface of 
tumor cells.198,199 HA chitosan-PEG nanoparticles synthesized for the delivery of pDNA and siRNA have 
been shown to have transfection efficiency equivalent to that of Lipofectamine 2000 in vitro.198 Nanoparticles 
for siRNA delivery composed of HA-spermine and HA-PEI have achieved above 90% knockdown in vitro 
with specificity for the CD44 receptor.199 When the HA-PEI particles were tested in vivo for targeting of a 
metastatic lung cancer model implanted subcutaneously in mice, knockdown measured by qPCR of up to 
55% was observed.199  Improving serum stability of nanoparticles is another area in which HA has been 
utilized in combination with polycations such as PEI, functioning in much the same way as glycosylation of 
proteins in vivo.200 HA has also been utilized in the creation of hydrogels capable of delivering DNA at 
controlled rates for in vivo tissue engineering applications.201 
 
Cyclodextrin 
β-Cyclodextrin, shown in Figure 2-3G, is a three-dimensionally stable oligomer of glucose that forms 
cup like structures with a hydrophobic core. Chemical modification of β-cyclodextrin with acetyl groups 
enables the polymer structure to complex with nucleic acids as a cationic polymer. Cyclodextrin-based 
nanoparticles developed in the lab of Mark Davis for the intravenous delivery of siRNA have reached clinical 
trials. These nanoparticles, shown in Figure 2-5A, are formulated from β-cyclodextrin, adamantine-PEG, and 
the targeting ligand transferrin, and have been shown to have favorable characteristics for the delivery of 
siRNA including a small nanoparticle size between 60-80 nm, a zeta potential +10-20 mV, and the ability to 
protect siRNA from nuclease activity in the presence of serum for at least 4 hours.202 In 2009 following 





Phase I clinical trials as a cancer therapeutic.203 The Phase I trial involving 24 patients has since concluded 
with favorable results for the nanoparticle safety, including evidence for the lack of a complement 
response.204 Additionally, RRM2 mRNA levels intratumorally were shown to have been reduced up to 77% 
and a 32% partial knockdown of RRM2 was measured for RRM2 protein levels in the tissue as shown in 
Figure 2-5B.205 While this level of knockdown may not be effective as a monotherapy for cancer, it provides 
early evidence that with this non-viral system siRNA can be targeted to tumor cells in human patients with 
measurable knockdown of a specific protein. 
 
 
Figure 2-5. Cyclodextrins for siRNA delivery.  (A) The three components that formulate CALAA-01, a 
cyclodextrin-containing nanoparticle for RRM2 RNAi tested in FDA phase I clinical trials. (B) mRNA and 
protein levels of RRM2 are both knocked down in the targeted tissue of one patient (C). RRM2 staining (red) 
of human tumor tissue before and after systemic administration of the cyclodextrin-containing nanoparticles. 









Dextran, shown in Figure 2-3H, is a branched polysaccharide of repeating glucose units and has been 
used in the formation of nanoparticles for the delivery of siRNA and pDNA. Dextran is often acetalated to 
improve solubility in organic solvents and allow for pH dependent degradation.206 While the structure of 
unmodified dextran does not fit the requirements of an ideal biomaterial for the delivery of nucleic acids, its 
status as an easily modified biocompatible and biodegradable polymer allows for it to be utilized with other 
materials in the formulation of nanoparticles for nucleic acid delivery. Acetalated dextran has been used in 
conjunction with PBAE and spermine for the successful delivery of both siRNA and DNA.182,207 Ac-
DEX/PBAE particles created for the delivery of DNA have been shown to undergo endosomal pH 




Spermine, shown in Figure 2-3I, is a natural oligoamine that has been used primarily as an oligomer 
grafted onto non-cationic polymers to enable the resulting polymer to have improved charge association with 
DNA. Biodegradable polysaccharide-based particles using spermine as a polycation have been explored with 
varying degrees of success. In 2002, a library of over 300 polysaccharide-oligoamine particles were created 
with some polysaccharide-spermine particles reaching transfection efficiency equal to that of Transfast 
cationic lipids.208 Since then, acetalated-dextran spermine nanoparticles have been created for siRNA as well 
and shown to cause up to 60% knockdown of GFP in HeLa cells.207 
 
Nucleic-acid based particles 
Nanoparticles composed entirely of nucleic acids have been created for the delivery of siRNA.  In 
this case, the natural biodegradable polymer is the nucleic acid itself, which functions as both the structure for 
the particle as well as the cargo of the particle. Lee et al. used six 30 bp segments of DNA with 
complementary overhanging siRNA segments to create self-assembling tetrahedral oligonucleotide 
nanoparticles by complementation between the DNA and overhanging siRNA as shown in Figure 2-3J.209 
These particles, each carrying six siRNA molecules, were shown to have a circulation time four times longer 
than unprotected siRNA.209 Oligonucleotide nanoparticles improved siRNA delivery for the knockdown of 
luciferase both in vitro and in vivo with a 60% reduction in bioluminescence of luciferase expressing tumors in 
a rat model two days after treatment.209 These initial studies, particularly for improved in vivo delivery of 
siRNA have indicated that nucleic acid origami particles are a high capacity siRNA delivery method that 
deserves further study.209 Paula Hammond and colleagues have used RNA polymerase to form long strands 
of RNA that can self-assemble into nanostructures and microstructures.64  These structures, RNA 





intratumorally in mice.64 In an alternative approach, Chad Mirkin and colleagues have developed spherical 
nucleic acids, which are densely packed nucleic acids arranged in a spherical geometry, with or without a core.  
These materials are promising for nucleic acid delivery for varied applications, including cancer therapy.  In 
one example, gold core siRNA-based spherical nucleic acid nanoparticles were found to cross the blood-brain 
barrier, knockdown Bcl2L12, and induce apoptosis of brain cancer cells, increasing in vivo survival.210 
 
Conclusion 
Gene therapy holds great promise in treating various diseases of genetic origin by introducing 
exogenous nucleic acid to express desired proteins and by knocking down the expression of undesirable 
genes. A key challenge to gene therapy is effective delivery, and significant effort has been invested into 
developing biomaterials that can form nanoparticles to deliver genes to specific targets safely and efficiently. 
As highlighted in this chapter, a number of non-viral, biodegradable polymers have been developed to form 
biodegradable nanoparticles for gene delivery and are promising due to their ease of synthesis, low toxicity, 
and efficacy at transfection. Importantly, strategies for polymer modifications have been identified to 
overcome major biological barriers to gene delivery. While a polymeric nanoparticle system for human gene 
therapy has yet to be FDA-approved, numerous systems for polymeric DNA and siRNA delivery are in 
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In this article, advances in designing polymeric nanoparticles for targeted cancer gene therapy are reviewed. 
Characterization and evaluation of biomaterials, targeting ligands, and transcriptional elements are each 
discussed. Advances in biomaterials have driven improvements to nanoparticle stability and tissue targeting, 
conjugation of ligands to the surface of polymeric nanoparticles enable binding to specific cancer cells, and the 
design of transcriptional elements has enabled selective DNA expression specific to cancer cells. Together, 
these features have improved the performance of polymeric nanoparticles as targeted non-viral gene delivery 
vectors to treat cancer.  As polymeric nanoparticles can be designed to be biodegradable, non-toxic, and to 
have reduced immunogenicity and tumorigenicity compared to viral platforms, they have significant potential 
for clinical use. Results of polymeric gene therapy in clinical trials and future directions for the engineering of 




Molecular origins of many human diseases, such as cancer, are increasing being elucidated and 
understood on a genetic level. Gene therapy is an emerging technology that could treat these disorders by 
permanently or transiently replacing genetic defects with exogenous nucleic acids.1, 2 Nucleic acids can be used 





or mutated oncogenes downregulated in affected cells, suicide genes can signal cell death, and DNA vaccines 
can trigger the immune system to fight cancer.3-6 
The challenge in gene therapy is to develop safe vectors that can efficiently deliver nucleic acids. Viral 
vectors, such as adenovirus and lentivirus, are highly effective yet liable to immunogenicity and/or 
tumorigenicity from insertional mutagenesis.7 While non-viral gene delivery vectors are considered safe, this 
increased safety comes at the cost of lower efficiency. Polymeric vectors, both natural and synthetic, compose 
a class of non-viral vectors that show great promise as their chemical structure can be tuned to allow design 
flexibility for increased safety and efficacy.  
A key component for cancer gene therapy success is delivery. While physical methods of delivery 
enhancement, such as using ultrasound, heat, light, and applied magnetic and electric fields, have been utilized 
to deliver gene carriers to target cancer sites, these methods rely on precise knowledge of the location of tumors.  
To reach both known and unknown locations of cancer cells, other research efforts have focused on the 
development of non-viral vectors, such as polymeric nanoparticles, as delivery systems to ensure site-specific 
accumulation and cancer-specific transfection through both passive and active targeting.2 As illustrated in 
Figure 2-6, small nanoparticles (or polyplexes) with neutral surface charge and steric hindrance can circulate for 
extended periods of time and accumulate near tumor sites through the enhanced permeation and retention 
(EPR) effect.  In addition, polymeric biomaterials, with or without targeting ligands, can induce tissue-specific 
accumulation and cell-specific uptake.  Finally, nucleic acid engineering can enable cell type-specific 
transcription and translation. 
This review highlights advances to improve the targeted delivery of therapeutic nucleic acids through 
the utilization of polymeric nanoparticle vectors. The presented nanoparticles are able to specifically target and 






Figure 2-6. Overall scheme of gene delivery to cancer cells using targeted polymeric nanoparticles. Three broad 
categories of targeting include biophysical targeting, ligand-mediated targeting, and transcriptional targeting. 
 
 






Intrinsic physicochemical characteristics of polymeric nanoparticles can facilitate tumor targeting. 
Characteristics such as particle size, surface charge, and chemical functional groups exposed on a biomaterial’s 
surface can either drive cellular uptake or block cellular interaction.  In some cases, biomaterial composition 
can dictate tumor specificity in the absence of known ligands.  Technology that enables passive targeting to 




  One of the most widely utilized mechanisms of passive targeting is based on size. The enhanced 
permeation and retention (EPR) effect, or leaky vasculature and a lack of lymphatic drainage around a tumor 
mass, allows for nanoparticles of less than 500 nm to accumulate in the regions of tumor vasculature.8, 9 Larger 
nanoparticles are usually eliminated from the body by the reticuloendothelial system (RES) or trapped in the 
lungs, while nanoparticles with hydrodynamic diameters smaller than 5 nm are rapidly excreted by the kidneys. 
To prevent particle aggregation and maintain the effective size for the EPR effect, nanoparticles are often 
coated with hydrophilic molecules, such as poly(ethylene glycol) (PEG) that provide neutral surface charge and 
steric hindrance.10-13  
Many polymeric nanoparticles for gene delivery are formed through electrostatic interactions between 
positively charged cationic polymers and negatively charged anionic DNA. The net balance of these charges 
determines a nanoparticle’s surface charge, which is one of its key biophysical properties. A positively charged 
nanoparticle surface interacts with negative charges on the cellular membrane and promotes cellular uptake.14 
In addition, non-specific adsorption of anionic serum proteins on to positively charged surfaces of 
nanoparticles changes the surface properties of nanoparticles. In some cases, these interactions have the 
potential to induce receptor-mediated endocytosis.15-17 Other studies have shown that adsorbed serum proteins 
can reduce cellular uptake.18 Moreover, these non-specific protein interactions can induce particle aggregation 
and opsonization, thereby shortening systemic circulation and reducing the EPR effect and cancer targeting 
potential.  
To prevent undesirable particle-serum interactions, various methods have been explored to shield the 
surface of polymeric nanoparticles with biomolecules. One common strategy is the utilization of neutrally 
charged PEG molecules as previously discussed.  Researchers have also made stimuli-responsive versions of 
PEG coatings that aid in tumor targeting. For example, with a stimuli-responsive linker, such as 
metalloproteinase-cleavable linker, PEG can detach from a nanoparticle surface, restore a positive nanoparticle 
surface charge in close proximity to cancer cells, and better interact with these target cells.19 Other approaches 





poly(ι-histidine), and hyaluronic acid (HA) to coat positively charged nanoparticle surfaces, promote colloidal 





 Many biomaterials have been investigated as polymeric vectors capable of delivering genetic cargo to 
cells of interest. Polymers used for gene delivery include polypeptides (i.e. poly(L-lysine)), natural polymers (i.e. 
chitosan, dextran, and HA), and synthetic polymers (i.e. polyethylenimine (PEI), polyamidoamine (PAMAM) 
and poly(β-amino ester) (PBAE)).26-41 Interestingly, some of these polymers have shown a bias for transfecting 
one cell type over another, indicating that they can enable tissue- or cell-specificity without an active targeting 
modification.  
 Tissue-targeting and biodistribution of polymeric nanoparticles is one of the key elements of 
pharmacokinetics in systemic delivery. Polymeric nanoparticles can demonstrate an intrinsic tendency to 
accumulate in particular organs or tissues. For example, dextran sulfate is able to bind to more receptors on 
liver sinusoidal endothelial cells than hyaluronic acid, and thus accumulates more in liver.42 Biodistribution of 
PEI nanoparticles varies depending on the molecular weight, the structure of the polymer, and the polymer 
amine to DNA phosphate (N/P) ratio.43 Polymer coatings can also generate tissue specificity as work by Harris 
et al. showed that PBAE nanoparticles coated with anionic poly(glutamic acid)-based peptides demonstrated 
changes in biophysical properties and tissue-specificity to spleen and bone marrow (Fig. 2-7A).44 Such tissue 
specificity of biomaterials could potentially be utilized to target tumors as well. 
Biomaterial-mediated targeting to specific cell-types has been demonstrated with PBAE polymeric 
nanoparticles. The physicochemical properties of PBAE nanoparticles can be tuned by the monomer 
composition used in the synthesis of the constituent polymers, and structure-function relationships have been 
extensively investigated.45-47 For example, specific PBAE structures have significant specificity of transfecting 
cancer cells over their healthy counterparts as shown in Fig. 2-7B/C. PBAE nanoparticles show an order of 
magnitude higher transfection efficacy at transfecting human primary brain tumor initiating cells (BTICs) over 
primary fetal neural progenitor cells (fNPCs) and similarly at transfecting hepatoma cells over hepatocytes.41, 48 
The authors also showed that the total uptake of nanoparticles as well as the division rate of cells were similar 
between BTICs and fNPCs from multiple primary samples, indicating that other factors are the major 
contributors of the biomaterial-mediated specificity. This research highlights that differential biomaterial-cell 
interactions can occur in cancer cells as compared to healthy cells and can enable gene delivery specific to 
cancer cells. Further research is needed in this area of drug delivery to elucidate the mechanisms responsible 







Figure 2-7. Biomaterial-mediated tissue- and cell-specificity of nanoparticles. (A) Accumulation of PBAE 
nanoparticles coated with poly(glutamic acid) chain terminating with additional cationic amino acid residues in 
spleen and bone marrow. (B) selective PBAE transfection of brain tumor initiating cells over fetal neural stem 
cells in vivo (Delivery of dsRed to BTIC labeled with GFP; Only Nanoparticles is a control group with 
nanoparticles but no tumor) and of (C) hepatoma cells over hepatocytes in separate cultures (left) and in co-
culture (right). Reprinted with permission from Elsevier: Biomaterials. 2010, 31, 998-1006, American Chemical 
Society: ACS Nano. 2014, 8(5), 5141-53, and John Wiley and Sons: Journal of Biomedical Materials Research. 2013, 











 The most well studied method to target cancer cells with polymeric nanoparticles is through the use of 
ligands conjugated to the surface of nanoparticles. Cancer results in the dysregulation of a large number of 
genes including many cell surface receptors, whose upregulation can be exploited for targeting via specific 
ligands. Transferrin49-56, folate57, 58, epidermal growth factor59, 60, RGD61, 62 and other peptides, hyaluronic acid63, 
64 and specific carbohydrates have been utilized as targeting moieties for selective polymeric nanoparticle 
delivery to tumor cells. Additionally, antibodies65, 66 and antibody fragments67 have been utilized to target cancer 
specific antigens such as the HER2 receptor and prostate specific antigen. Many of the targeting moieties used 
for polymeric gene delivery to treat cancer have been previously utilized for the delivery of chemotherapeutics 
and in targeting of liposomes for gene delivery.68, 69 Among factors affecting whether conjugation of targeting 
ligands improves transfection efficiency are ligand density58 and ligand binding affinity52, 70 as well as effect on 
zeta potential and nanoparticle stability.58, 61, 63 Ligand density can increase cooperative binding and avidity to 




Transferrin (Tf), an 80 kDa glycoprotein, has been conjugated to nanoparticles containing poly(L-
lysine) (PLL49), PEI50, 71, cyclodextrin52, and PAMAM54 to improve targeting to tumor cells overexpressing the 
Tf-receptor. Conjugation of transferrin to the surface of PEI and PEI-PEG nanoparticles for plasmid delivery 
has been shown to clearly improve tumor targeting and reduce off-target transfection as shown in Figure 2-8.51 
Importantly, conjugation of Tf to the PEI-PEG nanoparticles was shown to improve tumor cell transfection 
at 48 hours, thus Tf was thought to improve the number of plasmids that reached each transfected cell.51 These 
Tf coated PEG-PEI nanoparticles were shown to transfect distant tumor cells in vivo 10-100 times greater 
compared to non-tumor cells following intravenous injection.50, 71 Transferrin has continued to be used in many 
nanoparticle formulations, notably as a component of cyclodextrin-PEG-Tf nanoparticles (CALAA-01) having 








Figure 2-8. Conjugation of transferrin to PEI and PEI-PEG for xenograft tumor targeting was shown to 
clearly improve tumor transfection at 48 hours and reduce off-target transfection in mice following tail vein 
injection using the reporter gene luciferase and bioluminescent imaging. Reprinted by permission from Nature 
Publishing Group: Gene Therapy. 2003, 10, 758-764, copyright 2003.51 
 
Folic Acid (FA) 
 
Receptors for folate or folic acid (FA) are upregulated in rapidly dividing cell types, including tumor 
cells, and were proposed as an early target for drug delivery to cancer cells.72 For gene delivery, folate has been 
used to target bPEI-PEG nanoparticles for improved uptake and tranfection with a reporter gene by folate 
receptor expressing cells both in vitro and in vivo.57 Folate targeting for these nanoparticles was shown to improve 
transfection with minicircle DNA by approximately 3.6 fold in vivo although broad transfection was seen as 
folate receptors are expressed on the surface of most proliferating cells.57 In another study, folic acid was 
notably shown to be the most effective targeting ligand to cancer cells among 30 (primarily peptides) ligand 





shown to be effective for ~60% knockdown of a reporter luciferase gene in a xenograft tumor model in vivo 
following IV administration.58 
 
Epidermal growth factor (EGF) 
 
The epidermal growth factor receptor (EGFR) is a common molecular target for cancer therapy 
overexpressed in approximately 30% of solid tumors in addition to being a predictor of poor treatment 
outcome.73 EGF was conjugated to PEI-PEG as early as 2001 for improved transfection measured to be 
between 10-100 times greater than untargeted nanoparticle in vitro.59 Since then, synthetic peptides designed to 
target the EGFR, including GE11, have been conjugated to linear PEI-PEG nanoparticles for the delivery of 
plasmids coding for a sodium iodine symporter gene for treatment of liver cancer.60 These EGFR targeted 
polymeric nanoparticles were shown to improve tumor specific transfection compared to non-targeted 
nanoparticles and increased survival demonstrating the potential efficacy of targeting ligands.60 
 
RGD peptide  
 
The RGD peptide (arginine, glycine, aspartic acid) and other oligopeptide variations have been shown 
to strongly target the αvβ3 integrin receptor that is selectively expressed in tumor vasculature, with weaker 
binding to many other integrin receptors for improved cellular uptake.70 Conjugation of RGD peptide and 
cyclic-RGD peptide to nanoparticles for targeted delivery of plasmids to tumor cells has also been shown to 
improve transfection in vivo one day following IV administration in mice, although there were notably near 
equal increases in transfection of cells in the lungs and liver.62 The bPEI based nanoparticles for plasmid 
delivery Sakae et al designed utilized an anionic version of PEG having conjugated succinic acid residues, PEG-
suc, and RGD peptide, both of which increased transfection efficiency.62 RGD peptide has also been 
electrostatically attached to PBAE nanoparticles for the delivery of DNA and shown to improve transfection 
of cells overexpressing integrin receptors but was not specifically applied to targeting tumor cells.61 
 
Hyaluronic acid (HA) 
 
The CD44 cell receptor for hyaluronic acid is often overexpressed on tumor cells and is under active 
investigation for its putative role in cancer initiation/stem cells.74 As a targeting moiety, HA can greatly affect 
zeta potential of the nanoparticles created depending on the amount used due to its negative charge at 
physiological pH.63 Zwitterionic nanoparticles composed only of hyaluronic acid-bPEI in varying ratios have 





specifically, they could be adapted for this purpose based on the use of HA in targeted delivery of 




Antibodies can be used as efficient and specific targeting moieties for tumors expressing a tumor 
specific antigen such as HER265 or prostate specific antigen.66 The conjugation of HER2 antibodies to PEI for 
the delivery of DNA was shown to improve transfection of HER2+ breast cancer cell lines in vitro 20-fold.65 
Antibodies for prostate specific membrane antigen have also been used to target PEI/DNA nanoparticles to 
prostate cancer cells in vivo with 20-fold improvement over non-targeted nanoparticles.66 Antibody fragments 
have also been used to target cancer cells; specifically, a fusion protein composed of HER2 single-chain 
fragmented antibodies and a cationic polypeptide for the delivery of siRNA to HER2+ breast cancer cells was 
shown to improve tumor targeting and reduce metastasis in vivo following multiple weekly tail vein injection.67 
Although antibodies can bind with high affinity, the use of monoclonal antibodies and antibody fragments as 
targeting ligands can be significantly more expensive than other cell receptor ligands and are not necessarily 
more effective. Antibody use for targeting of therapeutics has increased dramatically yet with high associated 




For the case of DNA delivery, biological targeting of cancer cells can also be achieved following 
intracellular nanoparticle delivery. Although polymer, nanoparticle, and ligand properties are key to bind to 
target cells and lead to internalization by target cells, delivered DNA can be engineered to impart further cancer 
targeting on the intracellular level.  To further constrain therapeutic transgene expression to just targeted cancer 
cells, and obviate undesirable effects associated with expression in healthy cells, transcriptional targeting can be 
utilized.  Transcriptional targeting can be achieved by restricting the expression of transgenes to only tumors 
or particular tissues through the use of specific promoters.76 
 
Transcriptional Control of Gene Expression 
 
In eukaryotes, the transcription of protein-coding genes involves the interaction between RNA 
polymerase II, cis-regulatory DNA elements, transcription factors, co-factors and chromatin structure.77, 78 Cis-
regulatory DNA elements refer to promoters and distal regulatory sequences that contain recognition sites for 





site of a gene79 and comprise a core promoter and proximal regulatory elements.78 The binding of RNA 
polymerase II to the core promoter, which initiates transcription, requires general (basal) transcription factors.80 
Together, RNA polymerase II and general transcription factors form the preinitiation complex (PIC)81, which 
provides only basal levels of transcription.82 This basal machinery activity can be increased by the binding of 
other set of proteins, site-specific transcription factors, to the proximal and distal regulatory elements.79, 82 In 
contrast to the ubiquitous expression of general transcription factors, site-specific transcription factors are 
expressed in a spatiotemporal and/or condition-specific manner. This tight regulation is critical in determining 
where and to what extent a given gene is expressed.83, 84 Accordingly, a gene of interest will be expressed only 
in cells containing sufficient levels of the transcription factors involved in activating transcription from the 
promoter located upstream from this gene.76  
The regulation provided by the coordinated interaction between transcription factors is the primary 
mean by which cells orchestrate gene expression in response to various stimuli.85 Thus, the cis-regulatory 
elements that recruit these factors can be used and tailored to drive transcription of an exogenously delivered 
therapeutic gene in a tissue- or tumor-specific manner.85, 86 
It is important to highlight that the transcriptional targeting strategy for gene therapy relies on the 
accurate delivery of DNA to the cells of interest, i.e., the gene under control of a specific promoter must reach 
the cells containing the right transcriptional factors; otherwise no transcription occurs. Thus, the efficiency of 
the control at the transcriptional level is highly dependent on other levels of targeting, i.e. delivery to specific 
cells. Moreover, cell surface binding, endosomal escape, translocation to the nucleus, and nucleic acid release 
also represent barriers that have to be overcome in order to a gene reaches the transcription machinery.87 
 




The application of tissue-specific promoters in transcriptional targeting exploits genes that are 
specifically expressed in a tissue of interest.86 If a particular promoter is active in certain healthy tissues in 
addition to tumor cells, then the ability for cancer targeting is reduced. One of the first tissue-specific promoters 
evaluated for transcriptional targeting in cancer gene therapy was the promoter for the tyrosinase gene, which 
is preferentially active in melanocytes.89 In 1993, Vile et al. showed that this promoter can drive expression of a 
reporter gene to both human and murine melanoma cells and melanocytes, but not to a range of other cell 
types.89 Since then, the tyrosinase promoter has been extensively applied in the research of gene therapy for 
melanoma.90-92 Similarly, in the past two decades, candidates of prostate specificity, such as prostate-specific 





Tissue-specific promoters have also been applied to drive siRNA expression in target cells. Song et al. 
demonstrated that the siRNA expression driven by the prostate-specific antigen (PSA) promoter can lead to 
gene silencing specifically in the androgen-responsive prostate cancer cell line, in an androgen-dependent and 




Tumor-specific promoters are involved in the transcription of genes that are overexpressed in tumor 
cells but have limited or no activity in normal cells.86 Cancer-specific promoters can be specific to a particular 
cancer type85 or general to many types of cancer without  a particular tissue specificity.88, 97 The progression-
elevated gene-3 (PEG-3)98, for example, was identified as a mutant gene overexpressed during tumorigenesis of 
different cancer types that presents tumor progression promoting properties. The PEG-3 promoter was shown 
to drive cancer-specific gene expression and cell killing, while sparing normal cells.98, 99 Applying in vivo jetPEI 
(Polyplus transfection) as a vector for intravenous administration, Hyo-eun et al. successfully demonstrated 
PEG-3 promoter-driven firefly luciferase expression (PEG-Luc) specifically to small metastatic deposits of 
human melanoma and breast cancer in mouse models (Figure 2-9).100 Other relevant cancer-specific promoters 







Figure 2-9. Transcriptionally mediated targeting of gene expression. (A) Bioluminescence imaging showing 
cancer-specific expression of firefly luciferase gene in a representative of the metastatic melanoma group (Mel-
3) and no expression in a healthy control mouse (Ctrl-2). (B) Computed tomography imaging and gross 
anatomical views of the lung from a healthy control mouse (Ctrl-2) and one representative of the metastatic 
melanoma group (Mel-2). Black arrows are pointing toward the metastatic nodules in the lung. Scale bars: 5 
mm. (C) Quantification of bioluminescence imaging signal intensity in the control group (Ctrl) and metastatic 
melanoma group at 24 and 48 h following i.v. administration of the pPEG-Luc–PEI polyplex. Quantified values 
are shown in total flux. ***P < 0.0001. Reprinted with permission from Nature Publishing Group: Nat 








Tumor-selective promoters can take advantage of fetal genes that become re-expressed in certain 
malignancies88, 97, such as the promoters of the oncofetal α-fetoprotein (AFP) and carcinoembryonal antigen 
(CEA) genes, reactivated in hepatocellular carcinomas (HCC) and adenocarcinomas, respectively.86 Hu et al. 
used a construct with the fragment EA4D of the AFP promoter and a novel polymeric delivery system to 
induce cell killing mediated by tBid overexpression only in AFP-producing HCC.108 Other tumor-selective 
promoters are also able to induce gene expression only in particular cancer types. Huang et al. tested PBAE-
mediated delivery of a construct containing the diphtheria toxin suicide protein (DT-A) gene under control of 
two promoters of genes that are highly active in ovarian tumors, MSLN and HE4.109 The authors observed 
suppression of ovarian tumor growth following intraperitoneal (i.p.) injection of particles twice a week, while 
minimal nonspecific toxicity was observed in other tissues. Other groups have also explored promoters of genes 
whose activity is related to additional cancer hallmarks85, 86, 88, 97, such as the hypoxic tumor environment110, the 
proliferating endothelium of tumor blood vessels111, the altered signaling pathways112, and the cell-cycle 




In contrast to tissue/tumor-specific promoters, which usually induce constitutive transgene expression 
in a target tissue86, inducible promoters can be applied to achieve temporal, spatial and dose-dependent 
regulation.114, 115 These promoters can be regulated by agents such as drugs, radiation and heat.97 An example 
of such a promoter is the early growth response gene-1 (Egr-1) promoter, which is radiation-induced and has 
been used to optimize the control of gene expression in different tissues.116-120 
Inducible promoters essentially drive ubiquitous transgene expression121, however, tissue/tumor-
specific and inducible promoters can be combined to enable the control of transgene expression in a 
tissue/tumor specific and inducible manner.121, 122 Recently, Xiong et al.118 successfully combined the hTERT 
promoter to CArG elements, which is known to be the radiation-responsive motifs within 
the Egr1 promoter123-125, to drive radiation-inducible and cancer-specific gene expression. The synthetic 






Design of stronger promoters 
 
As shown in some of the examples described above, a composite promoter can be engineered by 
incorporating different functional elements from natural promoters.85 These strategies aim to optimize the 
natural promoter systems and to overcome the generally weak transcriptional activity of eukaryotic promoters, 




Controlled expression of factors encoded by exogenously delivered DNA can also be targeted to cancer 
cells by post-transcriptional targeting.  The expression of transgenes can be regulated post-transcriptionally by 




RNA splicing consists of the removal of introns and coupling of exons from the pre-mRNA transcripts 
to form mRNA before its transport to the cytoplasm.127 The variation of the splicing sites within a transcript, 
called alternative RNA splicing, generates multiple mRNA isoforms in different cell types, tissues, or stages of 
development.128 Changes in alternative RNA splicing are commonly observed in malignancies.127, 129 The 
alternative RNA splicing events involved on the expression of the CD44 gene, for example, generate mRNA 
isoforms called CD44R1, which exists on activated and/or malignant cell types. Only CD44R1-positive cells 
contain the necessary machinery to accurately splice a particular intron within the CD44 pre-mRNA. Hayes et 
al. observed that constructs in which the expression of a transgene is dependent upon removal of this intron 
from the sequence can be used to specifically target CD44R1-positive cells.129  
 
RNA stability  
 
The stability of mRNA molecules and their decay rates are determined by regulatory elements within 
the mRNA sequence and proteins or small non-coding RNAs that bind these elements.130 The post-
transcriptional regulation mechanism by which small non-coding RNAs interact with specific mRNAs and 
induce selective gene silencing is called RNA interference (RNAi).130, 131  siRNAs  perform RNAi by degrading 
mRNAs containing fully complementary sequences and by translation repression.132, 133 siRNA-mediated 





(e.g. Bax135 and Bcl-2136) and cell signaling (e.g. K-Ras137), and to knockdown viral oncogenes (e.g. HPV E6138). 
Recently, Urban-Klein et al. demonstrated significant growth inhibition following siRNA-mediated silencing of 
the HER-2 proto-oncogene139, which is overexpressed in a variety of human cancers and related with 
unfavorable prognosis.140 Micro RNA (miRNA) delivery for tumor targeting can cause inhibition of oncogenic 
nucleic acids.141 miR-34 and let-7 are tumor-suppressor miRNAs141 with reduced expression levels in many types 
of cancer cells.142, 143 Replacement therapy with miR-34 has been shown to successfully induce apoptosis in 
cancer cell lines144 while let-7 replacement can inhibit tumor grow.145 On the other hand, the knockdown of 
miR-155, overexpressed in many solid malignancies, has demonstrated to inhibit tumor growth, migration and 
invasion.146 Short hairpin RNAs (shRNA), which are transcribed in the nucleus, can be effective to target cancer 
cells when under control of efficient promoters.147 Gao et al. demonstrated silencing of an oncogene 
serine/threonine kinase specifically in hepatoma cells by shRNA under control of AFP promoter/hypoxia-
inducible enhancer.148 
 
RNA translation  
 
The translation initiation process consists of the recruitment and assembling of the initiator tRNA and 
the 40S and 60S ribosomal subunits at the start codon of the mRNA molecule.149 Excessive secondary 
structures in the 5′ untranslated region (UTR) of the mRNA are normally inefficiently translated.149-153 However, 
overexpression of the eIF4E factor, a rate-limiting component of translation initiation, results in a specific 
increase in the translation of highly structured 5′ UTR mRNAs.149, 154, 155 eIF4E is commonly overexpressed in 
solid tumors155 and many of the mRNAs with excessive secondary structures encode products that stimulate 
cell growth and angiogenesis155 (e.g.: fibroblast growth factor-2; FGF-2155, 156). DeFatta et al. found that the 5′ 
UTR of FGF-2 mRNA can be placed in front of the herpes simplex virus type 1 thymidine kinase (HTK) gene 
to restrict the translation of HTK mRNA and, therefore, the susceptibility of the prodrug ganciclovir, to cancer 
cells.155  
 
Other targeting strategies that can be utilized in polymeric nanoparticle-mediated cancer gene therapy  
 
The choice of the gene product to be expressed itself can introduce another level of tumor specificity 
for cancer gene therapy. Polymeric gene therapy can be used to restore function of tumor suppressor genes 
that have been inactivated during tumorigenesis, such as p53, by reintroducing the wild type gene into tumor 
cells.157, 158 The delivery of constructs encoding the TNF-related apoptosis-inducing ligand (TRAIL) gene 





in cancer cells.159 This cancer specificity involves enhanced activity of pro-apoptotic receptors (DR4 and DR5) 
in tumor cells and apoptotic priming of cancer cells by oncogenes.160 
An alternative method of active tumor targeting can be achieved by the capacity of mesenchymal stem 
cells (MSCs), such as the human adipose–derived MSCs (hAMSCs), to migrate towards tumors.161-163 MSCs can 
be used as a cell-based therapeutic delivery vehicle following gene delivery with DNA-encoded anti-cancer 
molecules.  For example, MSCs can be engineered with genes that encode differentiation agents such as bone 
morphogenetic protein-4 (BMP-4), which promotes the terminal differentiation of putative cancer stem cells 
(CSCs) and facilitates tumor eradication.164-166 This MSC plus gene therapy approach has proven to be useful 





The translation of polymeric gene delivery nanoparticles for cancer treatment has proved challenging 
and few polymeric nanoparticle formulations have yet made it to clinical trials. Table 1-1 lists selected polymeric 
nanoparticles used in clinical trials.  Phase I/II clinical trials listed in Table 1-1 were designed to evaluate safety, 
dose-response pharmacodynamics, dose-dependent accumulation of nanoparticles in tumor tissue, and show a 
signal of efficacy. The cyclodextrin-PEG-Tf nanoparticle formulation, termed CALAA-01, for the delivery of 
anti-RRM2 siRNA was notable for the first evidence of RNA interference in humans following systemic 
delivery in a Phase I trial.56 Multiple clinical trials have been undertaken using the PEI delivery system for 
diphtheria-toxin A termed BC-819 and developed by BioCancell Ltd.168 Other PEI based nanoparticle 
formulations have utilized glycosylated JetPEI169  and PEG-PEI-cholesterol.170 The genes chosen for delivery 
included DCK::UMK to increase chemosensitivity of tumor cells to gemcitabine, SSTR2 to inhibit tumor cell 
proliferation as well as IL-12 to induce anticancer activity from the patient’s immune system.169 PEI has also 
been evalauted in a clinical trial for the dual delivery of siRNA and plasmid DNA for treating a number of 
hematopoietic cancers.171 These phase I/II trials are notable for demonstrating RNAi and delivery of plasmid 
DNA using polymeric vectors, as well as preliminary clinical evidence of gene therapy efficacy in preventing 






































































































































Table 2-1. Examples of cancer gene delivery using polymeric nanoparticles in clinical trials. Reprinted with 
permission from Nature Publishing Group: Nature Reviews Genetics. 2014, 15(8), 541–555, copyright 2014.172 
Conclusion and Future Prospects 
 
Targeted polymeric gene delivery for cancer therapy has made advances through rational engineering 
of biomaterials, utilization of targeting ligands, and engineering of nucleic acids for transcriptional and 
translational regulation. In some ways, targeted gene therapy has followed similar improvements to delivery as 
nanoparticle-based chemotherapeutic formulations. Cancer is a disease well-suited for nanoparticle-based gene 
delivery strategies due to the multiple levels of targeting that can specifically treat cancer cells over health cells.  
These include opportunities for passive targeting via the EPR effect and active ligand targeting due to the 
changes in expression patterns of many cancer cell receptors. Polymeric nanoparticles can be readily engineered 
with active targeting moieties on their surfaces and produced on the scales required for pharmaceutical 
applications. Selection of biomaterials through broad polymer library screens and rational polymer engineering 
design have both been utilized to improve tissue and tumor cell specificity as well improve transfection efficacy. 
Furthermore, polymer structures can be readily modified with PEG and other biomolecules for charge shielding 
and to improve tumor cell specificity and transfection in vivo.  Compared to nanoparticle chemotherapeutic 
formulations, gene therapy possesses the additional level of targeting afforded in transcriptional and 
translational control for even greater reduction in off-target effects and potential reduction of side effects during 
treatment. Systemic delivery and tissue targeting improvements through charge shielding and targeting moieties 
will continue improve efficacy for intravenous administration. Improvements to nanoparticle stability in blood 
serum and reduction of alternative complement pathway activation for increased circulation time are also 
important aspects for improved systemic polymeric gene delivery. Although PEG is often used as a moiety to 
improve the stealth nature of nanoparticles, depending on how it is utilized, it may not be devoid of complement 
activation and can lead to hypersensitivity reactions.173 Targeting at the cellular level can be improved by 
identification of receptors and ligands that lead to improved uptake, delivery to the cytoplasm, and intracellular 
trafficking leading to efficient transfection. Increased understanding of endocytosis and resulting endosome 
trafficking pathways will lead to more rational design of targeting moieties for improved intracellular delivery. 
Additionally, determination of differences in transfection between tumor cells and healthy cells following equal 
levels of nanoparticle uptake will allow improved design of nanoparticles.  
Tissue- and tumor-specific promoters for transcriptional targeting and RNAi for gene knockdown 
have become key elements of non-viral gene therapy for cancer. Ongoing research will improve understanding 
of cancer cell-selective gene activity and enable the recognition of more potent regulatory components to drive 
cancer cell-specific gene expression and silencing. For the most effective cancer cell targeting, these orthogonal 





Polymeric nanoparticle based cancer gene therapy is still in its infancy at the clinical level but has great 
potential for the future. Compared to gene therapies utilizing viral vectors, polymeric nanoparticle based 
approaches to gene therapy have lagged in transfection efficacy but have improved safety, lower risks of 
immunogenicity and tumorigenesis, improved manufacturing and quality control, improved targeting 
capabilities, and much greater nucleic acid carrying capacity. With advances in transfection efficacy and tumor 
specificity through multiple targeting strategies, polymeric nanoparticle-based gene therapy has a bright future. 
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Polymeric Vector Nucleic Acid in vivo Animal Model Method of Targeting Results / Efficacy Ref. 
Biophysical (EPR)      
PEI DNA A/J mice with s.c. Neuro 2A tumor PEGylation 
Reduced plasma protein binding, prolonged 
circulation, tumor accumulation 1999
12 
PEI DNA (GM-CSF) 




Prevented aggregation, more concentrated particles via 




    
PEI DNA (IL-2) ICR mice 
Molecular weight 
and N/P ratio of 
PEI 
Longest half-life with bPEI 25kDa (10:1), different 
tissue accumulations depending on MW and N/P ratio 200743 
PBAE DNA Athymic mice with JHGBM-276 cells PBAE Structure 
PBAE structure 447 transfected in cell-specific 
manner: brain tumor initiating cells over fetal neural 
stem cells 
201441 
Ligand-mediated      
PEI-PEG-Tf 
DNA 
(Luc) A/J mice with human hepatoma Transferrin 
Transferrin ligand conjugation improved tumor 








(anti-RRM2) FDA phase I clinical trial Transferrin 














EGFR-specific peptide GE11 targeted delivery of NIS 




Oligonucleotide siRNA (anti-Luc) 
BALB/c nude mice with 
Luc-KB carcinoma Folic Acid 
FA conjugated oligonucleotide origami nanoparticles 










RGD ligand improved delivery to mouse melanoma 
tumor with following IV administration 
2008  
62 









Reduction of tumor metastasis for HER2+ breast 
cancer xenograft following weekly IV administration 
2012  
67 
Transcription-level      
in vivo-jetPEI* DNA       (PEG-Luc) 
Human melanoma or 
breast cancer metastasis 
Cancer-specific 
promoter 
PEG-3 promoter drive expression of Luc reporter 







Table 2-2. Examples of targeted polymeric nanoparticles with different targeting mechanism
model in 






BALB/C athymic mice 
with s.c. AFP-producing 
or non-producing HCC 
Tumor-selective 
promoter 
Cell killing and tumor growth inhibition only in AFP-





(MSLN or  
HE4/DT-A) 
Foxn1nu/Foxn1+ mice 




Suppressed tumor growth in ovarian carcinoma while 
little nonspecific toxicity occurs in other tissues after 
i.p. injection 
2009 109 
      
Post-transcription   
PEI siRNA (anti-HER-2) 
Athymic nude (nu/nu) 
mice with s.c. ovarian 
carcinoma 
Regulation at the 
RNA stability level  
Significant growth inhibition following intraperitoneal 
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Abstract: There is a need for new tools to better quantify intracellular delivery barriers in high-throughput 
and high-content ways. Here, we synthesized a triple-fluorophore labeled nucleic acid pH nanosensor for 
measuring intracellular pH of exogenous DNA at specific time-points in a high-throughput manner by flow 
cytometry following non-viral transfection. By including two pH-sensitive fluorophores and one pH-
insensitive fluorophore in the nanosensor, detection of pH was possible over the full physiological range. We 
further assessed possible correlation between intracellular pH of delivered DNA, cellular uptake of DNA, and 
DNA reporter gene expression at 24-hours post-transfection for poly-L-lysine and branched 
polyethylenimine polyplex nanoparticles. While successful transfection was shown to clearly depend on 
median cellular pH of delivered DNA at the cell population level, surprisingly, on an individual cell basis, 
there was no significant correlation between intracellular pH and transfection efficacy. To our knowledge, this 
is the first reported instance of high throughput single-cell analysis between cellular uptake of DNA, 





demonstrate that the ability of polymeric nanoparticles to avoid an acidic environment is necessary, but not 
sufficient for successful transfection. 
 
Keywords: polymeric nanoparticles, non-viral gene delivery, pH sensor, proton sponge 
 
Introduction: 
 Non-viral gene delivery has great promise in clinical applications such as for cancer therapy where 
transient expression can be sufficient to result in clinical efficacy.1 Compared to DNA based viral gene 
therapy, non-viral delivery methods are more amenable to repeat administration due to reduced risk of 
immunogenicity and insertional mutagenesis, but remain less efficient than viral delivery methods.1, 2 Despite 
extensive progress in the previous decade, many challenges in engineering successful non-viral gene delivery 
platforms remain.1, 3 Polymeric gene delivery in particular has made extensive progress towards increased 
performance through rational engineering of polymer structures as well as screening of broad libraries of 
polymer structures, but new quantitative bioassays are required to fully understand the mechanisms by which 
existing nanoparticles achieve transfection.4-11 
 Barriers to successful polymeric gene delivery at the level of individual cells include cellular 
internalization, endosomal escape, nucleic acid unpacking, and nuclear transport.12, 13 Of these barriers, 
overcoming endosomal escape has been specifically identified as a critical rate-limiting step in polycation 
nanoparticle mediated transfection as generally only a minor fraction of endocytosed polyplexes manage to 
escape to the cytoplasm.14 Non-endolysosomal trafficking that does not require endosomal escape, but 
enables nuclear entry through the endoplasmic reticulum, has been shown to occur for certain 
nanoparticulates, such as specific histone targeted nanoparticles, but has not been demonstrated for the 
majority of nanoparticle formulations.15, 16 The presence of intracellularly delivered nucleic acid at an acidic 
pH indicates that the nucleic acid is not in the cytoplasm and is not in the environment required for 
successful gene expression.  Failure to escape the endosome to the cytoplasm can result in nucleic acid 
degradation when the early endosome transitions to a late endosome/lysosome, typically within an hour 
following uptake.17 The shift from early endocytic vesicle to late endosome and eventually lysosome results 
from fusion of the early endosome with other vesicles. The latter contain hydrogen pump V-ATPases and 
digestive enzymes which result in acidification and degradation of the nucleic acid contents of polymeric 
nanoparticles.17, 18 
 To escape the endosome and avoid lysosomal degradation, polymeric nanoparticles have been designed 
specifically either with moieties that facilitate membrane pore formation or amine groups designed to enable 
them to buffer vesicle acidification and consequently escape the endosome via the hypothesized proton 





been engineered to take advantage of endosome acidification as a means to protect their nucleic acid cargo 
and enable endosomal escape.19 Despite extensive study in the two decades since the first use of bPEI, the 
mechanism of endosomal escape for cationic nanoparticles is still not universally agreed upon.19-27 The ability 
of the cationic polymers containing tertiary amines to effectively buffer in the physiological pH range 
between 5-7 has been demonstrated in multiple settings8, 9, 28, yet improved buffering capacity at low, 
physiologically relevant pH has been shown to not always result in more effective transfection.23 As a means 
of studying this mechanism universally among cell types and polymer systems, we sought to create an 
intracellular pH sensor for probing the mean compartmental pH environment of exogenously delivered DNA 
in individual cells and to design this sensor to be readable in a high throughput manner by flow cytometry.  
 Approaches to single cell and single compartment pH measurements have previously utilized 
fluorescence. A ratiometric, fluorophore-based assay utilizing a pH sensitive fluorophore and a pH insensitive 
reference fluorophore was reported by Murphy et al. using FITC and RITC to measure endosomal pH over 
time following insulin internalization.29 Similar assays have been utilized to measure endosomal pH by 
fluorophore labeling polymeric gene delivery vectors or plasmid DNA.22, 30, 31 More sensitive ratiometric pH 
probes have recently been developed for non-gene delivery applications using fluorescent polymers and have 
shown the importance of using multiple pH-sensitive fluorophores to effectively probe the lysosomal pH 
range.32, 33  
 Specifically for gene delivery applications, we aimed to investigate the local pH of the exogenously 
delivered DNA, not the local pH of delivery polymers that may dissociate from the DNA. Here we report a 
triple fluorophore-labeled plasmid DNA based pH nanosensor with improved sensitivity at lysosomal pH 
used for probing cellular pH of exogenously delivered DNA to individual cells and cell populations following 
polymeric gene delivery. This ratiometric pH nanosensor enabled an investigation of endosomal buffering 
following polymeric gene delivery in a high throughput manner by flow cytometry. Average pH of the nucleic 
acid pH nanosensor was monitored at specific time points within individual cells to quantify trends between 
cellular uptake of DNA, local pH environment of delivered DNA, and successful expression of the DNA in 
both easy-to-transfect and hard-to-transfect cell lines using bPEI and poly-L-lysine (PLL). 
 
Methods: 
Materials. Branched polyethylenimine 25 kDa (bPEI) (408727), Poly-L-Lysine sodium chloride 15-30 kDa 
(PLL) (P2658), buffer salts and organic solvents were purchased from Sigma Aldrich (St. Louis, MO). 
Succinimidyl-[4-(psoralen-8-yloxy)]-butyrate (NHS-psoralen) (23013), Oregon green cadaverine (O10465) and 
fluorescein cadaverine (A10466) were purchased from Thermofisher (Halethorpe, MD). Cy5-amine (230C0) 
was purchased from Lumiprobe (Hallandale Beach, FL). All fluorophores were dissolved in DMSO at a 





Cambridge, MA) was used for construction of the pH nanosensor, while peGFP-N1 (Addgene 2491) was 
used for initial transfection efficacy screens. 
 
Nucleic Acid pH Nanosensor Synthesis. DsRed plasmid DNA at a concentration of 1 µg/µL was mixed in a mass 
ratio of 16:1 with NHS-psoralen in DMSO at a concentration 1 µg/µL.46 The solution was distributed to a 
96-well round bottom plate with 50 µg DNA/well and placed on ice. Psoralen was then crosslinked into the 
DNA by 25 minutes of UV exposure using a 0.16 amp 365nm lamp placed directly over the plate. For each 
well, 8 µL of 10x PBS, 17 µL DMSO, 25 µg fluorescein cadaverine, 25 µg Oregon green cadaverine and 2.5 
µg Cy5-amine were added, well mixed and then incubated at room temperature for 1h while protected from 
light to prevent photobleaching. It was necessary to fine tune DMSO volume percent of the solution to 30% 
to facilitate reaction of the more hydrophobic fluorophores. Labeled DNA was then ethanol precipitated two 
times to remove excess reactants and purify the DNA. The purified pH nanosensor was then resuspended in 
ultrapure water at 75% of the original volume. The concentration and labeling efficacy were determined using 
a Nanodrop spectrophotometer (Thermofisher Scientific) and the volume was increased to make the pH 
nanosensor concentration 1 µg/µL. DNA was then divided into aliquots and stored at -20°C protected from 
light. Additional DNA was labeled using only fluorescein or Oregon green and Cy5 for comparison of the 
triple-labeled pH nanosensor to more commonly utilized dual labeling techniques with only one pH sensitive 
fluorophore. Fluorescence over the pH range from 3.0 to 9 for the different versions of the pH nanosensor 
was assessed using a Synergy 2 multiplate reader (Biotek, Winooski, VT) with four replicates. 
 
Cell Culture. Human glioblastoma astrocytes (GB319) were grown as adherent cells as previously described on 
tissue culture flasks in DMEM/F12 (11330057, Thermofisher) with 10% heat inactivated fetal bovine serum 
(16140071, Thermofisher) and 1% antimycotic/antibiotic (15240062, Thermofisher).5 HEK293T were 
purchased from ATCC (Manassas, VA) and cultured in DMEM (11965092, Thermofisher) with 10% fetal 
bovine serum and 1% penicillin/streptomycin. 
 
pH Standard Curves. The pH nanosensor was introduced to cells for creation of the standard curve relating 
fluorescence ratio to pH by electroporation using the Neon Transfection System (Thermofisher). In detail, 
cells were passaged to individual tubes with 200,000 cells/tube then fully aspirated and kept on ice for 20 
minutes. The cells were then resuspended in 10 µL of the Neon System supplied R-buffer containing 1 µg of 
100% labeled DNA and electroporated with 1 pulse at 1300V for 20ms. For the flow cytometry based pH 
curve the electroporated cells were transferred to a solution of PBS with 2% FBS, centrifuged and aspirated 
to remove R-buffer. Cells were then resuspended in PBS containing 4% formalin for 15 minutes for 





in known pH point buffers prior to flow cytometry. Known pH point 150 mM buffer solutions were made 
for pH values between 4.0-9.0 with a final concentration of 120 mM NaCl and 30 mM citrate phosphate 
buffer with 2% v/v FBS. Precise pH was measured using a SevenEasy pH Meter (Mettler Toledo, Columbus, 
OH) following addition of FBS.31 A BD Accuri C6 (BD Biosciences, San Jose, CA) flow cytometer with two 
lasers (488 and 633 nm) with four channels corresponding to green, yellow, red and far-red fluorescence (FL1 
at 530±15 nm, FL2 at 565±10 nm, FL3 at 610±10 nm, and FL4 at 675±12.5 nm respectively) was used for 
all flow cytometry experiments in combination with a Hypercyt autosampler (Intellicyt, Albuquerque, NM). 
For plate reader experiments, pH nanosensor was diluted to 0.01 µg/µL in known pH buffer solution in 96 
well plates with four replicates. Fluorescence measurements were taken with a Synergy 2 plate reader (Biotek, 
Winooski, VT). 
 
Transfection. For transfection efficacy experiments, cells were plated in CytoOne 96-well tissue culture plates 
(USA Scientific, Ocala, FL) plates 24h prior to transfection with 15,000 cells/well in 100 µL media. 
Nanoparticles were formed by mixing eGFP-N1 DNA and polymer solutions at 1:1 v/v ratio followed by 10 
minutes of incubation to allow for particle formation. PLL and bPEI from stock aqueous concentrations of 
10 µg/µL were diluted to their necessary concentrations in 10 mM HEPES or 150 mM NaCl respectively 
before being mixed 1:1 with DNA diluted to 0.06 µg/µL in the equivalent buffer. For notation, w/w 1 or 
w/w 2 for bPEI and PLL denotes a 1:1 or 2:1 weight-weight ratio with plasmid DNA respectively. 
Lipofectamine® 2000 was used according to manufacturer instructions, prepared in Opti-mem at w/w 2 and 
w/w 1 ratios. Twenty microliters of the nanoparticle solution were added to each well of cells containing 100 
µL of complete media and allowed to incubate for two hours, at which point the media was replaced. 
Transfection efficacy was assessed for percent-transfected cells and geometric mean expression approximately 
48h following transfection. Cell viability was assessed using MTS Celltiter 96 Aqueous One (Promegra, 
Madison, WI) cell proliferation assay approximately 24h following transfection. 
 
Cellular Uptake and pH Measurements. Cells were again plated at a density of 15,000 cells/well in 96 well plates 
in 100 μL media and allowed to adhere for 24h. Nanoparticles were formed identically to the procedure for 
determination of transfection efficacy other than the use of 20% plasmid pH nanosensor pre-mixed with 80% 
unlabeled DsRed DNA. Following two hours of incubation, media was aspirated and the cells were washed 
two times with 50 μg/μL heparin in 150 mM PBS with five triturations followed by a single PBS wash to 
remove surface-bound polyplexes. PBS was then aspirated and replaced with fresh complete media. At 
specified time points, cells were lifted and resuspended in 150 mM PBS containing 2% v/v FBS before being 
run through a BD Accuri C6 flow cytometer with HyperCyt CFlow autosampler as previously detailed. Flow 





cellular uptake and exclude cells with fluorescence in either channel of the pH nanosensor below background 
autofluorescence levels. Cellular uptake was quantified using Cy5 from the pH nanosensor for the percent of 
cells having uptaken polyplexes and geometric mean fluorescence. Data from the cells above background 
level for both FL1H and FL4H were exported and analyzed in Matlab. The ratio of FL1H/FL4H for pH 
sensitive/pH insensitive fluorescence (FL1H/FL4H) was calculated for each cell. Then the median 
FL1H/FL4H ratio for each well was determined and used to calculate the average pH for that well using the 
linear standard pH curve (Figure 3-2c). 
 
Confocal Microscopy. GB319 cells were plated on Nunc Lab-Tek chambered borosilicate coverglass well plates 
(155411, Thermofisher) at 37,500 cells per well for the same seeding density as transfections in 96 well plates. 
Cells were incubated for two hours with nanoparticles formed from 1500 ng of the plasmid pH sensor and the 
respective polymer. Cells were then washed three times with 50 µg/mL heparin (379059, Sigma Aldrich) in 150 
mM PBS. At 24 hours post-transfection, cells were stained for 10 minutes with Hoechst 33342 (H3570, 
Thermofisher) for nuclei visualization as well as Cell Navigator Lysosome Staining dye (AAT Bioquest, 
Sunnyvale, CA) then washed three times with PBS and imaged in live cell imaging solution (A14291DJ, 
ThermoFisher) at 37°C in 5% CO2. Images were acquired using a Zeiss LSM 780 microscope with Zen software 
and 63x oil immersion lens. Specific laser channels used were 405 nm diode, 488 nm argon, 561 nm solid-state 
and 639 nm diode lasers. Laser intensity and detector gain settings were optimized for cells transfected with 
PEI w/w 2 and maintained for all imaging experiments. 
 
Nanoparticle Characterization. Three samples were independently prepared for each nanoparticle formulation at 
the same concentrations as outlined in the transfection methods section. Nanoparticles for pH nanosensor 
measurements were formed from 100% labeled DNA. Nanoparticle hydrodynamic diameters were 
determined by dynamic light scattering (DLS) in disposable micro-cuvettes using a Malvern Zetasizer 
NanoZS (Malvern Instruments, Marlvern, UK) with a detection angle of 173°. Each sample was then diluted 
in 10 mM NaCl by a dilution factor of 5 and zeta potential was measured by electrophoretic light scattering in 
disposable zeta cuvettes at 25°C using the same Malvern Zetasizer NanoZS (Malvern Instruments, Marlvern, 
UK). 
 Heparin binding competition assay between polyplex nanoparticles and DNA was run similarly to 
previously published.35 Briefly, polyplex nanoparticles were formed between unlabeled or 100% labeled 
plasmid DNA and either bPEI or PLL at a w/w ratio of 2 and concentration of 0.03 ug/uL in 10 mM NaCl. 
The nanoparticles were then added to separate solutions of heparin sodium salt (Sigma H3393) diluted in 10 





nanoparticles with heparin were then diluted with 30% glycerol to give a 5% glycerol solution, after which 15 
uL were loaded into a 1% agarose gel. 
 Yo-Pro-1 iodide binding assays were run similarly to previously published results4, where DNA and 
Yo-Pro-1 iodide (Thermofisher) were both diluted to a concentration of 1 µM in 10 mM NaCl. For pH 
nanosensor trials, 100% Cy5 only labeled DNA was used to avoid fluorescence from the green channel 
fluorophores. The solution of Yo-Pro-1 and DNA was then mixed in a 1:1 ratio with a polymer solution to 
give the specified polymer concentration per well. Green channel fluorescence was then measured using a 
plate reader (Biotek Synergy 2). 
  
Data Analysis, Statistics and Figures. Prism 6 (Graphpad, La Jolla, CA) was used for all statistical analyses and 
curve plotting. Unless otherwise specified, statistical tests were performed with a global alpha value of 0.05. 
ChemDraw (Perkin Elmer, Waltham, MA) was used for chemical structures and schematics. Unless otherwise 
stated, absence of statistical significance markings where a test was stated to have been performed signified 
no statistical significance. Figures were structured such that red lines, bars or dots specifically denote DsRed 




Nucleic Acid pH Nanosensor Synthesis and Validation 
The triple-fluorophore labeled plasmid pH nanosensor was synthesized in a batch process using the reaction 
scheme shown in Figure 3-1a using NHS-psoralen UV crosslinked into DsRed plasmid DNA prior to 
reaction with fluorescein cadaverine (FL), Oregon green cadaverine (OG) and cyanine-5-amine (Cy5).34 It was 
designed to have a green channel to far-red channel fluorescence ratio that would increase with increasing pH 
as shown in Figure 3-1b,c. The reaction ensured that each plasmid statistically had all three fluorophores 
with approximately 50 green and 50 far-red fluorophores per 4700 base-pair plasmid as determined by 
spectrophotometry. The labeling efficacy was not particularly sensitive to the amount of NHS-psoralen used, 
but required sufficient DMSO (~30%) in the reaction solution to allow the more hydrophobic fluorophores 






Figure 3-1. pH Nanosensor Synthesis. (a) Synthesis of the triple-labeled pH sensor was achieved via a 
two-step process of UV photocrosslinking NHS-psoralen to plasmid DNA followed by reaction with three 
primary amine fluorophores (fluorescein, Oregon green and Cy5). (b) Far red channel fluorescence from Cy5 
is pH-insensitive over the physiological pH range of interest, whereas Oregon Green and fluorescein exhibit 
pH-sensitive quenching relative to their pKa values of 4.6 and 6.4. (c) The combination of these fluorophores 
results in a pH sensitive ratiometric relationship for cells electroporated, fixed and run through flow 
cytometry in known pH solutions. 
The pH nanosensor sensitivity over the entire pH range of interest was verified to be improved with 
the inclusion of two pH sensitive fluorophores and one pH insensitive fluorophore in comparison to 
plasmids labeled with only one pH sensitive fluorophore and one pH insensitive fluorophore (Figure 3-2a). 
This nanosensor was observed to have an approximately linear relationship between pH and fluorescence 
ratio over the physiological pH range of interest (Figure 3-2b). For flow cytometry experiments, a calibration 
curve relating fluorescence ratio to pH for the nanosensor was created by electroporating the pH nanosensor 
into human embryonic kidney cells (HEK293T) and human primary grade IV glioblastoma cells (GB319)5, 
fixing the cells to permeabilize them to free flow of ions, and running them through the flow cytometer 
following resuspension in known pH buffer solutions (Figure 3-2c). The pH nanosensor was further 
confirmed to be effective in a third cell line and was stable when stored at -20°C over six months 






Figure 3-2. Fluorescence ratio pH calibration curve. (a) Plate reader normalized fluorescence curves fit 
with a logarithmic function show that two pH sensitive fluorophores were necessary for pH sensitivity over 
the range of interest (all curves also contain Cy5 for pH-insensitive fluorescence on the FL4 channel; OG = 
Oregon green; FLC = fluorescein). The triple labeled pH nanosensor gave an approximately linear 
relationship over the pH range of interest measured using (b) a fluorescence plate reader and (c) flow 
cytometry following electroporation into HEK293T cells. Values shown are mean ± SEM of four wells for 
(a,b) and median ratio of >10,000 cells for (c). 
Additionally, fluorophore labeling of plasmid DNA to form the pH nanosensor was confirmed not 
to affect nanoparticle physicochemical properties in terms of hydrodynamic diameter or zeta potential when 
combined with cationic polymers to form polyplex nanoparticles (Figure 3-3a,b). Overall, PLL nanoparticles 
were approximately 50 nm in size with a zeta potential of +20 mV and PEI nanoparticles were approximately 
250 nm in size with a zeta potential of +25 mV. To test the influence of DNA labeling for the pH 
nanosensor on polymer/DNA binding strength, a heparin competition binding assay using gel 
electrophoresis35 and a Yo-Pro-1 iodide4 competition binding assay were performed that showed that 
polymer/DNA interaction was minimally affected by covalent labeling (Figure 3-3c,d).  
Intracellular trafficking of covalently modified plasmid DNA has likewise been a concern in previous 
studies36, which we sought to address by utilizing only 20% pH nanosensor DNA in studies involving cellular 
uptake and expression. While it is true that the fluorescent labeling method does prevent expression from 
labeled plasmids, this reduction in reporter gene expression was due to UV exposure that likely results in 
nicks in the DNA during the labeling process (Supplementary Figure 3-S2) and not necessarily fluorophore 
covalent conjugation. Recent studies have shown that bPEI polyplexes have on the order of 10 plasmids per 
nanoparticle37, meaning that with 20% pH nanosensor DNA used to form polyplexes in uptake and 






Figure 3-3. Biophysical properties of polymeric gene delivery nanoparticles were not affected by pH 
nanosensor labeling. Polymeric gene delivery nanoparticles were formed by self-assembly of cationic 
polymers using the pH nanosensor or unlabeled plasmid DNA and assessed using dynamic light scattering for 
(a) hydrodynamic diameter and (b) zeta potential, where no statistical differences were observed. Values 
shown are mean ± SEM of three independently prepared samples. Differences between nanoparticles 
formulations were assessed using multiple t-tests with multiple comparisons corrected for using the Holm-
Sidak method. Polymer binding strength with labeled pH nanosensor or unlabeled plasmid DNA was 
compared using a (c) Yo-Pro-1 binding assay and (d) heparin binding assay, where only minor differences 
were observed in polymer/DNA interaction. Values on the heparin binding assay show the weight-weight 
ratio of heparin to the mass of polycation per well. A possible increase in binding interaction between pH 
nanosensor DNA and cationic polymer may be accountable by the presence of carboxylic acid groups in two 
of the fluorophores used. 
Cellular Uptake and Transfection 
Polymeric nanoparticles have been demonstrated previously in HEK293 cells to traffic via an endolysosomal 
pathway and the cell line is particularly amenable as a well-established cell type for non-viral transfection 
experiments.30, 38 Human GB319 cells in contrast are a difficult to transfect primary cell line, which show 
relatively low reporter gene expression for a wide variety of transfection reagents.5 Initial screens of the 





were effective for transfection without being highly cytotoxic (Supplementary Figure 3-S3c,d), where 
polymer:DNA weight-weight (w/w) ratios of 1:1 and 2:1 were selected. These ratios between polymer and 
DNA were in line with polymer doses used previously20, and can be converted from w/w to N/P ratio by 
multiplying by 7.6 or 2.2 respectively for 25 kDa bPEI and PLL.  
For cellular uptake studies, including for pH measurements, cells were washed with the polyanion 
heparin prior to flow cytometry to remove any surface bound but non-internalized nanoparticles 
(Supplementary Figure 3-S4).35 Cellular uptake efficacy was determined via flow cytometry by the 
fluorescence of the pH insensitive fluorophore (Cy5) at two hours after adding nanoparticles to the cells 
(Figure 3-4a,b) as gated in Supplementary Figure 3-S5b. All nanoparticle formulations tested 
demonstrated similar levels of particle uptake within each cell type in terms of percent of uptake positive cells 
as well as the normalized geometric mean uptake, which correlates to the average number of nanoparticles 
taken up by each cell. Due to the high labeling efficacy using NHS-psoralen, and the sensitivity of the 
nanosensor, the fraction of fluorophore labeled DNA for pH determination and cellular uptake experiments 
was able to be reduced to 20% of the total DNA used to form polyplex nanoparticles. This was particularly 
important, as exposure of the plasmid DNA to UV to promote covalent bond formation in the pH 
nanosensor synthesis protocol resulted in DNA nicks that eliminated expression from the labeled plasmid 
DNA (Supplementary Figure 3-S2).  
Transfection efficacy was assessed via flow cytometry (Figure 3-4c,d) and fluorescence microscopy 
(Supplementary Figure 3-S3a,b) in HEK293T and GB319 cells, respectively. Despite the high levels of 
cellular uptake of PLL/DNA nanoparticles, transfection via PLL polyplexes at either w/w ratio was very 
ineffective in both HEK293T and GB319, as anticipated. bPEI/DNA nanoparticles were more effective in 








Figure 3-4. Cellular uptake and reporter gene transfection in two cell lines. (a) HEK293T and (b) 
GB319 cellular uptake as percent of all cells and normalized geometric mean fluorescence of Cy5 labeled 
DNA were similar between PLL and bPEI. Transfection efficacy in (c) HEK293T and (d) GB319 cells as 
percent of all cells and normalized geometric mean expression showed that bPEI was much more effective 
than PLL in transfecting cells. Lipofectamine® 2000 showed similar levels of cellular uptake and transfection 
to bPEI with the conditions tested. Bars show mean ± SEM of four wells. 
Calculated pH Measurements 
HEK293T and GB319 cells were transfected with the nanoparticle formulations using 20% pH nanosensor 
plasmid DNA and average pH of DNA was calculated at specified time points following the initial addition 
of nanoparticles (Figure 3-5a,e). The fluorescence on the FL1H pH sensitive and FL4H pH insensitive 
channels for individual cells as gated in the third panel of Supplementary Figure 3-S5a was imported to 
Matlab for processing. The ratio between the FL1H and FL4H from individual cells was computed and input 
into the linear standard curve relating fluorescence ratio to pH (Figure 3-2c) for individual cells and the 
median calculated cell pH per well was determined. For all polyplex nanoparticles studied, acidification 
rapidly occurred within the first 2 hours of transfection. pH of the nanosensor then remained effectively 
constant over the subsequent day for all nanoparticles except PLL in HEK293T, where acidification 
continued to occur at a slower rate until 8 hours post transfection. PLL/DNA polyplexes at both w/w 1 and 
w/w 2 acidified to an average pH of approximately 4.5 for HEK293T and 5.5 for GB319. bPEI/DNA 





pH of 6.0 at both polymer doses. bPEI nanoparticles in GB319s appeared to reduce acidification in a 
polymer dose dependent fashion with w/w 1 having an approximate median pH of 6.1 and w/w 2 having an 
approximate median pH of 6.6. 
At the 24-hour time point, DsRed expression was assessed as shown in flow cytometry gating 
(Supplementary Figure 3-S5c) to determine characteristics of cells having been successfully transfected 
compared to those cells that were not successfully transfected. Fluorescence from the pH sensitive (green), 
pH insensitive (far-red) and DsRed (red) channels could also be clearly seen for each nanoparticle 
formulation using fluorescence microscopy at 24 hours post-transfection (Supplementary Figure 3-S6). 
Overall, bPEI and PLL both showed statistically significant differences at the population level for median pH 
of the DsRed positive and negative populations (Figure 3-5b,f) but the pH distributions (Figure 3-5c,d,gh) 
were not qualitatively different except in the case for w/w 1 bPEI in GB319 cells. For transfections with 
bPEI w/w 1 in GB319 cells, acidic pH (5.0-6.0) correlated with a decreased frequency of successful 
transfection (DsRed- > DsRed+) whereas neutral pH (~7.0) weakly correlated with a higher frequency of 
successful transfection (DsRed+ > DsRed-). This trend was not noted in HEK293T cells however, despite 
the similar trend in increased transfection efficacy with bPEI w/w 2 particles. For PLL, in both cell types the 
DsRed negative population had a narrow, acidic pH distribution indicative of lysosomal fate (Figure 3-5d,h). 
For HEK293T cells positively transfected with PLL nanoparticles, the DsRed positive population was shifted 
to more neutral pH. 
 
Figure 3-5. Calculated population pH and relationship to transfection at 24 hours. Median pH of 
intracellular DNA calculated at various time points following transfection for the entire cell populations 





HEK293T and (e) GB319 cells. (b) Comparison via Holm-Sidak corrected multiple t-tests of the median pH 
values from the DsRed positively transfected populations and negative untransfected populations at 24 hours 
showed statistically significant differences between the populations for bPEI w/w 1, bPEI w/w 2, PLL w/w 
1, and PLL w/w 2 for HEK293T cells. (f) In GB319 cells, statistically significant differences in median pH 
values between the successfully transfected populations and untransfected populations for for bPEI w/w 1, 
bPEI w/w 2, and PLL w/w 1 were observed. (c) For HEK293T cells transfected with bPEI w/w 2 and w/w 
1, less acidic pH of the delivered DNA in individual cells (>5.5) was slightly correlated with an increase in 
fraction of cells transfected compared to more acidic pH of the delivered DNA in the individual cells (<5.5). 
(d) Interestingly, HEK293T cells transfected with PLL showed the same behavior to a greater extent. (g) For 
GB319 cells transfected with bPEI, transfection resulted in a wider distribution of calculated pH than with 
PLL particles. Following transfection with bPEI, acidic pH (5.0-6.0) correlated with a decreased frequency of 
successful transfection (DsRed- > DsRed+) whereas neutral pH (~7.0) correlated with a higher frequency of 
successful transfection (DsRed+ > DsRed-). (h) For GB319 cells transfected with PLL, there were only 
minor differences between the DsRed positive and negative populations. All errors bars show the mean ± 
SEM of four wells. Histograms show the binned flow cytometry data from four wells. 
 
Individual cell relationships between calculated pH, cellular uptake, and exogenous gene expression 
An advantage of the fluorescence-based nanosensor developed is the capability for high-throughput 
measurements of cellular uptake of exogenous DNA, measurement of local pH of the exogenous DNA, and 
expression of the exogenous DNA. Assessment of DsRed reporter gene expression at 24 hours post-
transfection as compared to pH nanosensor measurements and cellular uptake measurements on the pH-
insensitive channel of the nanosensor enabled the analysis of trends at the single cell level. To clearly elucidate 
the DsRed positive population of cells from possible increased autofluorescence, the ratio of FL3H 
fluorescence to FL1H fluorescence was calculated for each cell, which showed a clear difference for DsRed 
positive cells (see gating of Supplementary Figure 3-S6c). Plotting the DsRed expression in terms of 
FL3H/FL1H versus calculated pH on an individual cell level basis did not show a strong apparent correlation 
for bPEI or PLL at either w/w ratio or cell line tested (Figures 3-6,a-h). There did, however, seem to be a 
weak correlation with bPEI but only at w/w 1 ratio in GB319 cells (Figure 3-6f). Quantification of the 
correlation between variables specifically for the DsRed expressing cell populations using Pearson’s 
correlation coefficient (PCC) in Matlab showed that there was quantitatively minimal correlation between 
most of the variables (Figures 3-6i-n). Weak positive correlation (0.2<PCC<0.4) between DsRed expression 
and pH was observed only for bPEI in either cell line (Figure 3-6i,l), while cells transfected with PLL 
showed no significant correlation between the variables. This result was surprising, given the cases of strong 





both bPEI and PLL (Figure 3-5b,f). For other relationships, nanoparticle uptake and cell pH showed weak 
correlation only for bPEI w/w 2 in GB319 cells (Figure 3-6m) and nanoparticle uptake and gene expression 
showed weak correlation only for bPEI w/w 2 and PLL w/w 2 in GB319 cells (Figure 3-6n). 
 
Figure 3-6. Relationships between individual cell pH, uptake and gene expression at 24 hours. 
Representative scatter plots of DsRed positive (red) and negative (black/grey) populations of cells transfected 
with (a,e) bPEI w/w 2, (b,f) bPEI w/w 1, (c,g) PLL w/w 2 and (d,h) PLL w/w 1 qualitatively showed 
minimal correlation between gene expression and calculated pH. To quantify correlation between variables, 
Pearson’s correlation coefficient (PCC) was calculated for each well for variables in the case of HEK293T (i-
k) and GB319 (l-n). PCC between (i,l) pH and gene expression showed weak (0.2<PCC<0.4) correlation only 
in the case of HEK293T cells transfected with bPEI at w/w 1 and w/w 2 as well as GB319 cells with bPEI 
w/w 1. (j,m) pH and nanoparticle uptake showed weakly positive correlation only for GB319 cells 
transfected with bPEI w/w 2. (k,n) Nanoparticle uptake and gene expression showed weak correlation only 
for GB319 cells transfected with bPEI w/w 2 and PLL w/w 2. All errors bars show the mean ± SEM of four 
wells for PCC calculated for the cells in that well. 
Microscopy verification and lysosome colocalization 
The pH nanosensor was verified to function visually using confocal microscopy in the harder to transfect 





between individual endosomes, spanning both neutral and acidic pH ranges (Figure 3-7a). Following 
transfection with bPEI/DNA nanoparticles, within individual cells, some endosomes had a high fluorescence 
ratio indicating a near neutral pH, while other endosomes had the pH sensitive fluorophores effectively 
quenched, thus indicating their presence in lysosomes. PLL in contrast had low pH sensitive fluorescence and 
low fluorescence ratios with only the pH-insensitive fluorescence strongly observed. These results were 
confirmed by staining for lysosomes with a pH sensitive dye (see methods) and analyzing colocalization of 
the pH insensitive fluorophore with lysosomes (Figure 3-7a,b). The fraction of DNA colocalized with 
lysosomes was above 75% for PLL at both 3 hours and 24 hours post-transfection while for bPEI the 
fraction of DNA colocalized with lysosomes was below 40% at 3 hours and increased between the 3 and 24 
hour time points (Figure 7c). 
 
Figure 3-7. Confocal microscopy qualitative assessment of pH nanosensor function and lysosome 
colocalization. (a) Endosomes 3 hours post-transfection containing bPEI w/w 2 or PLL w/w 2 





microscopy using GB319 cells, whereby the pH insensitive fluorophore intensity was not dependent on pH 
while the pH sensitive fluorophores were quenched when DNA was present in lysosomes. Images were 
thresholded for analysis of colocalization of DNA via the pH insensitive channel with lysosomal tracking dye. 
Compartments containing DNA non-colocalized with lysosomes are shown in pink, while lysosomes not 
containing DNA are shown in red, and compartments containing DNA colocalized with lysosomes are 
shown in yellow. Scale bar 20 µm. (b) Scattergrams show the analysis of the representative microscopy images 
with distribution of pixels with DNA fluorescence intensity shown on the x-axis, lysosome fluorescence 
intensity shown on the y-axis and region 3 showing thresholded colocalized pixels. (c) Quantification of 
Pearson’s correlation coefficient M1 for colocalization of DNA and lysosomes showed PLL nanoparticles 
colocalized with lysosomes at both 3 hours and 24 hours post-transfection while bPEI nanoparticles partially 
avoided an initial lysosomal fate at 3 hours but not at 24 hours. Quantified results were tested using multiple 
t-tests corrected for multiple comparisons using the Holm-Sidak method. Errors bars show mean ± SEM of 
5 images taken with the same microscope settings. 
 
Application to non-polymeric non-viral nanoparticles: 
We additionally evaluated the pH nanosensor using the liposomal transfection reagent Lipofectamine® 2000 
to test its efficacy with a non-polymeric non-viral transfection agent. (Figure 3-8). Lipofectamine® 2000 at a 
w/w 1 ratio showed a median pH of DNA of approximately 6.0 demonstrating that some plasmids fail to 
fully escape a late endosome or lysosomal fate. The mechanism of endosomal escape of lipid reagents like 
Lipofectamine® 2000 is not fully established, but recent reports have shown that the vast majority of lipid 
nanoparticles still reach lysosomes and escape is a relatively rare event.39, 40 Overall, we detected only minimal 
differences in the calculated pH between DsRed positive and negative populations of cells transfected with 
Lipofectamine® 2000 and did not find any correlation between nanoparticle uptake and transfection or 
nanoparticle uptake and pH. That being said, acidic pH (4.0-6.0) correlated with a slightly decreased 
frequency of successful transfection (DsRed- > DsRed+) whereas higher pH (7.0-8.0) weakly correlated with 
a higher frequency of successful transfection (DsRed+ > DsRed-). However, as high transfection was seen 
with Lipofectamine® 2000 across the whole range of pH (4.0-8.0), significant trafficking of the delivered 
DNA to acidic compartments was not a significant barrier to Lipofectamine® 2000 as a non-viral 






Figure 3-8. Lipid nanoparticle pH nanosensor measurements. (a) pH of DNA in Lipofectamine® 2000 
nanoparticles introduced to HEK293T cells was determined to average approximately 6.0 at all time points 
following transfection. There was only a minor statistical difference between the (b) the median pH of cells 
that were dsRed positive and negative at 24 hours post-transfection, which was only slightly evident when 
looking at a (c) representative distribution of the populations. (d) Likewise to bPEI and PLL there was no 
highly significant correlation between DsRed expression and measured pH for the cell at 24 hours post-
transfection. (e) Cell pH and DsRed gene expression showed weak (0.2<PCC<0.4) correlation  using PCC 
and no significant correlation was observed between the other relationships. 
Discussion 
In this work, we have created a nucleic acid based pH nanosensor for investigating the local pH of 
plasmid DNA following transfection with non-viral carriers. Notably, the pH nanosensor synthesized here 
utilized two pH sensitive fluorophores, fluorescein and Oregon green, with respective pKa values of 4.6 and 
6.4 for improved sensitivity at lower pH ranges of interest (Figure 3-2a), which was required to probe 
lysosomal pH levels.32 Using the ratio of the fluorescence of the pH sensitive fluorophores to the pH 
insensitive fluorophore, a standard curve was calibrated for intracellular pH readings (Figure 3-2c) that could 





Previous studies have focused on labeling polymers directly as a pH probe while less research has 
been done constructing pH sensors from nucleic acids to specifically investigate vesicles containing DNA.20, 
24, 30, 31 Labeling of polymers directly has been shown to influence the size and properties of the particles 
studied.30 In this study, nanoparticles formed from cationic polymers complexed with 100% pH nanosensor 
DNA were not statistically different in size, zeta potential or polymer binding strength from nanoparticles 
formed with unlabeled DNA (Figure 3-3). Additionally, given that free polymer has been shown to play a 
large role in transfection and that some polymers may form particles in the absence of DNA, studying the 
trafficking of a fluorescently labeled polymer is a less direct method to assess the behavior of those particles 
and endosomes specifically containing plasmids.20, 41 Labeling plasmids directly with fluorophores also 
enabled a single ratiometric curve to be generated for the specific batch of labeled plasmid as nanosensors, 
eliminating the need to label and characterize multiple polymers individually when using the nanosensor to 
probe biomaterial structure/function relationships.  
PLL and bPEI were optimal polymers to use as a proof of concept, as they are established gene 
delivery materials and were shown to have similar degree of nanoparticle uptake (Figure 3-4a,b). As expected 
from previously published results in other cell types, bPEI was much more effective than PLL for overall 
transfection in both cell lines tested (Figure 3-4c,d). Using the pH nanosensor, we observed that plasmid 
DNA delivered with bPEI maintained a near neutral pH while DNA delivered with PLL was trafficked to 
acidic compartments (Figure 3-5a,e).24, 31 Interestingly, the dose-dependent difference in median pH of the 
GB319 cell population for bPEI was not observed in the HEK 293T cells and disappeared when examining 
only the DsRed positive population (Figure 3-5f). Examining differences between DsRed positive and 
negative populations at 24 hours post-transfection showed significant differences in the median pH of the 
populations for both bPEI and PLL, although the significance was greatest for bPEI at a w/w 1 dose (Figure 
3-5b,f). Analysis of the DsRed positive and negative populations (Figure 3-5) showed that for both polymers 
in both cell lines, when the average pH was close to neutrality, the relative frequency of successful 
transfection (DsRed+/DsRed-) increased. Intriguingly, when moving from a population perspective to a 
single cell perspective, the strong positive correlation between increased intracellular pH and increased 
transfection is no longer observed (Fig. 3-6). These results are in agreement with previous claims that only a 
small fraction of polyplexes ever manage to escape endolysosomes to the cytosol.20 Thus, the many 
polyplexes that do not escape the endolysosomes and the many cells that do not become successfully 
transfected obscure the potential correlation of those that do. Nonetheless, with the right polyplex material, 
these non-escaping polyplexes and these non-transfected cells can still all exhibit an increase in pH sensed by 
the nanosensor that correlates to a transfection advantage for the cell population overall. 
To further investigate functioning of the pH nanosensor following transfection and to evaluate 





the vast majority of polyplexes taken up by a cell fail to escape the endosomes, we performed confocal 
microscopy at 24 hours post-transfection (Figure 3-7). The pH sensor was confirmed to function as 
expected, further validating results from flow cytometry, with the pH sensitive channel showing much greater 
fluorescence in proportion to the pH insensitive channel for bPEI mediated transfection than for PLL. 
Interestingly, endosomes containing the pH nanosensor and bPEI appeared to exhibit a wide variance in pH, 
which was apparent from confocal images and was further confirmed by assessing the specific fraction of 
DNA in lysosomes via colocalization analysis (Figure 3-7b,c). For nucleic acid containing nanoparticles that 
manage to escape the endosome, they will no longer appear as punctate points in microscopy images and 
imaging would be hindered by the much brighter concentrated pixels of nanoparticles in endolysosomes; 
these same nanoparticles that have successfully escaped the endosomes would, however, be accounted for in 
total fluorescence with flow cytometry. This could explain in part the possible discrepancies between flow 
cytometry and confocal microscopy analysis, whereby nucleic acids delivered with bPEI have been reported 
in other cell types to maintain a median pH above five when assessed with flow cytometry, but below five 
with confocal microscopy.20, 24, 31  
Our studies set out to investigate to what extent certain non-viral gene delivery nanoparticles reach a 
state of acidification in endolysosomes or else manage to avoid that fate through the use of a DNA-based 
nanobiosensor. An important aspect to note is that there are a variety of means for a nanoparticle to avoid 
acidification. While preventing acidification through endosomal buffering and titratable amine groups has 
been demonstrated in part by some biomaterials such as PEI, this is not the only method by which particles 
escape a lysosomal fate.22 An alternative possibility is avoidance of these acidic pathways all-together through 
uptake into non-acidifying vesicles13, 16 or direct entry to the cytoplasm through induced nanopores.42 A 
related aspect is that the type of endocytosis, such as clathrin-mediated vs. caveolae-mediated, can also make a 
significant difference to the efficiency of transfection, and that this can occur in a polymer structure-specific 
manner.43 None-the-less, it is clear that sequestration of delivered DNA into acidic late-endosomes and 
lysosomes, means that those DNA molecules are not available to be transcribed in the pH-neutral nucleus, 
the target of the gene delivery. Thus, this nanobiosensor can play an important role in probing this barrier in 
a high-throughput, single cell, and dynamic fashion.  
Even given successful and canonical endocytosis of a nanoparticle, there are additional intracellular 
barriers beyond endosomal escape to successful transfection including DNA unpacking, nuclear import and 
nuclear retention of DNA that must be considered for a delivery approach, but the endosomal barrier 
remains in many cases the rate limiting step in expression following nanoparticle uptake.14 In recent studies, 
the rarity of endosomal escape of lipid nanoparticles as well as polymeric nanoparticles have been likewise 
well documented.39, 40 These studies in particular have noted the difficulty in using fluorescence based imaging 





total fluorescence detectable in the cytosol is very low. With this in mind, we have chosen to focus on the 
specific barrier to transfection of endosomal escape in our creation of a new tool. 
 The proton sponge hypothesis posits that due to endosomal buffering by a protonatable base, such 
as PEI (the “proton sponge”), there will be a concomitant flux of anions into the endosome to maintain 
electroneutrality and consequent buildup of osmotic pressure that can lead to endosomal rupture. The results 
of this study do not confirm or deny the existence of the proton sponge mechanism as it was first proposed 
by Boussif et al but do argue against a simple buffering limited endosomal escape path for polymeric 
vectors.19 If transfection of cells were to be limited by the buffering capacity of the polymeric vectors used, 
including bPEI, buffering capacity of nanoparticles in the pH 5-7 range would be expected to show strong 
direct correlation with transfection efficacy, which is not what we observe when we look at the cells on a 
single cell level in our study (Figure 3-6).  
Theoretical approaches to assessing the feasibility of the proton sponge mechanism are inconclusive. 
Purely theoretical assessment of the feasibility of the proton sponge mechanism based on the combination of 
osmotic pressure and pressure from the charged polymer has been used to argue that buffering of endosomal 
pH with enough free (uncomplexed) cationic polymer was sufficient for rupturing endosomes.26 Assessment 
of the feasibility of the proton sponge mechanism via quantification of the amount of fluorescently labeled 
bPEI that accumulated in endosomes in combination with the theoretical buffering capacity and estimated 
critical lysosomal membrane tension of 10 mJ/m2 has been used to argue that osmotic pressure could not 
lead to endosomal escape on its own.20 Likewise, the maximum endosomal osmotic pressure possible based 
on the buffering capacity of bPEI has been estimated to be below the level necessary for full endosomal 
membrane disruption.25  
Perhaps buffering capacity of polymers for gene delivery may make endosomal escape more likely 
without directly causing endosomal escape via the hypothesized proton sponge mechanism on its own. 
Polymer buffering capacity may cause an increase in osmotic pressure across the membrane in such a way as 
to make it more vulnerable to disruption by other attributes of the polymer, such as its increasingly high 
charge, similarly to how an overly inflated balloon is easier to pop with a pin than a partially inflated balloon. 
This hypothesis is supported by experimental results from multiple groups demonstrating interaction of 
polymer directly with cellular membranes, as charged cationic polyplexes have been demonstrated to lead to 
membrane disruption directly.14, 18 Further, the spacing of cationic charges in polymer structure has been 
demonstrated to affect both transfection efficacy and cellular viability, as observed in the odd-even effect 
with polyaspartamides.44 Coupled with results from groups demonstrating efficacy of amphiphilic polymers 
for gene delivery that have relatively low charge densities, this balance between ability to possibly generate 
osmotic pressure due to buffering capability and ability to disrupt membranes by physical means may be 





In conclusion, we have demonstrated that a triple-fluorophore labeled nucleic acid can function as a 
sensitive pH nanosensor to probe the environment of exogenous nucleic acid delivered by polymeric and 
liposomal non-viral carriers through the whole range of physiological pH. bPEI in comparison to PLL, 
exhibited a higher average intracellular pH as well as a higher variance in intracellular pH. Population average 
measurements of pH were found to correlate well to successful transfection of human cells, whereas single 
cell measurements were found to be only weakly correlative. These results suggest limitations to the proton 
sponge hypothesis and also that the ability of polymeric nanoparticles to avoid an acidic environment is 
necessary, but not sufficient for successful transfection. To our knowledge, this is the first reported instance 
of high throughput single cell analysis between cellular uptake of DNA, intracellular pH of delivered DNA, 
and gene expression of the delivered DNA. This nanosensor technology can be of benefit to increase 
fundamental quantitative understanding of how biomaterial properties affect intracellular delivery and to 
glean high-content and high-throughput information on the local environment of DNA as it transports 
through the cell.  
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Supplementary: 
Supplementary Figure 3-1: pH nanosensor flow cytometry standard curve relating pH to fluorescence ratio in 
two cell types 
Supplementary Figure 3-2. UV effect on plasmid DNA expression 
Supplementary Figure 3-3. Transfection efficacy in HEK293T and GB319 cells 
Supplementary Figure 3-4. Effectiveness of heparin washing. 
Supplementary Figure 3-5. Flow cytometry population gating 
Supplementary Figure 3-6. HEK293T cells 24-hours post-transfection with 20% pH nanosensor DNA 
polyplexes show clear reporter gene expression. 
 











Supplementary Figure 3-S1. pH nanosensor flow cytometry standard curve relating pH to 
fluorescence ratio in two cell types. The pH nanosensor gave consistent readings following electroporation 
into different cell types (GB319 and F54) and at time points six months apart. 
 
 
Supplementary Figure 3-S2. UV effect on plasmid DNA expression. UV exposure resulted in decreased 
expression of plasmid DNA, making the labeled plasmid unsuitable by itself to induce expression. HEK293T 
cells were transfected with bPEI 2 w/w nanoparticles with DNA post-exposure to UV. Bars show the mean 
± SEM of four wells. Transfection efficacy was assessed using flow cytometry and fluorescence intensity 



























shows geometric mean fluorescence on the red channel normalized to that of cells transfected with un-
exposed plasmid. Error bars show the mean ± SEM of four wells. Scale bars are 500 µm for 5x images. 
 
Supplementary Figure 3-S3. Transfection efficacy in HEK293T and GB319 cells. bPEI, PLL and 
Lipofectamine 2000 were complexed DNA and added at a dose of 600 ng of eGFP-N1 plasmid DNA per 
well to determine optimal reagent dose for (a) HEK293T and (b) GB319 cells. Images were captured with a 
10x fluorescence microscope with equal exposure time two days following transfection. Scale bar 200 µm. 
Cell viability following transfection for (c) HEK293T and (d) GB319 was assessed using MTT cell titer and 







Supplementary Figure 3-S4. Effectiveness of heparin washing. The protocol for washing cells was 
confirmed to be sufficient to remove surface bound but non-internalized polyplex nanoparticles. Cells were 
incubated with nanoparticles for one hour at 4 °C to inhibit endocytosis then washed two times with 
polyanion 50 µg/mL heparin sulfate in 150 mM PBS followed by a single PBS rinse. Cells incubated at 4 °C 
and washed (orange) were shown to have fluorescence on the pH insensitive channel FL4H for Cy5 reduced 
to that of the untreated control (red) compared to cells incubated at 4°C and unwashed (blue). Cells 
incubated with nanoparticles under standard conditions of a two hour transfection at 37 °C (green) had over 
two orders of magnitude higher fluorescence than washed cells demonstrating that washing was effective to 









Supplementary Figure 3-S5. Flow cytometry population gating. Flow cytometry data was gating 
according to the following plots. (a) Singlet cells were gated from all detected particles using FSC-H vs SSC-
H followed by FSC-H vs FSC-A. Gates for cells with fluorescein (FL) and Cy5 fluorescence greater than the 
untreated population of cells were selected as shown. (b) Cells were gated as being positive for uptake of 
DNA using the Cy5 channel (FL4-H) compared to the untreated population of cells. More than 90% of cells 





than cell autofluorescence on both channels were used for purposes of flow cytometry pH measurements. (c)  
From the cells in the Double+ region, cells were strictly gated in FL3-H vs FL1-H to determine those cells 
positively expressing the reporter protein dsRed at 24 hours post-transfection.  
 
Supplementary Figure 3-S6. HEK293T cells 24-hours post-transfection with 20% pH nanosensor 
DNA polyplexes show clear reporter gene expression. Microscope images were acquired with a 40x lens. 
Scale bar 40 µm.  
 
Supplementary Methods: 
Processing of flow cytometry data. Flow cytometry data acquired with an Accuri C6 flow cytometer and attached 
HyperCyt CFlow Automator were exported to FCS files for each well. The FCS files were imported to 
FlowJo and analyzed as shown (Supplementary Figure 3-S5) to identify singlet cells as well as DsRed positive 
and negative cell populations at 24 hours post-transfection. The individual cell data was then exported to .csv 
files from FlowJo and imported into Matlab for quantitive analysis with the following scripts. The plateTF 
script reformats vector matrices to a 96 well block plate format, while the import_flow_data script allows for 
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Foreword: This article came out effective concurrently with my pH Nanosensor article and was my first 
introduction to microfabrication practices and a frankly cool demonstration of using nanoparticle tracking 
analysis to specifically track particles containing fluorescently labeled plasmid DNA. Published in the Society 
for Biomaterials (SFB) society journal – Journal of Biomedical Materials Research Part A, the article has been 
well received by the field, having already been cited 26 times from 2017-2019. 
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ABSTRACT: 
Translation of biomaterial-based nanoparticle formulations to the clinic faces significant challenges including 
efficacy, safety, consistency and scale-up of manufacturing, and stability during long-term storage. Continuous 
microfluidic fabrication of polymeric nanoparticles has the potential to alleviate the challenges associated with 
manufacture, while offering a scalable solution for clinical level production. Poly(beta-amino esters) (PBAE)s 
are a class of biodegradable cationic polymers that self-assemble with anionic plasmid DNA to form polyplex 
nanoparticles that have been shown to be effective for transfecting cancer cells specifically in vitro and in vivo. 
Here we demonstrate the use of a microfluidic device for the continuous and scalable production of 
PBAE/DNA nanoparticles followed by lyophilization and long term storage that results in improved in vitro 





comparison to widely used commercially available transfection reagents polyethylenimine and 
Lipofectamine® 2000. We further characterized the nanoparticles using nanoparticle tracking analysis (NTA) 
to show that microfluidic mixing resulted in fewer DNA-free polymeric nanoparticles compared to those 
produced by bulk mixing.  




Non-viral gene delivery has great promise in clinical applications where transient expression can be 
sufficient to result in clinical efficacy.1 Compared to viral gene therapy, non-viral delivery of plasmid DNA is 
more amenable to repeated administration due to the reduced risk of immunogenicity and insertional 
mutagenesis, as well as also being generally less expensive to manufacture than its viral counterparts.1,2 Non-
viral gene delivery has traditionally been much less effective than viral delivery methods and presents many 
challenges in clinical scale production.1,2 Improvements in non-viral delivery methods for plasmid DNA and 
RNA via polyplex or lipoplex formulations have resulted in efficacy both in vitro and in vivo in preclinical 
models leading to improved therapeutic outcomes.3-5 With many studies demonstrating preclinical efficacy in 
animal models, there are now multiple clinical trials based on polyplex nanoparticles in the US and abroad for 
the treatment of a variety of diseases.1,6 Poly(beta-amino ester)s (PBAEs) in particular are a promising class of 
cationic polymers capable of transfecting a diverse variety of cells both in vitro and in vivo, typically more 
effectively than PEI and similar reagents as well as commercial transfection reagents such as Lipofectamine® 
2000.3,7-17 PBAEs offer design flexibility that allows for the synthesis of polymer libraries to screen for the 
ability to self-assemble with DNA and transfect different cell types.8,11,13,14,18,19 Beyond allowing chemical 
diversity in structure, PBAEs are biodegradable in water, making them less cytotoxic than non-biodegradable 
cationic polymers such as polyethylenimine.20,21  
 Production of non-viral gene therapeutics at clinically relevant scales of production is challenging, as 
nanoparticles prepared by batch processes have been shown to suffer from batch-to-batch and intra-batch 
variability and nanoparticle batch manufacturing processes can lead to nanoparticles with different properties 
when scaled-up to larger batch sizes.22-26 In an approach to overcome the aforementioned challenges, 
microfluidic mixing has been used to form nanoparticles from many materials including hydrophobic 
polymers such as PLGA to form hard nanoparticles as well as soft nanoparticles composed of lipoplexes and 
polyplexes for gene delivery.23,27,28 Microfluidic methods have been demonstrated to form polyplex 
nanoparticles in particular with smaller diameters and improved nanoparticle stability as well as more 
favorable cellular viability and increased transfection.23,28-30 Bulk mixing of solutions via pipetting results in 





solutions to occur in time scales of microseconds to milliseconds that have been documented to result in 
smaller and more monodisperse nanoparticles.24,25  
Polyplex nanoparticles that form as a result of electrostatic interactions are particularly vulnerable to 
heterogeneity resulting from bulk mixing via pipet or vortex.31 Microfluidic approaches have thus been 
applied to the formation of polyethylenimine (PEI) and similar DNA containing polyplex nanoparticles with 
promising results.23,26,28,32 Of the available approaches to microfluidic mixing for polyplex nanoparticle 
formation, three dimensional hydrodynamic flow focusing relies on diffusive mixing via inertial flow focusing 
for rapid formation of nanoparticle in a continuous flow process which is amenable to the scale-up with the 
possibility of parallelization.27,33,34 To analyze the effect of microfluidic mixing on nanoparticle properties, 
many of these studies have assessed nanoparticle stability on the time-span of hours in aqueous solution 
following formation, but few have addressed the challenge of storage of nanoparticle formulations once 
created over multiple months.  This is especially a concern for a biodegradable product where point of care 
fabrication prior to administration is not feasible.  Biomanufacturing processes must overcome multiple 
challenges during the synthesis of biodegradable nanoparticles, such as PBAE/DNA self-assembled polyplex 
nanoparticles, to be readily translatable from the lab bench to the clinic.  These challenges include robustness 
and scalability in the fabrication process and stability of the final nanomedicine product.      
In this report, we demonstrate microfluidic flow focusing for the rapid formation of PBAE and 
plasmid DNA nanoparticles followed by rapid freezing and lyophilization for long term storage. Following 
continuous microfluidic assembly, the lyophilized nanoparticles are shown to be more effective overall than 
bulk mixed nanoparticles at transfection of three cancer cell lines and are shown to retain equivalent efficacy 
in transfection at three months following production when stored at -20°C. We further characterize these 
nanoparticles with a novel assay using nanoparticle tracking analysis (NTA) to determine the properties and 
concentration of the nanoparticles specifically containing plasmid DNA, the effect of lyophilization on 




Small molecule monomers for PBAE synthesis, 4-Amino-1-butanol (S4) and 4-butanediol-diacrylate (B4) 
were purchased from Alfa Aesar; 2-(3-Aminopropylamino)ethanol (E6) was purchased from Fluka and 
Monomer-Polymer. Succinimidyl-[4-(psoralen-8-yloxy)]-butyrate (NHS-psoralen) was purchase from 
Thermofisher. Cy3-NH2 was purchased from Lumiprobe (Hallandale Beach, FL). Plasmid pDsRed-Max-N1 
(Addgene 21718, Cambridge, MA) and peGFP-N1 (Addgene 2491) were used for transfection efficacy 
screenings. 





PBAE 446 was synthesized in a Michael addition reaction as previously described (Figure 4-1) to create 
acrylate terminated polymer base structures, then dissolved in THF and reacted with small molecules to 
endcap the polymer.35,36 Specifically, monomers B4 (4-butanediol-diacrylate) and S4 (4-Amino-1-butanol) 
were mixed at a ratio of 1.1:1 to form 1g of base polymer and stirred for 24 hour at 90°C. The base polymer 
was then dissolved in THF at a concentration of 167 µg/µL and mixed in a 3:2 ratio with a 0.5M solution of 
the end capping molecule E6 (2-(3-aminopropylamino)ethanol) for 1 hour at room temperature. The end-
capped polymer was then ether purified by precipitating in diethyl ether two times and placed in a vacuum 
chamber for 3 days to remove residual ether. The purified PBAE 446 polymer was then dissolved in 
anhydrous DMSO at 100 µg/µL and stored at -20°C in small aliquots. The molecular weight was determined 
using gel permeation chromatography (GPC; Waters, Milford, MA) as previously described in comparison to 
polystyrene standards10 and nuclear magnetic resonance using a 500 MHz Bruker NMR. 
Microfluidic Chip Design and Simulation 
AutoCAD (Autodesk, Rafael, CA) was used for creating the design of the photolithography mask, which was 
printed by CAD/Art Services, Inc (Bandon, OR). The flow resistance due to channel diameters were 
designed to allow a volumetric flow ratio of 3:4:1:1 for the DNA, polymer primary inlet and polymer pinch 
channel inlets respectively. The mixing domain of the masks were extruded in AutoCAD to a depth of 100 
µm and exported as STL files to be imported to COMSOL Multiphysics 4.4 (COMSOL, Inc., Burlington, 
MA). COMSOL was used to simulate laminar, incompressible flow with convection and diffusion of dilute 
species of polymer and plasmid DNA. eGFP Plasmid DNA of 4700 bp was modeled with a diffusivity 
coefficient of 5.14*10-8 cm2/s.37,38 PBAE polymer in aqueous solution was modeled with a diffusivity of 
5.0*10-8 cm2/s based on results from NTA of polymer only nanoparticles. 
Nucleic Acid Fluorescent Labeling  
Plasmid DNA at a concentration of 1 µg/µL in water was mixed in a mass ratio of 16:1 with NHS-psoralen 
in DMSO at a concentration 1 µg/µL. The solution was distributed to a 96-well round bottom plate with 50 
µg DNA/well and placed on ice. Psoralen was then crosslinked into the DNA by 25 minutes of UV exposure 
using a 0.16 amp 365 nm lamp placed directly over the plate. For each well, 8 µL of 10x PBS, 17 µL DMSO, 
35 µg Cy3 were added, well mixed and then incubated at room temperature for 1h. Labeled DNA was then 
ethanol precipitated two times to remove excess reactants and purify the DNA. The labeled plasmid was 
resuspended in ultrapure water at 75% of the original volume after which, the concentration and labeling 
efficacy were determined using a Nanodrop spectrophotometer (Thermfisher Scientific) and the volume was 






Plasmid DNA was run in 1% agarose gels for DNA binding experiments as previously described.39 Similarly, 
for shear experiments, DNA at working concentration in buffer was run through the microfluidic chip at 
various flow rates, then diluted and run in a 1% agarose gel for 40 minutes. 
Microfluidic Chip Fabrication 
The master wafer was prepared using silicon wafers <100> (University Wafer, Boston, MA) 100 mm in 
diameter, which were dehydrated on a hot plate and plasma etched with oxygen for four minutes at 100 W 
and pressure between 0.3-0.5 Torr. The silicon wafer was then patterned with SU-8 2075 negative photoresist 
(Microchem, Woburn, MA) according to manufacturer instructions. Briefly, the plasma etched silicon wafer 
was spin coated with approximately 1 mL of SU-8 2075 photoresist by spinning at 2100 rpm for 30 seconds. 
The coated wafer was then soft baked for 5 minutes at 65°C followed by 15 minutes at 95°C. The wafer was 
exposed to UV light using a mask aligner for 240 mJ/cm2 followed by post exposure bakes at 65°C for 5 
minutes and 95°C for 12 minutes. The baked wafer was then washed in a bath of SU-8 developer for 10 
minutes to remove uncrosslinked photoresist followed by a rinse with isopropyl alcohol. 
Sylgard 184 (Dow Corning, Auburn, MI) polydimethylsiloxane (PDMS) was prepared at a monomer 
to crosslinker ratio of 10:1 and poured over the patterned wafer. The wafer and PDMS were baked for one 
hour at 80°C and the PDMS was carefully separated from the wafer. A biopsy punch (Fisher, 0.1 cm 
diameter) was used to create inlet and outlet holes for 20 gauge PTFE tubing (Cole Parmer, EW-06417-31, 
Court Vernon Hills, IL). The patterned PDMS and glass slides were oxygen plasma etched for 1 minute at 
30W and 0.4 Torr and then pressed together to bond the PDMS to the glass. Devices were then hard baked 
for 90 minutes at 85°C. Tubing was inserted into the PDMS without any adapter to connect devices to two 
syringe pumps. 
Nanoparticle Formation and Lyophilization 
Bulk mixed nanoparticles were formed by mixing plasmid DNA (0.06 mg/mL) and polymer solutions at 1:1 
v/v ratio in 25 mM sodium acetate (NaAc, pH=5.0) to give the stated weight-weight ratios. Ten minutes of 
incubation were then allowed for particle formation before analysis or addition to cells. Bulk lyophilized 
nanoparticles were formed as described above, then supplemented with sucrose to a concentration of 30 
mg/mL and frozen at -80°C. Bulk drip nanoparticles were formed as described above with the DNA solution 
supplemented with sucrose before being mixed with the polymer solution. Bulk drip nanoparticles were then 
dripped via pipet into a tube of liquid nitrogen to allow for near instantaneous freezing, mirroring 
nanoparticles formed in the microfluidic process. Lyophilization was achieved for all samples using a 
Labconco (Kansas City, MO) lyophilizer set to -45°C maintaining a pressure of approximately 14 Torr. 
Microfluidic mixed nanoparticles were formed with the assembly shown in Figure 4-2A using the 
microfabricated PDMS/glass chip and two syringe pumps to drive rapid chip-based mixing of aqueous 





solution flow rate was set to be two times the flow rate of the second syringe pump for controlling DNA 
flow rate. For all microfluidic prepared nanoparticles, DNA was diluted in 25 mM NaAc buffer to 0.09 
mg/mL and mixed in a 1:2 ratio with polymer solution to give a final DNA concentration of 0.03 mg/mL. 
For lyophilized nanoparticles, the DNA solution was additionally supplemented with sucrose to give a post-
mixing sucrose concentration of 30 mg/mL.  
 
 
Nanoparticle Tracking Analysis 
Nanoparticle hydrodynamic diameters and concentrations were determined by nanoparticle tracking analysis 
using a Nanosight NS500 with a 532 nm laser at 25 C (Malvern, Westborough, MA) running software version 
3.1. A minimum of three samples were independently prepared for each nanoparticle formulation using 
PBAE 446 and Cy3 labeled plasmid DNA at concentrations as outlined in the transfection methods section. 
Ten minutes were allowed for nanoparticle self-assembly in 25 mM sodium acetate (NaAc, pH=5.0), after 
which each sample was diluted in 150 mM PBS (pH = 7.4) between 500-2000 fold using a two or three step 
dilution to give a Nanosight particle concentration of 20-80 particles per frame. Each sample was then loaded 
into a disposable 1 mL plastic syringe and perfused into the Nanosight chamber. A fluorescent 565 nm long 
pass filter was inserted and three 60 second captures were made at the fluorescent stage position. Immediately 
after capture, analysis was postponed and another three 60 second captures were made with the fluorescent 
filter removed and the stage at the scatter position. For purposes of determining average number of plasmids 
per nanoparticle, the number of plasmids/mL was calculated to be 5.824*1012 plasmids/mL at a 
concentration of 0.03 mg/mL given a plasmid size of 4700 base-pairs and approximate molecular weight of 
3,102 kDa. This value was then used in relation to Nanosight concentration measurements and number or 
volume weighted diameter distributions to estimate the number of plasmids per nanoparticle. 
Cell Culture 
Patient derived human glioblastoma cells (GB319) were grown as adherent cells on tissue culture flasks in 
DMEM/F12 (Thermofisher) with 10% heat inactivated fetal bovine serum (Thermofisher) and 1% 
antimitotic/antibiotic (Thermofisher). 17,36 17,36 17,36 17,36 17,3617,36 Human triple-negative breast cancer cells 
(MDA-MB-231) and murine melanoma cells (B16-F10) from ATCC were grown as adherent cells on tissue 
culture flasks in DMEM (Thermofisher) supplemented with 10% heat inactivated bovine serum and 1% 
penicillin/streptomycin. All cells were incubated at 37°C in a 5% CO2 environment.. 
Transfection and Viability Assessment  
For transfection efficacy experiments, cells were plated in CytoOne 96-well tissue culture plates (USA 
Scientific) plates 24h prior to transfection with 15,000 cells/well in 100 µL media. PBAE nanoparticles were 





Lipofectamine® 2000 (Thermofisher) and 25 kDa branched polyethylenimine (PEI) were used as positive 
controls for transfection. Lipofectamine® 2000 was prepared in Opti-MEM 1 with GFP plasmid DNA 
according to manufacturer instructions at a ratio of 1x. PEI was prepared in 150 mM sodium chloride at 
weight/weight ratios of 1, 2, 4 and 8 to GFP plasmid DNA. Twenty microliters of the nanoparticle solution 
were added to each well of cells containing 100 µL of complete media and allowed to incubate for two hours, 
at which point the media was replaced. Transfection efficacy was assessed for percent-transfected cells and 
geometric mean expression approximately 48 h following transfection using an Accuri C6 flow cytometer and 
Hypercyt autosampler. Cell viability was assessed using MTS Celltiter 96 Aqueous One (Promega, Madison, 
WI) cell proliferation assay at 24 hours post transfection. 
Data Analysis, Statistics and Figures 
Results are reported as mean ± standard error of the mean (SEM) unless otherwise specifically stated. Matlab 
(Mathworks, Natick, MA) was used for quantitative analysis of Nanosight data. FlowJo (Ashland, OR) was 
used for flow cytometry gating as shown in Supplementary Figure 4-S1. ImageJ with FigureJ were used for 
image analysis and figure assembly.40 ChemBioDraw was used for schematics. Prism 6 (Graphpad, La Jolla, 
CA) was used for all statistical analyses and curve plotting. To assess statistical significance between 
differences in transfection efficacy, one-way ANOVA was performed using Dunnett’s method for multiple 
comparisons. To assess statistical significance between differences in nanoparticle concentrations, multiple t-
tests were performed using the Holm-Sidak method to correct for multiple comparisons. Statistical 
significance notation: *(p<0.05); **(p<0.01); ***(p<0.001); ****(p<0.0001). The absence of statistical 
significance notation on figures where a statistical test was stated to have been performed indicates that no 




Following the naming scheme for PBAEs established in previous publications, PBAE polymer 446 was 
synthesized in a ratio of 1.1:1 for the acrylate to amine small molecule monomers as shown in Figure 4-1.36 
PBAE 446 was selected for this study as it has been shown to be effective in a wide variety of cell 
types9,11,16,41,42 and demonstrated minimal autofluorescence, which was necessary for use in nanoparticle 
tracking analysis assays. PBAEs containing ring structures in the backbone or endcap were observed to have 
sufficient autofluorescence to interfere with fluorescent nanoparticle tracking analysis measurements using 
the 532 nm laser and 565 nm long-pass filter of the Nanosight NS500. GPC was used to determine the MN 
and MW of PBAE 446 to be 7.4 kDa and 14.0 kDa respectively with a PDI of 1.89 relative to polystyrene 
standards. 1H NMR of the endcapped polymer, shown in Supplementary Figure 2, was used to estimate the 






Figure 4-1. PBAE synthesis from small molecule monomers. PBAE base polymer (B4S4) was synthesized by 
step growth polymerization via Michael addition reactions from monomers B4 and S4. The base polymer was 
then dissolved into THF and endcapped with small molecule E6 to yield PBAE 446. 
 
Microfluidic chip fabrication and evidence against DNA shearing 
A microfluidic chip design shown in Figure 4-2 was designed based on previously reported chips in the 
literature for hydrodynamic flow focusing devices capable of rapid, transition state mixing of aqueous 
solutions of cationic polymer and anionic plasmid DNA.23,43,44 COMSOL Multiphysics simulations of 
laminar, incompressible flow with convection and diffusion of dilute species were performed for microfluidic 
chip designs with minor variations in the chip dimensions and design. The chip was purposefully designed to 
confine uncomplexed DNA to the center of the channel via flow focusing in both the vertical and horizontal 
axes via the hairpin turn and pinch channels respectively. At the primarily utilized flow rate of 45 mL/h, 
simulation of plasmid DNA and polymer only particle diffusion resulted in equilibrium being reached less 






Figure 4-2. Schematic of microfluidic device for 3D-HF for polyplex formation. (A) The chip was designed 
to be run with two syringe pumps flowing aqueous solutions of PBAE polymer and plasmid DNA. 
Lyophilized particles from the microfluidic device were frozen by allowing the particles to drip directly into 
liquid nitrogen. (B) The negative mask designed in Autocad for the microfluidic device with single inlets for 
aqueous polymer and DNA solutions. The mixing domain is outlined in red. (C) The schematic shows the 
dimensions of the microfluidic chip mixing domain with 100 µm feature height. (D) The COMSOL 
multiphysics simulation of laminar flow with transport of diluted species showed rapid mixing of DNA, 
shown here as concentration isosurfaces as a function of the final DNA concentration. Simulation showed 
focusing of the DNA in the vertical z-dimension to occur via inertial focusing around the hairpin turn 
followed by focusing in the y-dimension via 90° pinch channels. At flow rates used for in vitro experiments, 
the simulation showed complete mixing in less than 10 ms. 
 





laminar and turbulent flow with a maximum Reynolds number up to 125 for the primarily utilized flow rate 
of 45 mL/h. High shear forces in microfluidic devices can result in nicks to the DNA backbone that cause 
relaxation of plasmid DNA from the more effective supercoiled state to the relaxed open circular form.45,46 
Three dimensional hydrodynamic flow focusing devices have been shown not to result in DNA shear 
previously23, which we confirmed for this device via simulation (Supplementary Fig. 4-S3) and gel 
electrophoresis (Fig. 3A). Shear was shown via simulation to occur as anticipated near the top, bottom and 
sides of the channel with maximum shear occurring immediately after the horizontal pinch channels. As 
shown in Supporting Information Fig. 4-3, uncomplexed DNA was confined to the center of the channel and 
minimal if any DNA shear was anticipated. To confirm no evidence of DNA shear, we ran plasmid DNA 
through the MF chip at various flow rates up to 240 mL/h and then separated the supercoiled and relaxed 
circular DNA using gel electrophoresis (Fig. 4-3A). 
 
Figure 4-3. Gel electrophoresis of plasmid DNA. (A) At total flow rates up to 240 mL/h, plasmid DNA was 
not sheared as evidenced by the lack of a DNA smear by gel electrophoresis. (B) PBAE 446 was 100% 
effective at binding plasmid DNA at 10, 30, 60 and 90 w/w ratios of polymer to DNA. 
 
Nanoparticle characterization via nanoparticle tracking analysis 
Nanoparticle tracking analysis (NTA) was used to characterize PBAE 446 polyplex nanoparticles formed at 
different w/w ratios with plasmid DNA via bulk or MF mixing. Certain PBAE nanoparticles have been 
documented previously to form polymer only micellar nanoparticles due to their amphiphilic structure even 
in the absence of DNA.7 To assess the characteristics of nanoparticles specifically containing plasmid DNA 





plasmid DNA was labeled with the fluorophore Cyanine-3 (Cy3). Cy3 labeling enabled those nanoparticles 
containing plasmid DNA to be detectable by fluorescence using NTA while non-fluorescent nanoparticles 
containing no plasmid DNA would be filtered out and not tracked. To validate that DNA was fully bound to 
polymer at all weight-weight ratios tested, gel electrophoresis was used to show retardation (Fig. 4-3B). Using 
these methods, the total nanoparticle and DNA containing nanoparticle diameter distributions of bulk 
prepared PBAE nanoparticles were compared at different w/w ratio as seen in Figure 4-4. Interestingly, for 
the total nanoparticle size distribution, as w/w ratios increased, the size distribution approached that of 
PBAE only (DNA-free) nanoparticles (Fig. 4-4A). In contrast, nanoparticles containing plasmid DNA 
maintained approximately the same size distribution across the tested w/w ratios (Fig 4-4B). 
 
Figure 4-4. Bulk prepared nanoparticle properties assessed using NTA. (A) As w/w ratio increased from 10 





the absence of DNA. (B) In contrast, nanoparticles containing plasmid DNA as assessed by fluorescent NTA 
showed only minimal differences in the diameter distribution between the tested w/w ratios. (C) The 
concentration of all nanoparticles and those nanoparticles specifically containing plasmid DNA were analyzed 
by fluorescent and non-fluorescent NTA.  An increase in w/w ratio was shown to increase the total 
nanoparticle concentration assessed using multiple t-tests performed using the Holm-Sidak method to correct 
for multiple comparisons while the concentration of nanoparticles containing plasmids did not statistically 
change when assessed using one-way ANOVA. Bars show ± SEM with n ≥ 4 independently prepared 
samples. (D) The average number of plasmids per nanoparticle was assessed at the different w/w ratios using 
the volume-weighted and number-weighted diameter distributions. Bars show ± SEM of n ≥ 4 independently 
prepared samples. 
 
NTA also enabled determination of total nanoparticle concentration and DNA containing 
nanoparticle concentrations for the samples (Fig. 4-4C). Total nanoparticle concentration was shown to 
increase with increasing w/w ratio between polymer/DNA, but DNA containing nanoparticle concentration 
did not statistically change with increasing w/w ratio when assessed using multiple t-tests performed using the 
Holm-Sidak method to correct for multiple comparisons. Using the known plasmid DNA concentration, 
knowledge that all of the DNA was fully encapsulated in the nanoparticles (Fig. 4-3B), and the measured 
particle size distributions, the number of plasmids per nanoparticle was then estimated (Fig.4-4D). The 
number-weighted average of plasmids per particle was between 8-12 plasmids , whereas the volume-weighted 
average47 of plasmids per particle was 14-20. The number-weighted average gives an estimate of the number 
of plasmids in a randomly chosen nanoparticle, whereas the volume-weighted average gives an estimate of the 
number of plasmids in the same nanoparticle as a randomly chosen plasmid.  Most nanoparticles containing 
DNA were estimated to contain fewer than 20 plasmids as can be seen in from the volume and plasmid per 
particle distributions in Supplementary Figure S-S4. In comparison to our previously reported plasmids per 
particle findings with related PBAE/DNA nanoparticles composed of differently structured polymers, our 
volume-weighted plasmid per particle findings with polymer 446 are smaller than what was reported with 
polymers 551, 537, and 447.  This difference may be due to the differences in the polymer structures and/or 
may be attributable in part to the previous estimate having been made using an older version of the 
Nanosight hardware (LM10) and software. 
 To determine any effect MF mixing may have on nanoparticle characteristics, MF mixed 
nanoparticles were prepared equivalently at a 30 w/w concentration and total flow rate of 45 mL/h. For 
freshly prepared PBAE nanoparticles, microfluidic mixing had no effect on the particle size distribution of all 
nanoparticles or DNA containing nanoparticles (Fig. 4-5A). For a therapeutic application, these hydrolytically 





the feasibility of long-term dry storage, bulk and MF mixed nanoparticles were lyophilized and analyzed by 
NTA following resuspension in water. For both bulk and MF mixed nanoparticles, the nanoparticle size 
distribution was not strongly affected by lyophilization (Fig. 4-5B). However, the concentration of total 
nanoparticles before and after lyophilization was shown to be dependent on the mixing method (Fig. 4-5C), 
as the total nanoparticle concentration of bulk prepared nanoparticles significantly decreased (P<0.001 when 
multiple t-tests were performed with Holm-Sidak method) with lyophilization while the DNA containing 
nanoparticle concentration decreased to a smaller degree following lyophilization as well. Presumably, this 
indicates a loss of the polymer-only nanoparticles during freezing and lyophilization as well as a partial 
decrease in DNA-containing nanoparticles too. In contrast, the nanoparticles formed by microfluidic mixing 
contain relatively few polymer-only (DNA-free) nanoparticles, and the concentrations of both total and DNA 
containing nanoparticles formed by microfluidic mixing was not observed to change significantly with 
lyophilization (Fig. 4-5C). 
 
Figure 4-5. NTA diameter distribution and concentration of MF and bulk mixed 30 w/w PBAE 446 
nanoparticles. (A) For 30 w/w nanoparticles, there was no significant difference in the nanoparticle diameter 
distribution with the different mixing methods or between all nanoparticles and those nanoparticles 
containing plasmid DNA. (B) The diameter distribution also did not change following lyophilization of the 
nanoparticles. (C) NTA concentration measurements comparing fresh and lyophilized nanoparticles did show 
a difference in particle concentration upon lyophilization for the total nanoparticle concentration of bulk 
mixed nanoparticles only. Bars show ± SEM with n ≥ 4 independently prepared samples. 
 
Transfection efficacy of three cancer cell lines 
Efficacy of the PBAE nanoparticles formed via either MF or bulk mixing was assessed by reporter gene 
expression two days following transfection in three cancerous cell lines of variable transfection difficulty. The 





PBAE nanoparticles, with over 70% transfection efficacy previously reported.10,36,49 Murine melanoma cells 
(B16) were selected as a more difficult to transfect cell line and human triple negative breast cancer (MDA-
MB-231) cells were selected as a very difficult to transfect cell line.41 In vitro transfection efficacy of the three 
cell lines with PBAE 446/DNA nanoaprticles at three weight/weight ratios of polymer:DNA was assessed 
using flow cytometry in terms of percent of cells transfected (Fig. 4-6A) and geometric mean fluorescence 
(Fig. 4-6B) from GFP expression. For freshly made PBAE nanoparticles formed via MF mixing, no 
difference in transfection efficacy was detectable when compared to fresh PBAE nanoparticles formed via 
bulk mixing, as was evident from both flow cytometry data and fluorescence microscopy images (Fig. 4-7) 
from treated cells. Additionally, MF mixing did not statistically affect cytotoxicity for freshly prepared 
nanoparticles when compared against the fresh bulk mixed nanoparticles at the same dose (Fig. 4-6C). 
Positive transfection controls Lipofectamine® 2000 and branched PEI were prepared in parallel and used to 
transfect the same three cell lines with three different doses tested for each material (Supplementary Fig. 4-
S5). PEI was minimally effective even with evident cytotoxicity, while Lipofectamine® 2000 was moderately 
effective for transfection in some of the cells at a 1:1 w/w ratio. However, PBAE 446 was more effective for 







Figure 4-6. Flow cytometry assessment of transfection efficacy of in three cell lines using PBAE 446 
nanoparticles prepared either fresh and lyophilized at three w/w ratios. Lipofectamine® 2000 and 25 kDa 
PEI were included as transfection controls. (A) The percent of cells transfected ranged from 2% to 92%. 
Conditions with significantly lower transfection efficacy than the fresh bulk mixed nanoparticles are denoted 
by α, while conditions with significantly lower transfection than MF lyophilized nanoparticles are denoted 





comparisons of each treatment against either bulk fresh of MF lyophilized nanoparticles. (B) Geometric mean 
expression, presented on a logarithmic scale showed clear differences in efficacy of transfection between MF 
and bulk or BD lyophilized nanoparticles. Symbols α and β again corresponded to signficant differences in 
geometric mean expression compared to the bulk fresh and MF lyophilized nanoparticles respectively. (C) 
Cellular viability assessed by MTT metabolic activity assay 24 hours post-transfection showed minimal 
cytotoxicity under nearly all conditions. Only GB319 cells treated with 60 w/w and 90 w/w nanoparticles 
showed a drop in cellular viability. Lipofectamine® 2000  showed significant toxicity in all cell lines. Bars 
show ± SEM with n=4 wells. 
 
 
Figure 4-7. Transfection efficacy using freshly prepared PBAE nanoparticles with GFP plasmid DNA. No 
differences in transfection efficacy between freshly made bulk and MF mixed PBAE 446 nanoparticles were 
observed in the three cell lines. Images show brightfield with GFP overlay and GFP fluorescence on the 






Lyophilized nanoparticle efficacy 
To prepare nanoparticles for storage in a lyophilized form, sucrose was added as a stabilizer to a final 
concentration of 30 mg/mL for all samples prior to freezing. Bulk prepared and lyophilized nanoparticles 
were frozen at -80°C, while nanoparticles coming out of the microfluidic chip effluent tube were allowed to 
drip directly into a container of liquid nitrogen as shown in Figure 4-2A to promote near instantaneous 
freezing. To determine if the method of freezing influences nanoparticle efficacy, control nanoparticles 
termed bulk drip (BD) were prepared by dripping the bulk mixed nanoparticles prepared with sucrose into a 
tube containing liquid nitrogen. For GB319 cells, transfection efficacy as measured by both percent of cells 
transfected and geometric mean expression was generally not affected by lyophilization (Fig. 4-6A and Fig. 4-
6B). Lyophilization of the bulk prepared nanoparticles did however significantly reduce transfection efficacy 
in the more difficult to transfect B16 melanoma and MDA-MB-231 human breast cancer cell lines when 
compared against the bulk fresh prepared nanoparticles when assessed using one-way ANOVA (Fig. 4-6A 
and Fig. 4-6B, p<0.05 using Dunnett’s method for multiple comparisons). The manner of freezing for the 
bulk mixed nanoparticles prior to lyophilization was shown to have no significant impact on transfection 
efficacy, as the BD prepared nanoparticles rarely performed differently than the bulk lyophilized 
nanoparticles. Nanoparticles prepared by microfluidic mixing followed by drip freezing and lyophilization did 
perform statistically better than both bulk lyophilized and BD lyophilized nanoparticles (Fig. 6A and Fig. 6B, 
p<0.05 using Dunnett’s method for multiple comparisons). Transfection when using the lyophilized MF 
prepared nanoparticles was greater than lyophilized bulk prepared nanoparticles in multiple instances, 
particularly for 60 and 90 w/w formulations in the harder to transfect B16 and MDA-MB-231 cells (Fig. 4-8). 
To evaluate whether MF produced PBAE/DNA nanoparticles could be stably stored over multiple months, 
microfluidic prepared and lyophilized nanoparticles were stored for three months at -20°C and tested for 
transfection efficacy in the same three cell lines with no significant decrease in efficacy (Fig. 4-9). Specific 






Figure 4-8. Transfection efficacy of cells with lyophilized PBAE 446 nanoparticles that were prepared by 
bulk, bulk drip (BD) or MF methods. No differences in transfection efficacy were observable for GB319 
cells, while transfection was visibly greater when using the MF prepared lyophilized nanoparticles in harder to 
transfect B16 and MDA-MB-231 cells. Images show brightfield with GFP overlay and GFP fluorescence on 






Figure 4-9. PBAE nanoparticles prepared by microfluidic mixing retained efficacy for at least three months 
following lyophilization and storage at -20°C. Bars show ± SEM with n=4 wells. 
 
Multiple plasmid delivery 
To confirm the results from NTA indicating the ability of the PBAE nanoparticles to contain 
multiple plasmids within one nanoparticle transfections were performed transfections using plasmid DNA 
premixed with two reporter genes on separate plasmids. In the three different cell lines MF produced PBAE 
nanoparticles enabled successful delivery of multiple types of DNA and co-expression (Fig. 4-10). Co-
expression followed the same trends as delivery of a single gene and MF fabricated nanoparticles had the 






Figure 4-10. Dual reporter gene delivery in PBAE nanoparticles. (A) An example micrograph of cells 
transfected with either GFP, dsRed or both plasmids pre-mixed with co-expression shown in yellow. Scale 
bar 200 µm. Flow cytometry analysis of cells transfected under the different conditions showed expression of 
both GFP and dsRed in a majority of cells for (B) GB319 cells while for harder to transfect (C) B16 and(D) 





significant differences between nanoparticles prepared by bulk or MF mixing methods were observed in the 
reporter gene expression. Bars show ± SEM with n=4 wells. 
 
Discussion 
Polymeric gene delivery has the potential to address a wide variety of maladies through the delivery 
of exogenous DNA, siRNA or miRNA but has been slow to translate from the benchtop to the clinic. Our 
group has demonstrated improved tumor survival following polymeric nanoparticle delivery of plasmid DNA 
specifically in an orthotopic brain cancer rat model via suicide gene delivery3 and through transfection of 
cancer-honing mesenchymal stem cells that lead to a reduction in stem-characteristics of tumor initiating 
cells.50 Other groups have demonstrated similar approaches for polymeric nanoparticle delivery of plasmid 
DNA in the lungs51 for treatment of cystic fibrosis, demonstrating the potential for clinical translation of 
polymeric particles for delivery of DNA. A related challenge is the robust and scalable manufacture of such 
nanobiotechnology for use in the clinic, a challenge that the developed microfluidic system for gene therapy 
aims to address. To date, no non-viral gene delivery formulations have successfully passed through clinical 
trials in the US.1,52 
Translation of nanoparticle formulations to the clinic requires reproducible, large-scale production to 
be an economically viable approach. Here we have demonstrated continuous flow assembly via microfluidic 
mixing of PBAE/DNA nanoparticles effective for delivery of plasmid DNA to a variety of cancerous cell 
lines. Continuous processes are advantageous for manufacturing compared to batch processes as they can be 
run in an uninterrupted fashion, easily scaled up without changing the properties of the product, and can 
effectively eliminate batch-to-batch variability.26 To this end, many nanoparticle formulations prepared by 
microfluidic means have recently been demonstrated with equivalent or improved efficacy from freshly made 
nanoparticles.23,28,32,34,53 Unlike some microfluidic platforms for nanoparticle formation, our device does not 
require two immiscible phases or removal of organic solvents.28 Additionally, the lack of turbulent mixing and 
chip design for uncomplexed DNA confinement to the center of the channel, where shear forces were greatly 
reduced, was shown to prevent DNA shearing that could lead to DNA relaxation and lower rates of 
transfection.45,46 
While continuous flow formation of nanoparticles is arguably more translatable than batch processes 
for clinical scale nanoparticle synthesis, the rate of nanoparticle production from a microfluidic process has 
been a concern in many studies.23,26,54 In this study, nanoparticles were produced at a rate of approximately 
100 mg/h from a single device operating at a relatively fast flow rate of 45 mL/h. At this flow rate and the 
concentrations used in the study, an estimated clinically relevant size dose (100 mg) could be produced in one 





be manufactured by increasing the DNA concentration, running the device for longer periods of time, and/or 
running multiple devices in parallel.3 
Another important feature of nanoparticle manufacturing is the evaluation of the product stability 
following continuous microfluidic assembly and long-term storage. Storage of polyplex nanoparticles is 
particularly challenging, as they exist in a partial dynamic equilibrium while in aqueous solution that can lead 
to aggregation over time.23,49 PBAEs in particular are not amenable to long-term storage in aqueous solutions 
as they possess hydrolysable ester linkages in the backbone of the polymer and are subject to degradation 
with a bond half-life on the time span of hours depending on the pH of the solution.20 To overcome this 
challenge, our group has demonstrated long-term storage of lyophilized, bulk mixed, sucrose stabilized PBAE 
nanoparticles that maintained comparable transfection efficacy in terms of percent of cells transfected for 
some cell types through two years when stored at -20°C.36,49 Geometric mean expression was noted to be 
variable depending on sucrose concentration and length of time stored to -20°C.36 Here, utilizing bulk 
nanoparticle fabrication methods, we likewise observe no decrease in transfection efficacy of glioblastoma 
cells (GB319) following lyophilization of bulk nanoparticles but did observe modest decreases in transfection 
of melanoma (B16) and breast cancer (MDA-MB-231) cells. Microfluidic produced PBAE nanoparticles, in 
contrast, retained efficacy in all cell lines following lyophilization, including after storage for three months.  
This finding is highly significant as it ensures robustness, scalability, and stability of these MF fabricated 
nanoparticles over time.  
We developed a new assay to evaluate plasmid-containing polyplex nanoparticles utilizing new NTA 
hardware and software on the NS500 with the capability of discerning fluorescent nanoparticles that contain 
plasmid DNA from non-fluorescent nanoparticles. The estimated number of plasmids per PBAE 
nanoparticle from this method agrees with those published for bPEI nanoparticles analyzed by single particle 
microfluidic analysis when scaled by particle volume, providing validation for our method.55 While NTA does 
require dilution of the sample for analysis, we hypothesize that the characteristics of the particles analyzed 
following dilution accurately represent the characteristics of the nanoparticles as they would exist following 
effective dilution for in vitro or in vivo use. In contrast to methods such as TEM56 that have previously been 
used to estimate the number of plasmids contained in a nanoparticle, relatively little perturbation of the 
particles occurs with our methods utilizing NTA . We showed that for PBAE 446/DNA nanoparticles 
formed at higher w/w ratios, there was a significant difference between the measured concentration of all 
nanoparticles and those nanoparticles specifically containing plasmids. Using fluorescent NTA, we studied 
the effect of polymer to DNA weight/weight ratio on the particle size distribution of all nanoparticles and 
the particle size distribution of those nanoparticles specifically containing plasmids. Interestingly, the number 
of nanoparticles containing plasmid DNA and the particle size distribution of those particles remained 





Microfluidic mixing, particularly three-dimensional hydrodynamic flow focusing used here, has been 
shown to reduce nanoparticle sizes of some polyplex nanoparticles that only form when they electrostatically 
complex with DNA and have their high density of positive charges rapidly neutralized.23,32 In contrast to 
other types of polyplex nanoparticle formations, microfluidic mixing did not result in a statistically different 
PBAE/DNA nanoparticle size distribution when analyzed via NTA. We hypothesize that this result may be 
attributable to the fact that PBAE polymer is less charged and more amphiphilic than other cationic gene 
delivery polymers, such as PEI.  Differences in freshly made nanoparticles formed via bulk or microfluidic 
mixing indicated a difference in the fraction of nanoparticles containing plasmid DNA, as there were fewer 
polymer only, or DNA-free nanoparticles measured when assembled via microfluidic mixing.  
For PBAE/DNA nanoparticles lyophilized with sucrose, we find that microfluidic mixing enables 
enhanced stability and transfection efficacy compared to bulk prepared lyophilized nanoparticles.  These 
readily scalable methods of producing stable and efficacious self-assembled biodegradable PBAE/DNA 
nanoparticles are promising for translational utilization.  
 
Conclusions 
We have demonstrated a continuous flow process for microfluidic mixing and lyophilization of highly 
effective PBAE/DNA nanoparticles for plasmid DNA delivery. The microfluidic assembled lyophilized 
nanoparticles were more effective than bulk assembled lyophilized nanoparticles in multiple cell lines and 
enabled co-delivery of multiple plasmids. As these microfluidic assembled, biodegradable nanoparticles were 
demonstrated to be efficacious, safe, robust, easily scalable, and stable following long-term storage, they may 
be promising biomaterials for therapeutic non-viral gene therapy. 
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Supplementary Figure 4-S1. Flow cytometry gating. (A) Singlet cells were gated as shown in frame one and 
two for each cell population. Cells expressing GFP were gated against the untreated population as shown in 
frame 3. Gates were adjusted to have an average of 0.1% false positive cells in the untreated control well. (B) 
Cells were gated into four regions for untransfected (Region 1), GFP expression (Region 2), dsRed expression 







Supplementary Figure 4-S2. 1H NMR (500 MHz Bruker) of end-capped and diethyl ether purified PBAE 
446 in CDCL3. Shifts were integrated and estimated MN was determined to be 6.2 kDa with a mean repeat 
unit number of 21. Some diethyl ether with a shift at ~1.4 ppm from ether precipitation to eliminate excess 








Supplementary Figure 4-S3. COMSOL simulation of laminar flow and transport of dilute species. (A) The 
numbered cut lines show locations of cross sectional frames used to assess DNA mixing and shear rate. (B) 
Calculated shear rate was greatest near the walls immediately downstream of the pinch channels (frame 4) at 
the primarily utilized flow rate of 45 mL/h. (C) At the flow rates used for all in vitro experiments, DNA was 
shown to be fully mixed with the solution of polymer within 10 ms of initial contact. Cross sections of DNA 
concentration showed flow focusing in both the vertical and horizontal directions, preventing uncomplexed 







Supplementary Figure 4-S4. Number-weighted (A) volume and (B) plasmid distributions were calculated 
along with volume-weighted (C) volume and (D) plasmid distributions of DNA containing bulk prepared 
PBAE nanoparticles. Distribution shapes demonstrate that the majority of DNA-containing nanoparticles 








Supplementary Figure 4-S5. Positive controls Lipofectamine® 2000 and 25 kDa branched PEI were tested 
at three different weight/weight ratios in the three cell lines. (A) Microscopy images of brightfield with 
overlay and GFP with 100 ms exposure overlay showed substantial transfection only for B16 cells and 
substantial cytotoxicity in both GB319 and MDA-MB-231 cells. Scale bar 200 µm. (B) Transfection efficacy 
was quantitatively assessed using flow cytometry and cell viability was assessed by MTT cell metabolic assay. 
Lipofectamine® 2000  and PEI both showed substantial cytotoxicity in the three cell lines and only 









Table 4-S1. Statistical test of differences in transfection efficacy measured by percent of cells transfected. 
One-way ANOVA was performed using Dunnet’s method for multiple comparisons of each treatment to the 
control treatment of bulk, freshly prepared nanoparticles with P<0.05 noted as α in Figure 4-6a. 
Polymer:DNA Ratio Cell Line Bulk Lyo BD Lyo MF Fresh MF Lyo 
 GB319 ns ns ns ns 
30 w/w B16 **** **** ns ns 
 MDA-MB-231 ** ns ns ns 
 GB319 *** ns ns ns 
60 w/w B16 ** ** ns ns 
 MDA-MB-231 *** ns ns ns 
 GB319 ns ns ns ns 
90 w/w B16 **** * ns ns 
 MDA-MB-231 *** * ns ns 
 
 
Table 4-S2. Statistical test of differences in transfection efficacy measured by percent of cells transfected. 
One-way ANOVA was performed using Dunnet’s method for multiple comparisons of each treatment to the 
test treatment of MF lyophilized nanoparticles with P<0.05 noted as β in Figure 4-6a. 
Polymer:DNA Ratio Cell Line Bulk Fresh Bulk Lyo BD Lyo MF Fresh 
 GB319 ns ns ns ns 
30 w/w B16 ns *** ** ns 
 MDA-MB-231 ns * ns ns 
 GB319 ns *** ns ns 
60 w/w B16 ns ** ** ns 
 MDA-MB-231 ns ** ns ns 
 GB319 ns ns ns ns 
90 w/w B16 ns **** * ns 








Table 4-S3. Statistical test of differences in geometric mean expression of all cells. One-way ANOVA was 
performed with using Dunnet’s method for multiple comparisons of each treatment to the test treatment of 
MF lyophilized nanoparticles with P<0.05 noted as β in Figure 4-6b. 
Polymer:DNA Ratio Cell Line Bulk Fresh Bulk Lyo BD Lyo MF Fresh 
 GB319 ns ns ns ns 
30 w/w B16 ns * * ns 
 MDA-MB-231 ns * ns ns 
 GB319 ns *** * ns 
60 w/w B16 ns **** *** ns 
 MDA-MB-231 ns ** ns ns 
 GB319 ns * ns ns 
90 w/w B16 ns ** * * 




Table 4-S4. Statistical test of differences in geometric mean expression of GFP positive cells. One-way 
ANOVA was performed using Dunnet’s method for multiple comparisons of each treatment to the test 
treatment of bulk fresh nanoparticles with P<0.05 noted as α in Figure 4-6b. 
 
Polymer:DNA Ratio Cell Line Bulk Lyo BD Lyo MF Fresh MF Lyo 
 GB319 ns ns ns ns 
30 w/w B16 ** ** ns ns 
 MDA-MB-231 *** * ns ns 
 GB319 * ns ns ns 
60 w/w B16 **** **** ns ns 
 MDA-MB-231 *** ** ns ns 
 GB319 ns ns ns ns 
90 w/w B16 **** *** ns ns 
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Intracellular delivery of nucleic acids to mammalian cells using polyplex nanoparticles remains a challenge 
both in vitro and in vivo, with transfections often suffering from variable efficacy. To improve reproducibility 
and efficacy of transfections in vitro using a next-generation polyplex transfection material poly(beta-amino 
ester)s (PBAEs), the influence of multiple variables in the preparation of these nanoparticles on their 
transfection efficacy was explored. The results indicate that the even though PBAE/pDNA polyplex 
nanoparticles are formed by self-assembly of polyelectrolytes, their transfection is not affected by the manner 
in which the components are mixed, facilitating self-assembly in a single step, but a timing for self-assembly 
of 5-20 min is optimal.  In addition, even though the biomaterials are biodegradable in water, their efficacy is 
not affected by up to 8 freeze-thaw cycles of the polymer. It was found that there is greater stability of nucleic 
acid-complexed polymer as a polyplex nanoparticle compared to free polymer. Finally, by exploring multiple 
buffer systems, it was identified that utilization of divalent cation magnesium or calcium acetate buffers at pH 
5.0 are optimal for transfection using these polymeric materials, boosting transfection several fold compared 





similar polyplex nanoparticle transfections and improve the robustness of using these biomaterials for 
bioengineering and biotechnology applications. 
Keywords: Polyplex nanoparticle, gene delivery, poly(beta-amino ester), transfection 
 
1. Introduction: 
 Non-viral gene delivery is a routinely used approach in the laboratory to introduce genetic materials 
to mammalian cells. Nanoparticles (NPs) are often used to mediate effective cellular uptake, endosomal 
escape, and delivery to either the cytosol or the nucleus. Cationic polymeric materials, including 
polyethyleminine (PEI) 1 and poly(beta-amino ester)s (PBAEs) 2-4, have been used extensively for gene 
delivery both in vitro and in vivo with promising results but to date have been slow to advance to the clinic due 
largely to insufficient efficacy of the materials 5. 
  In contrast to non-biodegradable PEI-based polymers, PBAEs are cationic polyesters that contain 
tertiary amines in the backbone of the polymer that facilitate rapid hydrolysis in aqueous solution, enabling 
PBAEs to be used with generally low cytotoxicity and effectively no risk of accumulation following repeat 
administration in vivo. PBAE NPs have been demonstrated to yield higher transfection efficacy than many 
commercial reagents in vitro and have been demonstrated to effectively deliver nucleic acids in vivo, even 
leading to improved survival outcomes in multiple tumor models with delivery of various plasmid DNA 
cargoes 6-7. Many researchers performing simple in vitro transfections may further benefit from the utilization 
of PBAEs for routine transfections for bioengineering and biotechnology applications due to their high 
efficacy, low cytotoxicity and rapid degradation rates that fully eliminate the polymers prior to peak gene 
expression approximately two days following transfection 8-9. The relative ease of synthesis of these materials 
and improvements in performance over many canonical transfection reagents makes PBAEs prime 
candidates for use as routine transfection reagents. Unlike many current commercial reagents, however, 
PBAEs are susceptible to degradation in aqueous solution, which may make them more sensitive to the 
manner in which these materials are stored and their NP derivatives are prepared. 
 To improve the reproducibility and efficacy of pre-clinical experiments using PBAE NPs and better 
enable high throughput methods for studying these materials, we performed assays to assess the influence of 
various experimental factors on transfection efficacy. To achieve this, we utilized two canonical, linear, end-
capped PBAE polymers to transfect two well characterized cell lines with a reporter gene in vitro and 
quantified expression via flow cytometry. Multiple experimental parameters were explored with a focus on 
factors that can affect polyplex self-assembly including order of polyelectrolyte addition during polyplex self-
assembly, volume of polyelectrolyte components during self-assembly, environmental conditions during 





approach enabled the discovery of parameters that produced optimized transfection as well as the 
determination of parameter ranges that ensure robust reproducibility. 
2. Experimental Section: 
2.1 Materials 
Monomers for PBAE synthesis were purchased from vendors listed in Table S1. Stock solutions of 3 M 
sodium acetate (NaAc) (Sigma), 1 M HEPES (Quality biological), 1 M magnesium acetate (MgAc2) (Boston 
Bioproducts), 1 M calcium acetate (CaAc2) (VWR) were diluted to desired osmolarity and adjusted to set pH 
values. Buffer salts for 2-ethanesulfonic acid (MES), sodium citrate (Na2HCitr), sodium phosphate 
(Na2HPO4), magnesium citrate (MgHCitr) and calcium citrate (CaHCitr) were purchased from Sigma Aldrich. 
Branched PEI (BPEI, 25 kDa MW) was purchased from Sigma Aldrich. Plasmid eGFP-N1 (Addgene 2491) 
was used for assessment of transfection efficacy. 
2.2 Transfection Assessment  
All PBAE NPs were prepared in 25 mM NaAc, pH 5.0 at a 60 weight-weight (w/w) polymer/DNA 
ratio for all experiments and pipetting to mix as previously described unless otherwise noted 8. BPEI NPs 
were prepared in 150 mM NaCl by adding polymer to DNA in a 1:1 volume ratio at a 2 w/w ratio. Particles 
were added to HEK293T or MDA-MB-231 cells at DNA doses of 200 and 400 ng per well, respectively, in 
complete medium containing 10% serum and incubated for two hours, followed by a complete media change. 
Transfection efficacy was observed using a fluorescence microscope (Axiovert Observer A.1, Zeiss) and 
quantified using flow cytometry approximately 48 hours following transfection, using an Accuri C6 flow 
cytometer (BD Biosciences, Franklin Lakes, NJ) with Hypercyt high‐throughput sampler and reader (Intellicyt 
Corp., Albuquerque, NM). Transfection efficacy is generally reported as percent transfection in MDA-MB-
231 cells and as normalized geometric mean expression in HEK293T cells, as the transfection was typically 
too high across all PBAE transfection conditions (>90% cells positive) in this cell type to differentiate 
between conditions using percent transfection. Figure 5-S14 shows gating for flow cytometry analysis. 
2.3 Mixing Volume ratio 
PBAE NPs were prepared by pipet-mixing polymer and DNA at several volumetric ratios, with the 
polymer volume fractions varying from 0.15 to 0.95 in 25 mM NaAc buffer, pH 5.0. Follow-up experiments 
in which PBAE in DMSO was resuspended directly with dilute plasmid DNA were performed by aliquoting 
the PBAE in anhydrous DMSO (100 mg/mL) to tubes or round-bottom plates, then directly pipetting 
plasmid DNA pre-diluted in 25 mM NaAc, pH 5.0, to resuspend the PBAE for complexation into NPs. 
2.4 Pre-transfection incubation time 
To determine the influence of preparation time on transfection efficacy, NPs were prepared by pipet-
mixing in a 1:1 volume ratio of dilute polymer and plasmid DNA at set times prior to addition of NPs to 





buffer was performed two minutes prior to mixing dilute polymer solution with dilute plasmid DNA. 
Additional experiments were conducted in which polymer was dissolved in 25 mM NaAc by vortexing and 
pre-incubated for set amounts of time prior to complexation with plasmid DNA; after mixing with DNA, 
NPs were further incubated 5 minutes then added to cells. For all presented experiments, NPs were then 
added to HEK293T and MDA-MB-231 cells at low doses (200 ng and 400 ng DNA, respectively) and 
incubated with cells for two hours, after which media was aspirated and replaced with 100 μL/well of fresh, 
complete medium.  
2.5 Freeze-Thaw Cycles and Water Content 
Individual PBAE aliquots at 100 mg/mL in anhydrous DMSO were subjected to repeated freeze-
thaw cycles performed on subsequent days. For thaw only cycles, polymer aliquots were thawed at room 
temperature for one hour in a container with desiccant then refrozen at -20°C a set number of times. Under 
matched conditions for open-air thaw conditions, polymer aliquots were thawed at room temperature with 
desiccant for one hour, then opened to the laboratory atmosphere for 5 minutes, capped, and refrozen to 
simulate controlled multiple uses from a single polymer aliquot. After freeze-thaw cycles were completed, all 
polymer aliquots were stored at -20°C for one month then used for assessment of transfection efficacy as 
described above. For water fraction experiments, PBAE 4-4-6 in anhydrous DMSO at 100 µg/µL was diluted 
to 50 µg/µL with additional solvent so that the final aliquot contained between 0-50% water by volume. 
Aliquots were then frozen at -20°C for two months, thawed, and held at room temperature for set amounts 
of time prior to be used for transfection efficacy assessment as described above.  
2.6 Polymer degradation: 
Two replicates each of PBAE (free polymer) and PBAE/DNA (60 w/w NPs) were incubated in 
either PBS (pH 7.4), citrate buffer (pH 6), or sodium acetate buffer (pH 5.2) at 37°C. At each specified time 
point, samples were frozen and lyophilized to remove aqueous solvent. Polymer was then dissolved in THF, 
filtered, and analyzed by gel permeation chromatography (GPC) as previously described 10. Number average 
(Mn) and weight average (Mw) molecular weights were determined against linear polystyrene standards at each 
time point. One-phase decay plots were fit to degradation plots to determine ester bond half-life. 
2.7 Buffer system 
 For the initial experiment, buffer solutions of sodium acetate (NaAc), 2-(N-
morpholino)ethanesulfonic acid (MES), sodium phosphate (NaH2PO4), sodium citrate (Na2HCitr), potassium 
acetate (KAc), and magnesium acetate (MgAc2) were prepared as 1 M stocks in ultrapure water and sterile-
filtered. Each stock buffer was split into four groups, diluted to 25 mM in ultrapure water, and adjusted to pH 
4, 5, 6, or 7 assessed with a Mettler Toledo SevenEasy pH meter. PBAE NPs were formed in each buffer by 
resuspending PBAE polymer at 100 mg/mL in DMSO in a 96-well round-bottom plate, followed by mixing 





231 cells at low doses (200 ng and 400 ng DNA, respectively) and incubated with cells for two hours, after 
which media was aspirated and replaced with 100 μL/well of fresh, complete medium. Following results from 
the first experiment, additional buffers of calcium acetate (CaAc2) magnesium citrate (MgHCitr), and calcium 
citrate (CaHCitr) were prepared at 25 mM concentrations and pH 5.0. Divalent cation citrate buffers were 
marginally soluble and used at their solubility limits, estimated to be approximately 4 mM. Composite buffers 
mimicking calcium phosphate transfection conditions were also utilized 11. Uptake experiments were 
performed with 20% of the plasmid DNA labeled with Cy5 as previously described 12. 
2.8 Data analysis, statistics and Figures:  
FlowJo (FlowJo, LLC) was used for flow cytometry analysis. Servier Medical Art (CC license) was 
used for illustrations. Prism 6 (Graphpad, La Jolla, CA) was used for all statistical analyses and curve plotting. 
For multiple comparisons between all tested conditions, ordinary one-way ANOVA with Tukey corrected 
multiple comparisons were performed. Similarly, for multiple comparisons tests against a specific control 
condition one-way ANOVA with Dunnett corrected multiple comparisons was performed. Following one-
way ANOVA, a Brown-Forsythe test of equal variance was performed to assess if specific conditions 
possessed significantly different standard deviations. Unless otherwise specified, statistical tests were 
performed with a global alpha value of 0.05, and experiments were repeated at least twice with representative 
results shown. Unless otherwise stated, absence of statistical significance markings where a test was stated to 
have been performed signifies no statistical significance. Statistical significance is denoted as follows: *p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001. 
3.  Results and Discussion 
We sought to determine if incubation time influences transfection efficacy with these materials since 
PBAE polymers undergo hydrolysis following dissolution in aqueous solutions, with ester bond half-life 
usually between 2-6 hours 9, 13. The experiments revealed that the optimal aqueous incubation time for PBAE 
polymer prior to and after mixing with plasmid DNA are <10 minutes and between 5-20 minutes, 
respectively. Further exploring the influence of hydrolysis in stored aliquots of PBAE on NP efficacy, our 
results indicated that polymer aliquots stored at -20°C were stable over up to eight freeze-thaw cycles, making 
these materials promising for use as general-use transfection reagents where a single polymer aliquot can be 
used multiple times without concern of reduction in efficacy. 
We further explored the influence of volumetric ratio of PBAE to DNA during NP mixing to show 
that, as long as NPs are sufficiently mixed, the volume of each solution prior to mixing made no difference in 
transfection efficacy. These results were further expanded to show that PBAE polymer in DMSO could be 
directly resuspended with dilute plasmid DNA in buffer to give equally effective NPs, which has implications 
for making NPs at high DNA concentrations where PBAE polymer solubility would otherwise limit the dose. 





discovered that divalent cation magnesium and calcium acetate buffers improve transfection efficacy. Here, 
we explored the influence of assembly parameters on only two relatively hydrophilic PBAE structures which 
are representative of the most commonly used PBAE materials for gene delivery in the literature. PBAEs 
possessing more hydrophilic (such as PEG-diacrylate based) or hydrophobic (such as PBAE utilizing alkyl 
side chains 14) may perform differently. 
Polymer synthesis and characterization 
PBAE polymers were synthesized as previously described 8, 15. PBAE 4-4-6 used in this study was 
characterized via GPC to have Mn 5,170 Da, Mw 10,220 Da, and dispersity (D) 1.98, while PBAE 4-5-39 was 
characterized to have Mn 4,580 Da, Mw14,290 Da, and dispersity (D) 3.12. PBAE 4-5-39 is a new chemical 
entity using end-cap E39, which is similar to our previously reported E7 end-cap but is slightly more 
hydrophilic, possessing a secondary amine in the piperazine ring instead of a tertiary amine. Together, these 
two PBAE structures are representative of relatively hydrophilic PBAE structures (via the use of PBAE 4-4-
6) and more hydrophobic structures similar to C32 (via 4-5-39) 16. 
Pre-Transfection Incubation Time 
We performed experiments to test if the incubation time of PBAE NPs in buffer prior to adding to 
cells influenced transfection efficacy. Many transfection reagents recommend rapidly pipetting or vortexing 
aqueous solutions of transfection reagent and plasmid DNA followed by an undisturbed incubation period 
ranging from 5-30 minutes for DNA complexation. We hypothesize that the rapid degradation of PBAE 
polymers in aqueous solution might influence the optimal incubation time of these materials prior to adding 
them to cells. To explore this variable, we tested both the pre-incubation time effects of free PBAE polymer 
and the incubation time effects of complexed PBAE/DNA NPs (Fig. 5-1A). First, the pre-incubation time of 
PBAE polymer alone in aqueous solution was tested, showing decreases in efficacy following pre-incubation 
times greater than 10-20 minutes (Fig. 5-1B,C). This result was consistent across cell lines and with two 
PBAE polymers of varying hydrophobicity (Fig. 5-S2A,B). Following these results, we tested the effect of 
incubating PBAE/DNA NPs following NP formation to determine optimal incubation time to allow for 
effective polymer/DNA self-assembly and found that an incubation time of between 5-20 minutes was 
optimal (Fig. 5-1D,E and 5-S2C,D). While long incubation times showed decreases transfection efficacy 
presumably due to degradation, short incubation times of less than one minute following mixing of plasmid 






Figure 5-1. Effect of pre-incubation time of free PBAE polymer and of formed PBAE/DNA nanoparticles 
on transfection. A) Either PBAE 4-4-6 nanoparticles were formed and pre-incubated for set timepoints 
before adding to cells or PBAE 4-4-6 was pre-dissolved in 25 mM NaAc buffer and pre-incubated for set 
timepoints before forming nanoparticles that were then added to cells. PBAE polymer pre-incubated for 10 
minutes or less prior to nanoparticle formation was most effective for transfection in (B) HEK293T and (C) 
MDA-MB-231 cells. Nanoparticles that were pre-incubated 5-20 minutes before adding to cells were most 
effective for transfection of (D) HEK293T and (E) MDA-MB-231 cells.  
To identify why PBAE NPs were susceptible to optimal incubation times, we assessed the diameter 
of PBAE 4-4-6 free polymer and NPs over the time span of one hour in 25 mM NaAc buffer, pH 5. 
Supporting the transfection results, PBAE/DNA NPs were stable over one hour (Fig. 5-S3), indicating that 
PBAE/DNA NPs were effectively stable in acidic buffer over time. We also measured the degradation rate of 
free PBAE polymer and PBAE polymer/DNA complexes in aqueous buffer at different pH values (Fig. 5-
S4). At pH 5.2 in NaAc buffer, the ester bond half-life of free PBAE polymer MN was only 1.6 hours, while 
PBAE/pDNA polyplexes was 3.5 hours (Table 5-S2). This difference in degradation rate for free PBAE 
polymer compared to PBAE/pDNA complexes was statistically significant as assessed by a one-phase decay 
model at pH 5.2 (p<0.0001 for both MN and MW). Free PBAE polymer was further shown to degrade faster 





and PBAE/pDNA polyplexes in degradation rate at higher pH values. This result is consistent with ours and 
others' previously published results showing that degradation of this class of polymers is more rapid at neutral 
pH 2, 13, 17 than at weakly acidic conditions. We hypothesize that when many of the amines in the PBAE 
backbone are not protonated (i.e., >pH 6), they behave as bases and can locally generate -OH species near 
the ester backbone. The -OH species is then free to act as a nucleophile and degrade the ester bonds. At 
lower pH values (<pH 6), when more amines in the PBAE backbone are protonated, the amines no longer 
generate as much hydroxide, and degradation of the polymer backbone is slowed, although this degradation is 
still significantly faster than the degradation of other polyesters such as PLGA, which degrade with a half-life 
on the order of weeks 18. 
Together, these results support limiting the residence time of free PBAE polymer in aqueous 
solution to <20 minutes and keeping the PBAE polymer/DNA complex incubation time between 5-20 
minutes for optimal transfection. In contrast, we performed a similar assay with BPEI/DNA and found that 
pre-incubation times between 10-60 minutes were not statistically different in transfection efficacy for this 
non-degradable cationic polymer (Fig. 5-S5). We hypothesize that the differences observed in the optimal 
pre-incubation time between PBAE NPs and BPEI NPs are primarily attributable to degradation associated 
with PBAEs. 
Mixing Volume Ratio 
Polyplex NPs of pDNA interacting with PBAEs and BPEI prepared by pipet mixing have 
traditionally been mixed in a 1:1 volume ratio of dilute nucleic acid to dilute polymer for simplicity 1, 19. Other 
strategies for forming polyplex NPs, including microfluidic mixing 20 and flash nanoprecipitation 21, vary from 
this 1:1 mixing volume ratio only minimally, with nucleic acids accounting for at least one third of the total 
volume of solution. For many assays, including semi-automated high throughput screening situations, and for 
in vivo administration, however, the ability to vary the volume fraction of the polymer solution in forming 
polyplex NPs would be beneficial. For PBAEs, their amphiphilic nature makes them less water-soluble than 
many other polyplex NP systems with a solubility limit generally approximately 20 mg/mL in acidic buffer. 
For this purpose, we sought to test if the volume fraction of mixing dilute PBAE polymer with dilute 
plasmid DNA influenced the transfection efficacy of the resulting NPs (Fig. 5-2A). Testing PBAE polymer 
volume fractions of 0.15-0.95 demonstrated that the mixing volume ratio did not have a statistically 
significant influence on the transfection efficacy in either cell line with PBAE 4-4-6 (Fig. 5-2B,C). These 
results were confirmed with PBAE 4-5-39 as well (Fig 5-S6), where no statistically significant difference in 
transfection efficacy was noted among the different polymer volume fractions. The standard deviations of 
wells transfected with high polymer volume fractions were statistically higher as assessed by the Brown-






Figure 5-2. Effect of polymer and plasmid mixing ratio. (A) PBAE NPs are not highly sensitive to the mixing 
volume ratio between dilute polymer and plasmid DNA. There were no statistical differences (one-way 
ANOVA with Tukey corrected multiple comparisons) between any transfected groups for (B) HEK293T or 
(C) MDA-MB-231 cells transfected with PBAE 4-4-6. The method of resuspending PBAE polymer in 
aqueous solution likewise did not influence the efficacy of the nanoparticles in (D) HEK293T or (E) MDA-
MB-231 cells. Bars show mean ± SEM of four wells. 
To facilitate high-throughput screening of polymeric NPs, we further sought to test if resuspending 
PBAE polymer by vortexing, resuspending by pipetting in a plate with buffer, or resuspending by pipetting in 
a plate with pre-diluted pDNA in buffer influenced the resulting transfection efficacy. The ability to 























































































to a set volume of stock polymer at 100 mg/mL in DMSO would considerably facilitate rapid testing of these 
materials by skipping the polymer dilution step and enable parallelization in preparation of NPs. Surprisingly, 
we found no difference in transfection efficacy resulting from resuspending PBAE polymers in a round-
bottom plate by forming the NPs in two steps or by direct resuspension to NPs in a single step by pipetting 
dilute pDNA in buffer to resuspend the polymer (Fig. 2D,E). Together, these results regarding methods of 
self-assembly are promising for using PBAEs in parallel semi-automated screening techniques and for their 
use as routine transfection reagents, robust to mixing technique variability among users. 
Freeze/Thaw Cycles 
 PBAE polymers are notable for their rapid degradation in aqueous solution compared to traditional 
polyesters such as poly(lactide-co-glycolide) (PLGA) or polycaprolactone (PCL) 2, 4. The degradation half-life 
of the ester bond in the backbone of PBAE polymers has been measured to typically range from 2 to 6 hours 
depending on hydrophobicity 2, 9 and local pH 2, 9, 13, 17. To avoid the early degradation that would be expected 
to reduce efficacy of the polymers, PBAEs are traditionally stored in anhydrous DMSO at -20°C with silica 
desiccant, but the use of molecular sieves or other stronger desiccants is not needed. Utilization of PBAE 
polymers as routine in vitro transfection reagents or for clinical formulations requires sufficient stability during 
storage to ensure the polymers have the same efficacy after storage. 
To address these concerns, we performed thawed PBAE aliquots in anhydrous DMSO repeatedly on 
subsequent days either under anhydrous conditions or under open-atmosphere laboratory conditions to 
simulate multiple opening-closing events for individual aliquots of polymer. After a set number of freeze-
thaw cycles on subsequent days, polymer aliquots were stored at -20°C for one month, then thawed a final 
time and used for transfection. We hypothesized that the repeated freeze-thaw process or water absorption 
from the atmosphere would result in sufficient polymer degradation to reduce efficacy of the materials 
following multiple freeze-thaw cycles. DMSO is a highly hygroscopic solvent, and water absorption from the 
atmosphere can be a major limiting factor for high throughput compound library screening when compounds 
are stored as DMSO stocks 22. As reported, open-air exposure of DMSO to typical laboratory air for one 
hour can result in absorption of 6% water by volume 22. 
  Transfections were conducted on two cell lines with two PBAE structures (Fig. 5-3 and 5-S7) and 
surprisingly demonstrated no statistical change in transfection efficacy of these materials over eight freeze-
thaw cycles for the PBAE aliquots exposed to anhydrous or open-atmosphere conditions compared to the 
control aliquot of polymer thawed only once. While the hygroscopic nature of DMSO was a concern, the 
amount of time the polymers spent at room temperature and open to laboratory air did not seem to 






Figure 5-3. PBAE polymers are not prone to freeze-thaw induced reductions in efficacy. (A) Schematic of 
experimental outline for testing effect of freeze-thaw cycles on polymer efficacy. (B) HEK293T and (C) 
MDA-MB-231 cell transfection efficacy were not statistically different even with PBAE 4-4-6 having 
undergone eight freeze-thaw cycles (one-way ANOVA with multiple comparisons to the fresh polymer). 
Similarly, PBAE 4-4-6 aliquots pre-mixed to 50 mg/mL prior to storage with varying degrees of hydrated 
DMSO showed no loss in efficacy when stored at -20°C for two weeks and then used within an hour after 
thawing in (D) HEK293T or (E) MDA-MB-231 cells. 
We next sought to determine if water absorption, specifically in anhydrous DMSO, and subsequent 
degradation when stored at -20°C has the potential to reduce efficacy of these materials over time. For this 
experiment, polymer aliquots were prepared with defined water content ranging from 0.25% to 50%, frozen 
































































































4-4-6 lost no efficacy over two months when stored at -20°C and used immediately after thawing, even with 
50% water solutions (Fig. 5-S8). The amount of time that polymer spent in hydrated DMSO at room 
temperature did, however, affect transfection efficacy. Aliquots stored with 25% and 50% water by volume 
became completely ineffective at three and five hours of room temperature incubation respectively, while 
aliquots with 10% water by volume maintained equal efficacy to anhydrous polymer aliquots even after five 
hours of room temperature incubation (Fig. 5-3D,E). These results were consistent between both HEK293T 
and MDA-MB-231 cells, which we hypothesize is attributable to appreciable polymer degradation in hydrated 
DMSO solutions. Given the water absorption rate of DMSO, we recommend limiting room temperature 
incubation of these polymers to less than five hours and open-air exposure of the DMSO stocks to less than 
an hour to keep absorbed water content below 10%. With these recommendations, PBAEs are unlikely to 
suffer degradation induced reductions in efficacy. These results are largely consistent with previous reports of 
storing lyophilized PBAE NPs at 4°C and -20°C, demonstrating that the minute amounts of water absorbed 
from the air are effectively inconsequential as long as the materials are stored at -20°C and the amount of 
time at room temperature is limited to during use for transfection 23. 
Buffer System 
 PBAE NPs have traditionally been prepared in low salt (25 or 50 mM), acidic, pH 5 sodium acetate 
(NaAc) buffer, which ensures tertiary amines in the backbone of the polymer are charged, facilitating 
complexation with anionic DNA 3. Due to the amphiphilic and pH-sensitive nature of PBAE polymers, 
buffer pH as well as osmolarity and valence were all expected to influence NP formation conditions by 
affecting the cationicity and hydrophobicity of the PBAE polymer as well as potentially influencing DNA 
structure. At pH 5, most tertiary amines of linear PBAE structures are protonated, whereas, at neutral pH, 
tertiary amines in the polymer backbone remain largely unprotonated 9. This increase in cationicity likewise 
influences the solubility of PBAE structures, as more highly charged cationic structures are able to undergo 
hydrogen bonding at low pH but are less soluble above pH 6.0. 
The sodium acetate buffer system is notably monovalent for both ions, which are expected to 
participate minimally in interactions between cationic polymer and anionic DNA. To explore the influence of 
buffer valence, we evaluated buffer systems with both divalent cations and anions, which were anticipated to 
participate in binding interactions with either the cationic polymer or anionic DNA. Among anions, citrate 
buffers have long been used when forming liposomes and lipid NPs, typically at pH 4 24-26. Similarly, the 
zwitterionic buffer HEPES has often been used to buffer BPEI in 150 mM NaCl, but due to its limited 
neutral buffering range, we substituted MES as a single-component zwitterion buffer 27. Phosphate buffers 
have likewise been used in transfection, although primarily as a means to precipitate calcium phosphate DNA 





We initially tested six biological buffer systems at 25 mM concentration and pH values of 4, 5, 6 and 
7 with PBAE 4-4-6/pDNA polyplex NPs. Comparing by pH across all buffer systems, PBAE 4-4-6 yielded 
statistically higher transfection efficacy in both cell lines when using acidic buffers of pH of 4 or 5 compared 
to pH 7 buffers (Fig. 5-4A,B), although this result was not universal across all buffer systems and was more 
pronounced in HEK293T cells. No buffers resulted in dramatic differences in measured cell viability (Fig. 5-
4C,D), and all buffer systems yielded some level of transfection. Magnesium acetate and sodium citrate 
buffers at pH 5 repeatedly yielded the highest transfection efficacy and were further explored in subsequent 
transfection screens in which we also included a calcium acetate (CaAc2) buffer (pH 5, 25 mM). 
 
Figure 5-4. Buffer effect on PBAE polyplex NP transfection efficacy. Buffers from six salts were prepared at 
25 mM osmolarity and pH values of 4, 5, 6 and 7 and used to make PBAE 4-4-6 nanoparticles compared 
against the historical buffer of pH 5 sodium acetate (NaAc) shown as the hatched bar. Several buffers showed 
promising increases in transfection efficacy in (A) HEK293T and (B) MDA-MB-231 cells with effectively no 
difference in cytotoxicity (C,D). To assess the influence of buffer pH on transfection, we performed a Tukey-
corrected matched comparisons one-way ANOVA across all buffer conditions with respect to pH to 
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demonstrate that pH 4 and pH 5 buffers were statistically the most effective buffers among all groups with 
significantly greater transfection than pH 7 buffers. Bars show mean ± SEM of four wells. 
 
Divalent cation MgAc2 and CaAc2 buffers at pH 5 and 25 mM concentrations were observed to 
statistically improve transfection efficacy in all tested cases with PBAE NPs 4-4-6 and 4-5-39 in both 
HEK293T and MDA-MB-231 cells (Fig. 5-5 and 5-S9). The improvement in transfection efficacy was notable 
in both cell types as assessed by either geometric mean expression, where calcium acetate yielded five-fold 
higher expression in either cell type, and percent transfection, where calcium acetate yielded 20% and 50% 
higher number of cells detectably expressing GFP in HEK293T and MDA-MB-231 cells respectively. To 
identify why divalent cation buffers improve transfection efficacy, we measured the uptake of PBAE 4-4-6 
NPs formed in different acetate buffers but found no statistically significant differences in the level of NP 
uptake in HEK293T cells (Fig. 5-S10). MDA-MB-231 cell uptake was statistically but only modestly higher 
with divalent cation buffers (Fig. 5-S10,C,D). We also measured the particle diameter and zeta-potential of 
NPs formed in NaAc and MgAc2 buffers, which were observed to have the no statistically significant 
difference between particles prepared in either buffer (Fig. 5-S11). These results indicated that the presence of 
divalent cations was not leading to aggregation of the PBAE NPs or a change in their diameters that would 
bias them towards greater uptake or transfection efficacy exclusively due to size differences. 
 
Figure 5-5. Acetate anion buffers with divalent magnesium or calcium cations improve transfection efficacy 
over monovalent sodium acetate buffer. PBAEs 4-4-6 and 4-5-39 had statistically higher transfection efficacy 
with MgAc2 and CaAc2 buffers than NaAc in (A) HEK293T cells and (B) MDA-MB-231 cells, shown as 



























normalized to the level of transfection efficacy in pH 5, 25 mM NaAc buffer. (C) Microscopy showed 
increase in geometric mean expression of HEK293T cells using divalent cation acetate buffers. Results show 
multiple experiments with four replicates each, normalized to NaAc buffer transfection efficacy for that 
experiment. Scale bars 200 µm. 
To further examine how divalent cation buffers might be affecting transfection efficacy, we measured 
the degree of pDNA binding with PBAE polymer using a variety of assays. Gel electrophoresis retention 
assays with a PBAE w/w titration and heparin sulfate competition binding assay both showed slightly 
reduced binding efficacy between PBAE polymer and pDNA in MgAc2 buffer compared to NaAc buffers 
(Fig. 5-S12). Competition binding assays performed using the DNA-binding carbocyanine nucleic acid dyes 
YO-PRO-1 and YOYO-1 were further consistent with gel retention assay results, indicating slightly stronger 
binding of PBAE polymers to pDNA in NaAc buffer (Fig. 5-S12,F,G). The presence of magnesium ions 
notably affected the fluorescence of YOYO-1 and YO-PRO-1 even in the absence of PBAE polymer, 
indicating that the concentration of divalent cation salts used were likely influencing DNA structure (Fig. 5-
S12,C-E). YOYO-1 and YO-PRO-1 are known to primarily interact with DNA via intercalation, resulting in 
approximately 1000-fold higher fluorescence upon binding double stranded nucleic acids 28. In the absence of 
PBAE polymer, we observed a dramatic increase of over 40% in the fluorescence of YOYO-1 binding to 
pDNA in MgAc2 buffer compared to that in NaAc, whereas YO-PRO-1 fluorescence decreased by 85% in 
MgAc2 buffer compared to that NaAc buffer, which is consistent with the magnesium ion's influencing 
pDNA structure via electrostatic interactions. 
The presence of magnesium, calcium and other divalent cations in solution has long been known to 
affect DNA structure, as hexahydrated magnesium ions bind the major groove of double stranded DNA and 
are involved in stabilization of single-stranded RNAs 29-30. Magnesium or calcium ions are further required to 
facilitate the DNA binding activity of many enzymes and affect the melting temperature of oligonucleotides 
in predictable fashions. To determine if the presence of magnesium and calcium improved transfection by 
changing NP properties or by changing cell phenotype due to their presence in media during transfection, we 
added extra divalent cation salts to cell culture media directly either before or after transfection with PBAE 
NPs formed in NaAc buffer (Fig. 5-6A). Interestingly, the increase in transfection efficacy associated with the 
use of divalent cation buffers only occurred when PBAE NPs were prepared directly with divalent cation 
acetate buffers and not when divalent cation salts were simply added to media (Fig. 5-6B,C). Magnesium 
sulfate and calcium chloride are present at 0.8 and 1.8 mM concentrations in DMEM, respectively, meaning 
that the addition of NPs formed in 25 mM divalent cation acetate buffer increased the media concentration 
of magnesium or calcium only by 5.2 and 2.3 fold respectively. This short duration of exposure to higher 
divalent cation salt concentrations was not expected to change cell phenotype directly in vitro. Magnesium and 





magnesium and calcium between 0.6-1.1 and 2.1-2.6 mM respectively. The fact that divalent cation buffers 
improved transfection only when used to form PBAE NPs and not when simply added to cell culture 
medium indicates that these buffers may likewise improve in vivo transfection efficacy. 
 
Figure 5-6. Divalent cation buffers only improve transfection when used directly to prepare NPs instead of 
simply by being added to media. (A) To identify if divalent cations were affecting NPs or cells directly, NaCl, 
MgCl2 or CaCl2 were added at concentrations to mimic presence when using MgAc2 or CaAc2 buffers and 
added to cells either prior to or after removal of NPs prepared in NaAc buffers only. In parallel, NPs formed 
with divalent cations were complexed in NaAc, MgAc2 or CaAc2 buffers and added to cells. Transfection 
efficacy with PBAE 4-4-6 was improved only for NPs prepared in divalent cation acetate buffers in both (B) 
HEK293T and (C) MDA-MB-231 cells and not by addition of divalent cation salts to media. Bars show mean 
± SEM of four well replicates. 
 
Inspired by historical transfection systems using divalent calcium and phosphate buffers to co-
precipitate plasmid DNA, we also explored using composite buffer systems that, once mixed, resulted in 
insoluble or marginally soluble composites designed to purposefully precipitate NPs of polymer and plasmid 
DNA (Fig. 5-S13). While calcium phosphate transfection is no longer commonly used due to its inconsistency 
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and low transfection efficacy (usually <10% cells), we hypothesized that the ability to selectively enrich the 
media in direct contact with cells with NPs containing plasmid DNA may prove useful 11. Our results 
indicated that these buffer systems were either generally ineffective, unreliable in the distribution of 
transfected cells or highly cytotoxic at the doses explored. Divalent calcium and magnesium acetate buffers 
outperformed all other buffer combinations, with notably higher cell viability and consistency of transfection 
throughout each well. 
4. Conclusions: 
The transfection studies demonstrate the importance of multiple experimental variables involved in 
the reproducible utilization of polyplex poly(beta-amino ester)/pDNA NPs for transfection. Importantly, 
these results demonstrate that PBAE polymers are largely insensitive to changes in the ratio of mixing 
between polymer and pDNA and are able to be resuspended directly from DMSO stocks using dilute DNA 
solutions to self-assemble into nanoparticles in a single step. These polymers are further insensitive to freeze-
thaw cycles and contamination by water as long as they are stored at -20°C and are not kept thawed at room 
temperature for extended times. While consistent when used within 20 min, the polyplex NPs formed with 
these polymers become sensitive to degradation in aqueous buffers beyond 20 min of complexation time. 
Finally, our exploration of buffer systems other than sodium acetate identified divalent cation acetate buffers, 
such as magnesium acetate and calcium acetate, as optimal for transfection efficacy in multiple PBAE 
structures and cell lines in vitro, boosting transfection by severalfold. Together, these results demonstrate 
PBAE polymers a promising general-purpose transfection reagent for in vitro transfections and high-
throughput screening applications. 
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Poly(beta‐amino ester)s (PBAEs) were synthesized following previously described methods shown in 
Fig. S1 8. Briefly, one diacrylate‐terminated backbone monomer (B) was polymerized with one primary 
amine‐containing sidechain monomer (S) in a neat solution by stirring for 24 hours at 90°C, forming the base 
polymer via Michael addition. This base polymer was dissolved in anhydrous tetrahydrofuran (THF) and 
mixed with one end‐cap small molecule (E), then stirred at room temperature for 1 hr. The end‐capped 
PBAE was then precipitated into diethyl ether, washed twice, and left under vacuum for 48 hours for 
complete removal of ether. The dry PBAE was dissolved in anhydrous DMSO at 100 mg/mL and stored at 
−20°C in small aliquots to minimize freeze‐thaw cycles. The specific PBAEs used for the following studies 
were referred to as 4-4-6 or 4-5-39 for polymers composed of monomers B4-S4-E6 and B4-S5-E39 
respectively. 
Cell Culture 
HEK293T human embryonic kidney cells and MDA-MB-231 human triple-negative breast cancer 
cells were maintained in high-glucose DMEM with 10% FBS and 1% penicillin/streptomycin. All cells were 
cultured at 37°C in a 5% CO2 atmosphere. For transfection, cells were plated at a density of 12,000 cells/well 
in 100 µL media approximately 24 hours prior to transfection on CytoOne 96-well tissue culture plates (USA 
Scientific). Transfections were performed in complete medium containing 10% serum. 
Dynamic Light Scattering 
 NPs were prepared independently in triplicate for each condition at 60 w/w mass ratio of polymer to 
DNA with DNA concentrations of 0.06 µg/µL. The NP Z-average hydrodynamic diameter was then 
determined by dynamic light scattering in disposable micro-cuvettes using a Malvern Zetasizer NanoZS 
(Malvern Instruments, Malvern, UK) with a detection angle of 173°. Samples were then diluted six-fold in 





following dispersion in media. For time-course sizing experiments, NP samples were prepared, and a 
measurement was acquired from undisturbed samples every ten minutes for one hour. 
DNA Binding Assays 
 Gel retention assays were performed as previously described 31 to assess binding affinity between 
PBAE polymer and DNA by titrating the PBAE:DNA w/w ratio or by competition binding with heparin 
sulfate. Quantitative DNA binding assays were performed using the DNA binding fluorophores YO-PRO-1 
and YOYO-1 (Thermo Fisher) at a concentration of 1 µM and 1:1 molar ratio of fluorophore to plasmid 
DNA as previously described 13. Fluorescence was measured using a plate reader (Biotek Synergy 2), and 
percent quenching of the fluorophore was calculated by normalizing to plasmid DNA and dye without 
polymer in the matched buffer system. 
Figure 3. PBAE polymers are not prone to freeze-thaw induced reductions in efficacy. (A) Schematic of 
experimental outline for testing effect of freeze-thaw cycles on polymer efficacy. (B) HEK293T and (C) 
MDA-MB-231 cell transfection efficacy were not statistically different even with PBAE 4-4-6 having 
undergone eight freeze-thaw cycles (one-way ANOVA with multiple comparisons to the fresh polymer). 
Similarly, PBAE 4-4-6 aliquots pre-mixed to 50 mg/mL prior to storage with varying degrees of hydrated 
DMSO showed no loss in efficacy when stored at -20°C for two weeks and then used within an hour after 






Figure 5-S1. Schematic of PBAE synthesis for polymer (A) 4-4-6 and (B) 4-5-39. Acrylate terminated base 
polymers were synthesized at a 1.1:1 ratio of acrylate to amine monomers followed by end-capping to yield 









Figure 5-S2. PBAE 4-5-39 pre-incubation time in HEK293T cells. Pre-incubation of dilute PBAE polymer in 
aqueous solution showed similar levels of transfection efficacy (A) and geometric mean expression (B) with 
no significant difference with incubation times between 1-30 minutes. Complexation time incubation of dilute 
PBAE polymer with dilute plasmid DNA showed reduced efficacy in percent of cells transfected (C) and 
geometric mean expression (D) for incubation times of <1 minute and >30 minutes. Differences analyzed by 
one-way ANOVA with Dunnett corrected multiple comparisons. 
 
 


















































































Figure 5-S3. PBAE 4-4-6 in 25 mM NaAc, pH 5 
over time. DLS z-average measurements of PBAE 
polymer + DNA at a 60 w/w ratio showed no 
difference over the span of an hour in acidic buffer. 
PBAE polymer in the absence of DNA gave poor 
quality detectable measurements with DLS. Points 
show mean ± SEM of three individually prepared 
replicate samples. 
 
Figure 5-S4. Effect of DNA interaction on PBAE degradation. Free PBAE 4-4-7 or PBAE 4-4-7/DNA 
nanoparticles at a 60 w/w ratio were dissolved in buffers at pH 5.2, 6.0 or 7.4 and incubated at 37°C. Fitted 
curves show one-phase decay models fit to the data. 
  






















































Figure 5-S5. BPEI 25 kDa pre-incubation time. Dilute BPEI was mixed with dilute plasmid DNA and 
allowed to self-assemble to form polyplex nanoparticles for a set duration prior to adding the polyplex 
nanoparticles to HEK293T cells. A pre-incubation complexation time of 20 minutes was optimal for 
HEK293T (A) transfection efficacy and (B) geometric mean expression, although no statistically significant 
differences were detectable for incubation times between 10-60 minutes. Incubation time of 5 minutes or less 
resulted in statistically lower transfection efficacy. Differences analyzed by one-way ANOVA with Dunnett 














Figure 5-S6. PBAE 4-5-39 mixing ratio. Mixing aqueous solutions of dilute PBAE 4-5-39 and plasmid DNA 
resulted in no statistical differences in (A) transfection efficacy or (B) geometric mean expression in 
HEK293T cells for PBAE volume fractions between 0.15-0.95. Differences analyzed by one-way ANOVA 
with Dunnett corrected multiple comparisons. Geometric mean values did not demonstrate statistically 
significant variation in variance as assessed by Brown-Forsythe test (P = 0.8612). Bars show mean ± SEM of 
four wells. 
 
Figure 5-S7. PBAE 4-5-39 freeze-thaw cycle influence. No significant difference was detectable in the level of 
transfection following up to 8 freeze-thaw cycles of the polymer aliquots in (A) HEK293T or (B) MDA-MB-
































































































































231 cells. Differences analyzed by one-way ANOVA with Dunnett corrected multiple comparisons. Bars 
show mean ± SEM of four wells. 
 
Figure 5-S8. The effect of water fraction content over time on PBAE 4-4-6 NP transfection efficacy over 
time. PBAE 4-4-6 aliquots were diluted to have specific water volume fractions, frozen at -20°C for two 
months and then thawed and held at room temperature for set amounts of time prior to transfection.  
Immediately after thawing (0 hours at room temperature) and at one hour of incubation at room temperature, 
no significant difference was detectable in the level of transfection in (A) HEK293T or (B) MDA-MB-231 
cells. Efficacy of polymer aliquots containing 50% water fraction dropped to zero transfection by three hours 
of room temperature incubation, while efficacy of aliquots containing 25% water fraction Differences 
between the 0% water fraction aliquot and others were analyzed by one-way ANOVA with Dunnett 
corrected multiple comparisons with results statistically lower than the anhydrous DMSO (0%) polymer 
aliquot are shown in red. Bars show mean ± SEM of four wells. 
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Figure 5-S9. The role of buffer cation for PBAE nanoparticle transfections in acetate buffers. MgAc2 and 
CaAc2 resulted in statistically higher percent transfection efficacy as a percent of all cells transfected in (A) 
HEK293T and (B) cells. Results are shown normalized to 25 mM NaAc transfection efficacy results. (C) 
Microscopy images show high levels of viability with no difference from untreated cells for any of the acetate 




















































































buffer conditions of cells transfected with PBAE 4-5-39. Level of GFP expression visibly increases with 
MgAc2 and CaAc2 buffers. Scale bar 200 µm. Bars show mean ± SEM of four wells. 
 
Figure 5-S10. PBAE 4-4-6 acetate buffer DNA uptake. MgAc2 and CaAc2 buffers marginally improved DNA 
uptake with PBAE 4-4-6 nanoparticles. Differences in geometric mean level of DNA uptake were 
insignificant in (A,B) HEK293T cells but statistically significant in (C,D) MDA-MB-231 cells. (E) No 
differences in level of uptake or appearance of internalized DNA were visually observable by microscopy of 




















































Figure 5-S11. PBAE 4-4-6 buffer diameter measurements. (A) PBAE 4-4-6 nanoparticles prepared in pH 5.0, 
25 mM NaAc or MgAc2 were not statistically different in diameter either in the nanoparticle formation buffer 
or following 1:5 dilution into complete media containing 10% serum. (B) Zeta-potential of nanoparticles 
formed in pH 5.0, 25 mM NaAc or MgAc and dilute 1:6 in 10 mM NaCl had no statistically significant 
differences in nanoparticle zeta potential. Each value represents the z-average diameter measured by dynamic 
light scattering of individually prepared nanoparticles.  


























Figure 5-S12. Buffer influence on DNA binding. Nanoparticles prepared in MgAc2 showed reduced DNA 
binding capacity as assessed by all assays. (A) Gel electrophoresis with PBAE 4-4-6 nanoparticle w/w 
titration showed a greater release of DNA at 7.5 and 3.8 w/w ratios in MgAc2 compared to NaAc buffer. (B) 
Similarly, DNA binding in competition binding assay with heparin sulfate showed greater release of DNA at 
heparin w/w ratios 7.5 and 3.8. (C) MgAc2 influenced fluorescence of YOYO-1 and Yo-Pro-1 in the absence 
of PBAE polymer making YOYO-1 bind 40% more effectively and (F) Yo-Pro-1 bind 85% less effectively in 
the absence of DNA. (D,E) In the presence of PBAE polymer these dyes were quenched due to competition 
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specifically for (F) YOYO-1 and (G) Yo-Pro-1 showed reduced binding efficacy of PBAE polymer in MgAc2 
compared to NaAc buffer. All points show mean ± SEM of four well replicates prepared independently. 
 
Figure 5-S13. Composite buffer transfection. (A) Buffers systems in which plasmid DNA and PBAE polymer 
were diluted in separate buffer were explored. MgAc2 and CaAc2 buffers remained most effective. Minimally 
soluble buffer systems including MgHCitr and CaHCitr were also utilized and showed high levels of 
expression but high levels of cytotoxicity at the 200 ng DNA dose used (highlighted in red). (B) Microscopy 



























































DNA Buffer PBAE Buffer
NaAc, 25 mM NaAc, 25 mM
MgAc2, 25 mM MgAc2, 25 mM
CaAc2, 25 mM CaAc2, 25 mM
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CaAc2, 25 mM Na2HPO4, 25 mM
CaCl2, 250 mM, pH 7.05 Na2HPO4, 2.5 mM, pH 7.05








calcium phosphate. Phosphate buffers in particular were notable for causing PBAE nanoparticles to crash out 
of solution as visibly cloudy particulates and no composite buffers showed greater transfection in HEK293T 
or MDA-MB-231 cells. Bars show mean ± SEM of four wells. 
 
Figure 5-S14. Flow cytometry gating in FlowJo. Single cells were identified by gating forward-scatter height 
(FSC-H) against side-scatter height (SSC-H) followed by elimination of double cells by gating forward-scatter 
height against area (FSC-A). Cells were gated for eGFP expression in 2D plot of FL1H vs FL2H and for Cy5 







Table 5-S1.  




1,4-Butanediol diacrylate B4 Alfa Aesar 32780 198.22 
4-amino-1-butanol S4 Fisher Scientific AC176350050 89.14 
5-amino-1-pentanol S5 Alfa Aesar L01979 103.16 
2-(3-Aminopropylamino)ethanol E6 Sigma Aldrich 09293 118.18 







Table 5-S2. PBAE 4-4-7 degradation as free polymer or polyplex nanoparticles with one-phase decay model 
   


















Single Curve  
Both Sets 
  MN MN MN MN   MN MN 
pH R2 Half Life (h) R2 Half Life (h) pH p value R2 
5.2 0.995 1.551 0.983 3.51 5.2 <0.0001 0.942 
6 0.966 1.882 0.994 3.288 6 0.066 0.972 
7.4 0.999 0.505 0.999 0.541 7.4 0.072 0.998 
  
    
  
  
        
   
   










)   




NP   
  
  MW MW MW MW   MW MW 
pH R2 Half Life R2 Half Life pH p value R2 
5.2 0.97 0.717 0.99 2.327 5.2 <0.0001 0.934 
6 0.971 0.919 0.971 1.348 6 0.227 0.964 
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ABSTRACT: 
Safe and effective delivery of DNA to post-mitotic cells, especially highly differentiated cells, remains a 
challenge despite significant progress in the development of gene delivery tools. Non-viral and biodegradable 
polymeric nanoparticles (NPs) can offer an array of advantages for gene delivery over viral vectors due to 





of a high-throughput screening (HTS) platform to synthesize and screen a library of 148 biodegradable 
polymeric nanoparticles, successfully identifying structures that enable efficient transfection of human 
pluripotent stem cell differentiated human retinal pigment epithelial (RPE) cells with minimal toxicity. These 
NPs can deliver plasmid DNA (pDNA) to RPE monolayers more efficiently than leading commercially 
available transfection reagents. Novel synthetic polymers are described that enable high efficacy non-viral gene 
delivery to hard-to-transfect polarized human RPE monolayers, enabling gene loss- and gain-of-function 
studies of cell signaling, developmental, and disease-related pathways. One new synthetic polymer in particular, 
3,3′-iminobis(N,N-dimethylpropylamine)-end terminated poly(1,5-pentanediol diacrylate-co-3 amino-1-
propanol) (5-3-J12), was found to form self-assembled nanoparticles when mixed with plasmid DNA that 
transfect a majority of these human post-mitotic cells with minimal cytotoxicity. The platform described here 
can be utilized as an enabling technology for gene transfer to human cells that are primary, fragile, and resistant 
to conventional approaches of gene transfer. 
 
Key Words: 
Retinal pigment epithelial cell, human stem cell, nanoparticles, non-viral gene therapy, poly(beta-amino ester), 
polymer, ophthalmology 
 
Lay Summary:  
Many retinal diseases are attributable to dysregulation in gene expression or lack of expression of specific genes, 
allowing for the possibility of prevention or cure of these diseases by effective delivery of nucleic acids coding 
for the necessary gene to the retina. Delivery of nucleic acids to cells of the retina is challenging due to the non-
dividing nature of most retinal cells, preventing DNA from reaching the nucleus. To overcome this barrier, we 
engineered and tested a library of nanoparticle formulations to identify polymers that enabled safe and effective 
delivery of nucleic acid cargoes to retinal pigment epithelial cells. The nanoparticle technology explored here 
has the potential to be utilized for therapeutic delivery of nucleic acids to retinal cells, possibly enabling 




Gene therapy holds promise for treating many acquired and inherited blinding disorders [1]. Gene 
therapy for long-term expression, particularly in vivo, has traditionally utilized viral vectors to deliver double 
stranded DNA. For retinal gene therapy, adeno-associated virus (AAV) in particular has been successfully 
utilized for effective delivery to various cells of the retina [2]. However, utilization of AAV vectors for gene 





insertional mutagenesis,[6] the challenge of large scale production of clinical grade vector for human therapy,[7] 
difficulty in transducing some cell types, and as pre-existing patient immunity to specific AAV serotypes [2, 8]. 
To overcome these challenges and to develop a potentially safer approach, an alternative strategy that is 
receiving increased attention is the formulation and development of biodegradable non-viral vectors to facilitate 
delivery of the gene of interest to the target site of interest. Non-viral vectors, although they have their own 
challenges such as relatively low efficiency, have the potential to overcome many of the drawbacks of AAV and 
other viral-based gene delivery methods[9]. 
With this goal of developing safe and efficient non-viral methods for gene delivery, a wide variety of 
non-viral nanoparticles (NPs) have been engineered and tested [10-16]. NPs have been developed that can 
effectively complex with nucleic acids, mediate cell uptake, achieve endosomal escape, and result in cellular 
gene expression. However, despite these significant successes, DNA transducing NPs that have been developed 
to date have tended to suffer from low efficacy [17]. Efficacy of non-viral transfection reagents in post-mitotic 
cell types that have exited the cell cycle is particularly low, as nuclear uptake of plasmid DNA remains a major 
hurdle to effectively mediating expression [18, 19]. Poly(beta-amino ester)s (PBAEs) are a promising class of 
synthetic, cationic polymers with large structural diversity that have been demonstrated to effectively transfect 
a wide variety of cells including embryonic stem cells [20], as well as immortalized human RPE cell lines in vitro 
and mouse RPE cells in vivo [21].  
The RPE, which is essential for retinal function, is composed of a monolayer of pigmented bipolar 
epithelial cells at the backside of the retina. Compromise of the cellular environment of the RPE is associated 
with many hereditary and acquired retinal diseases, including age-related macular degeneration (AMD) and 
retinitis pigmentosa (RP) [22]. Mutations of genes expressed in the RPE are associated with a number of 
retina diseases, and viral-based gene therapies are actively being pursued for several of these diseases [23]. In 
fact, the first FDA approved gene therapy for an inherited disease (voretigene neparvovec-rzyl) is for an 
RPE-related disease, using an AAV-based vector system. Building upon this success, a number of academic 
and industry groups are pursuing gene therapies for a number of other RPE-related genetic diseases. A 
challenge in this work is that a number of the diseases of interest involve genes that exceed the limited 
carrying capacity of AAV. One approach to address this challenge involves clever efforts to artificially 
increase AAV’s carrying capacity [24]  A second approach involves efforts to develop other classes of viral 
gene vectors for retinal disease [25, 26].  A third approach, as noted above, involves development of non-viral 
approaches. However, despite the testing of many different non-viral strategies to deliver DNA to RPE, the 
success of the technologies that have been tested to date has been limited [27-36]. To address this challenge, 
we first established a high throughput-assay platform to screen potential PBAE nanoparticles for their ability 
to efficiently transfect iPSC-derived human RPE monolayers in vitro. Additionally, we hypothesized that the 





tuning the hydrophilicity and end group chemistry of the constituent polymers. To test this hypothesis, we 
synthesized 4 PBAE base polymers with different backbones and then end-capped the linear polymers in a 
parallel plate-based format to yield a library of 148 polymer structures. This library of polymers, that included 
novel amine-containing small molecules as end-groups to serve as putative transfection enhancers, was then 
screened using the high throughput human iPSC RPE monolayer assay. Here we describe identification of 
several promising NPs for RPE transfection. 
2. MATERIALS AND METHODS: 
2.1 Polymer synthesis and characterization 
Monomers for base polymer synthesis were purchased from vendors listed in Table S2, while end-cap 
monomers used were purchased from vendors listed in Table S3 and S4. Acrylate monomers were stored with 
desiccant at 4°C, while amine monomers were stored with desiccant at room temperature. PBAE polymers 
were synthesized neat at 1.1:1 B:S monomer ratios for polymers 3-5-Ac, 4-4-Ac and 4-5-Ac and 1:1.05 
monomer ratio for 5-3-Ac for 24 hours at 90°C. Following synthesis, neat polymers were dissolved at 200 
mg/mL in anhydrous DMF then precipitated in diethyl ether twice at a solvent ratio of 1:10 by vortexing the 
solvents and centrifuging at 3000 rcf. Polymers were allowed to dry under vacuum for 24 hours, at which point 
they were massed and dissolved at 200 mg/mL in anhydrous DMSO and allowed to remain under vacuum to 
remove additional diethyl ether for another 24 hours. Finally, acrylate terminated polymers were aliquoted and 
stored at -20°C until use in end capping reactions. 
For polymer characterization, samples of the initial neat polymer and neat polymer following diethyl 
ether removal were set aside for characterization via 1H NMR and gel permeation chromatography (GPC).  
GPC was performed on polymer samples both before and after double precipitation in diethyl ether using a 
Waters system with auto sampler, styragel column and refractive index detector to determine MN, MW and PDI 
relative to linear polystyrene standards. GPC measurements were performed as previously described with minor 
changes consisting of a modified flow rate (0.5 mL/min) and an increase in sample run time to 75 minutes per 
sample[37]. Analysis of polymers via 1H NMR (Bruker 500 MHz) following diethyl ether precipitation and 
drying was performed to confirm the presence of acrylate peaks. For NMR, neat polymer was dissolved in 
CDCl3 containing 0.05% v/v tetramethylsilane (TMS) as an internal standard. 
2.2 Polymer library preparation 
PBAE polymers were prepared for transfection screening experiments by high-throughput, semi-
automated synthesis techniques using a ViaFlo 384 (Figure 6-2B). For end capping reactions, 25 µL of endcap 
molecules in anhydrous DMSO at a concentration of 0.2 M were distributed to source wells of a deep-well 384 
well plate, then distributed to corresponding replicate wells in groups shown in multiple colors of the end 
capping reaction 384-well deep plate (240 µL volume). Acrylate terminated base polymers at 200 mg/mL in 





well containing DMSO only for the acrylate terminated polymer control. End capping reactions were allowed 
to proceed for two hours at room temperature on a gentle shaker, after which endcapped PBAE polymers were 
diluted to 50 mg/mL in anhydrous DMSO and aliquoted to 5 µL per well on the left side of 384-well 
nanoparticle source plates. Nanoparticle source plates were sealed and stored at -20°C with desiccant until 
needed for transfection. Following large-scale screening of the PBAE library in 384-well plates, larger batches 
of top PBAE structures were synthesized from frozen base polymer using the same protocol described above. 
Endcapped polymers were then aliquoted to individual tubes and stored at -20°C with desiccant. 
For end capping, reaction volumes of 50 µL at 100 mg/mL polymer concentration and 0.1 M amine 
monomer End-cap concentration were selected as sufficient to enable effective reactivity over a two-hour time 
period. For initial studies, endcap molecule E1 was titrated between 0.2 and 0.0625 M in reactions with base 
polymer PBAE 4-5-Ac at 100 mg/mL over two hours. Reacted polymers were then precipitated twice in diethyl 
ether to remove excess endcap monomer, dried and assessed using 1H NMR to determine efficacy of the end 
capping reaction by the disappearance of acrylate moiety peaks between 5.5-6.5 ppm. These results 
demonstrated effective end capping down to a concentration of 0.05 M for endcap molecule E1. To allow for 
varying levels of reactivity between endcap molecules, an endcap molecule concentration of 0.1 M was used for 
parallel large-scale end capping reactions. 
 
2.3 Nanoparticle characterization 
The hydrodynamic diameter of top PBAE structure 3,3′-iminobis(N,N-dimethylpropylamine)-end terminated 
poly(1,5-pentanediol diacrylate-co-3 amino-1-propanol) (5-3-J12) was characterized at three different w/w 
ratios to assess the influence of w/w ratio on nanoparticle characteristics. For dynamic light scatter (DLS) 
measurements, nanoparticles were initially formed in 25 mM MgAc2, pH 5.0 then diluted 1:6 into 10% FBS in 
PBS dynamics and analyzed in disposable micro-cuvettes using a Malvern Zetasizer NanoZS (Malvern 
Instruments, Malvern, UK) with a detection angle of 173°. For zeta potential, nanoparticles were prepared and 
diluted as for DLS, but were analyzed by electrophoretic light scattering was in disposable zeta cuvettes at 25°C 
using the same Malvern Zetasizer NanoZS. For nanoparticle tracking analysis, nanoparticles were formed in 25 
mM MgAc2, pH 5, then diluted 1:500 in 150 mM PBS as previously described using a Nanosight NS300 [38].  
A gel retention assay to assess PBAE: DNA binding strength was performed as previously described 
[39] using a 1% agarose gel. Acrylate terminated PBAE 5-3-Ac was compared against top PBAE structure 5-3-
J12 at w/w ratios from 0 to 50 to demonstrate improved binding of endcapped PBAE structures. 
Transmission electron microscopy (TEM) images were acquired using a Philips CM120 (Philips 
Research, BriarcliffsManor, New York) on 400 square mesh carbon coated TEM grids. Samples were prepared 





µL were allowed to coat TEM grids for 20 minutes. Grids were then dipped briefly in ultrapure water, wicked 
dry and allowed to fully dry before imaging. 
 
2.4 Plasmid Design 
For the in vitro transfection, a plasmid coding for the mCherry open reading frame was created by PCR 
amplification of the mCherry-N1 plasmid (catalog no. 632523; Clontech). Since this plasmid has no start site, 
an ATG initiation codon was added to the forward primer. After PCR amplification, mCherry was inserted into 
the directional pENTR-D-TOPO gateway entry vector (catalog no. K240020; Invitrogen). Positive colonies 
were selected by PCR and confirmed by sequencing. 100ng of purified entry plasmid was mixed with pCAGG-
DV destination vector, created by incorporating a gateway cassette containing attR recombination sites flanking 
a ccdB gene into the pCAGEN vector (Addgene #11160), in the presence of LR clonase II (catalog no. 
11791019). After recombination clones were selected and sequenced and deposited (Addgene 108685). For 
experiments using co-delivery of two plasmids, iRFP670-N1 (Addgene 45457) [40] was used. 
2.5 Differentiation and Culture of RPE From hPSCs 
RPE monolayers were differentiated as described previously [41, 42] from the EP1-GFP human iPS 
cell line that constitutively expresses H2B-nuclear-GFP. In brief, iPS cells to be differentiated were plated at 
60,000 cells per cm2 on Matrigel-coated 384-well plates and allowed to grow for 25 days in RPE medium 
consisting of 70% DMEM (catalog no. 11965092; ThermoFisher Scientific), 30% Ham’s F-12[43] Nutrient Mix 
(catalog no. 11765-054; Invitrogen), serum free B27 supplement  (catalog no. 17504044; ThermoFisher 
Scientific), and antibiotic-antimycotic (catalog no. 15240062; ThermoFisher Scientific). Coating of plates with 
Matrigel (25 μL per well), seeding of cells (50 μL per well), and media change every other day (replaced with 
fresh 25 μL per well) were accomplished using a high throughput Viaflo microplate dispenser (catalog no. 6031; 
Intergra). Cells were confirmed to possess an RPE monolayer phenotype at day 25 following plating. 
2.6 Imaging and Analysis using HCS studio 2.0 Software 
Images were acquired on an ArrayScan VTI HCA Reader (Thermo Fisher Scientific) using a 20x 
objective. For analysis, the Thermo Scientific AdvancedTargetValidationV4.1 application was used with the 
assay described in Figure 6-S4. 
2.7 In vitro nanoparticle mediated gene delivery  
On the day of transfection, the old media was discarded and replaced with 40 μL of fresh RPE media. 
To form PBAE/DNA nanoparticles, pDNA was diluted in 25 mM magnesium acetate buffer (MgAc2, pH 5) 
and aliquoted to individual wells on the right half of the 384-nanoparticle-source plate. End capped PBAEs 
from the left half of the 384 well round bottom source well place (Figure 6-2D) were then resuspended in 
parallel in 25 mM MgAc2 using a Viaflo microplate dispenser. After a brief centrifugation (1000 RCF for 1 





bottom source well place containing pDNA (Figure 6-2D) in a 3:1 (vol/vol) ratio, resulting in a defined weight-
weight (w/w) ratio between 20-100 of PBAE:DNA. The nanoparticle source plate containing the PBAE/DNA 
mixtures was then briefly centrifuged (1000 RCF for 1 minute). To dispense nanoparticles to cells, 5 µL volumes 
of the NPs in each well were then added to the RPE monolayer (Figure 6-2E) and incubated with cells for 2 
hours inside the 37°C incubator; all nanoparticles and media were then replaced with 50 μL of fresh RPE media. 
After 48 hours to allow for reporter gene expression, images were acquired using an automated fluorescence-
based imaging system (Cellomics ArrayScan ; Thermo Fisher Scientific) for nuclear-GFP and mCherry. 
Transfected cells were identified as those expressing both the endogenous nuclear GFP and exogenous 
mCherry reporters, and the percent of transfected cells, as well as cell viability, was determined for each NP 
and condition. 
2.8 Immunostaining and Confocal Microscopy 
iPS EP1 cells, without a nuclear-GFP reporter, were differentiated by plating them at 25,000 cells per 
cm2 on Matrigel-coated borosilicate sterile 8-well chambered cover glasses (catalog no. 155409; Lab-Tek II; ) 
and allowed to grow for 25 days in RPE medium. On the day of transfection, the old media was discarded and 
replaced with 300 μL of fresh RPE media. The PBAE 5-3-J12 was then mixed with CAG-mCherry pDNA in 
a 3:1 (vol/vol) ratio, resulting in a defined weight-weight (w/w) ratio of 90:1 of PBAE:DNA. To dispense 
nanoparticles to cells, 50 µL volumes of the NPs containing 1500 ng DNA were then added to the RPE 
monolayer and incubated with cells for 2 hours inside the 37°C incubator; all nanoparticles and media were 
then replaced with 300 μL of fresh RPE media. After 48 hours, to allow for reporter gene expression, the cells 
were fixed with 4% paraformaldehyde in PBS, cells were blocked and permeabilized for 30 min in 5% goat 
serum, 0.25% Triton X-100 in PBS, and then incubated for 1 h at room temperature with polyclonal mouse 
anti–ZO-1 (1/500; catalog no. 40-2200; Invitrogen) monoclonal rat anti–mCherry (1/1000; catalog no. M-
11217; Molecular Probes). Cells were then incubated for 1 h at room temperature with the corresponding 
secondary antibody conjugated to Alexa 488 or Alexa 568 (Invitrogen), and counterstained with Hoechst 33342 
(Invitrogen). Images were captured with a confocal microscope (Zeiss LSM 710). 
2.9 Co-expression Assay 
To assess the ability of top PBAE nanoparticles to co-deliver two plasmids, plasmids CAG-mCherry 
(Addgene 108685) and CMV-iRFP670 (Addgene 45457) [40] were diluted together in 25 mM MgAc2 and used 
to form PBAE 5-3-J12 nanoparticles at a 90 w/w ratio. These nanoparticles were used to transfect  and DNA 
dose of 200 ng/well in 384 well plates. For the co-delivered condition, plasmids in 25 mM MgAc2, were pre-
mixed prior to complexation with PBAE and added to RPE monolayers together in the same nanoparticles. 
Transfection efficacy for iRFP and mCherry was then assessed 72 hours following transfection using the HCS 
assay described below. 





Graph pad prism software (v.7.0) was used for data analysis. One-way ANOVA test was used for 
comparison of the results. For finding the differences between groups, data was analyzed by post-Hoc, 
Dunnett’s multiple comparisons test. P values of ****p<.0001; ***p<.001; **p<.01; *p<.05 were considered 




3.1 Polymer Synthesis and Characterization 
Four acrylate-terminated PBAEs that were shown previously to be effective for gene delivery in various 
cell types were synthesized as previously described [44] as neat polymers from small molecule diacrylate and 
amino monomers (Figure 6-1). The acrylate-terminated polymers were also washed twice with diethyl ether 
and characterized via gel permeation chromatography and 1H NMR to assess number average molecular weight 
(MN) and to ensure that the majority of polymer molecules were acrylate terminated to allow for effective end-
capping (Figure 6-S1). The results indicated that all synthesized polymers, were acrylate terminated with 
number average molecular weights between 6.2 to 7.8 kDa (Figure 6-S2). Precipitation in diethyl ether has 
previously been utilized to remove excess end-cap monomers reacted with base-polymers to avoid free 
monomer induced cytotoxicity [45]. We hypothesized that precipitation via diethyl ether even in the absence of 
end-cap monomers to be removed would increase molecular weight and reduce polydispersity of synthesized 
acrylate terminated polymers by removing oligomers that have been shown to be ineffective for gene delivery 
purposes [46, 47]. This effect was confirmed by GPC analysis of polymer before and after precipitation, 
whereby MN increased by an average of 41 ± 9% (mean ± SD) and PDI decreased by an average of 16 ± 9% 
(mean ± SD). The molecular weights of the base polymers are all within the optimal range for transfection 
efficacy previously reported for similar polymer structures [46]. 
Utilization of end-cap monomers in linear PBAEs has been demonstrated to greatly improve 
transfection efficacy compared to side-chain monomer terminated polymers (i.e. C32) [48-52]. Furthermore, 
polymer end-capping groups have been shown to significantly increase the efficacy of acrylate terminated base 
polymers that are almost entirely ineffective for both uptake and transfection [53]. With this rationale, we 
selected potential end-cap monomers from those previously published and available potential primary amine 
monomers from chemical supply companies. Polymer 4-4-Ac was endcapped with each potential monomer 
initially and pre-screened for transfection efficacy in HEK293T cells to separate out wholly ineffective end-cap 
monomers (Figure 6-S3 and Table S6-4). From this pre-screen, we selected 36 end-cap monomers (Figure 6-1) 
to use for polymeric library preparation, having eliminated 24 of the structures for RPE screening tests. 
The polymer nomenclature “BN-SN-XY” in the synthesized polymer library denotes base monomer (B) 





between hydroxyl as previously described.[44]  Due to the large number of amino end-cap monomers, we 
utilized a new naming scheme whereby end-cap monomers were given a letter (J-P) for specific structural 
category (denoted X above) followed by a number for specific monomer in the category (denoted Y above). 
Structural categories of end-cap monomers included amino alkanes (J), amino piperidines (K), amino 
pyrollidines (L), amino alcohols (M), amino piperizines (N), diamino-ethers (O) and amino morpholinos (P). 
By this nomenclature, 3,3′-iminobis(N,N-dimethylpropylamine)-end terminated poly(1,5-pentanediol 
diacrylate-co-3 amino-1-propanol) (PBAE 5-3-J12) was synthesized from monomers B5 and S3 to yield an 
acrylate terminated PBAE followed by endcapping with monomer J12 to yield a linear, end-capped polymer. 
 
Figure 6-1. Sequential poly(beta-amino ester)s (PBAEs) library construction and synthesis scheme (A) 
Synthesis scheme of linear PBAEs from diacrylate and primary amine small monomers to yield acrylate 
terminated polymers, followed by end-capping to yield linear end-capped PBAEs. (B) Representative PBAE 
5-3-J12 formed from monomers B5, S3 and end-cap J12. (C) Τhree diacrylate monomers and (D) three side-
chain amino alcohols utilized in library synthesis. (E) 36 end-cap monomers identified as effective for 
transfection. 
 
2.2 Polymer Library Preparation 
The polymer library described above was prepared in a semi-automated, high-throughput manner to 
identify polymer formulations effective for transfection of iPSC derived RPE cells in a highly parallel manner 
as shown in Figure 6-2. For high-throughput polymer end-capping reactions, end-cap monomers in DMSO 


























































































































































































































in parallel and allowed to react for two hours at room temperature with gentle shaking. End-capped polymers 
in the master reaction plate were diluted further in DMSO and a set volume was distributed in parallel to 
individual nanoparticle source plates (384 well round-bottom plates). Nanoparticle source plates were then 
sealed and stored at -20°C with desiccant until the time of transfection. This method allowed many nanoparticle 
source plates to be prepared at one occasion to ensure reproducibility between transfections on different days.  
 
Figure 6-2. Schematic of combinatorial PBAE library construction (A) Linear base polymer PBAEs were 
synthesized in vials to be acrylate terminated, then characterized via 1H NMR and GPC (B) Synthesized 
polymers were dispensed into a 384 well round bottom plate using a Viaflo  96/384 microplate dispenser and 
end-capped with each base polymer. A total of 4 different base polymers as shown in different color scheme 
were end-capped per master plate containing 36 end-cap monomers each. (C) Source plates were then 
replicated from one master plate and stored them at -80 oC for future use. (D) End capped linear polymers 
(left 12 columns of the plate) were mixed with plasmid DNA (right 12 columns of the plate) to formulate NPs. 
(E) The RPE monolayers were transfected using an automated Viaflo microplate dispenser and incubated for 
2 hours with NPs. (F) Images were captured using Cellomics. 
 
 
2.3 High Throughput Semi-Automated NP Transfection to RPE Monolayers 
To access the transfection efficacy of the PBAE nanoparticles in mature RPE monolayers at day 25 
following seeding of differentiated RPE cells (Figure 6-S5), we conducted a high throughput-screening assay 
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with the prepared library of 148 PBAE structures. For high-throughput transfections, a nanoparticle source 
plate with polymers in one-half of the wells was thawed and DNA diluted in pH 5 magnesium acetate 
(MgAc2) buffer was distributed to the right half of the plate. For initial screening assays we choose to use a 
plasmid in which expression of the fluorescent reporter mCherry is driven by the chicken β-actin with a CMV 
enhancer (CAG) promoter because the CAG promoter was previously shown to be highly active in human 
iPSC-derived RPE cells [54]. Each polymer was resuspended in pH 5 MgAc2 buffer in parallel and mixed with 
the dilute DNA to form polyplex nanoparticles by electrostatic self-assembly. Nanoparticles were then 
distributed to plates of cells in parallel to screen for transfection efficacy using an image-based High Content 
Screening assay (Figure 6-S4). This setup enabled 148 polymer structures per nanoparticle source plate to be 
tested with two replicates for each polymer per plate of cells. 
Our library of polymers was first screened at a 60 w/w ratio of polymer to plasmid DNA to assess 
transfection efficacy (Figure 6-3A) and viability (Figure 6-3B) relative to untreated RPE monolayers. As 
previously observed, acrylate terminated polymers (5-3-Ac, etc) lacking any end-cap monomer failed to yield 
detectable transfection [55]. Heat map arrays of transfection efficacy demonstrated that more hydrophobic 
polymer structures (base polymers 5-3- and 4-5-) generally yielded greater transfection and the end-cap played 
an important role in the efficacy of polymers overall. Several leading PBAE structures, 5-3-J12, 5-3-F3 and 5-
3-F4, resulted in 42%, 37% and, 34% positively transfected cells, respectively while maintaining high cell 
viability (90%, 97% and, 98%, respectively). Among all polymers evaluated, cell viability was not directly 
proportional to a polymer’s ability to transfect RPE monolayers, as some other PBAEs demonstrated extremely 
low transfection efficacy despite high cell viability. Interestingly, the results of screening this library of polymers 
on mature RPE monolayers at day 25 post-seeding differed from transfection efficacy screening in mitotic RPE 
cells on day 3 post-seeding (Figure 6-S6), where more hydrophilic polymer structures demonstrated the highest 
efficacy and greater cytotoxicity was notable among all polymers. These results thus confirm our prior 
experience that polymer transfection efficiency can be highly cell type/state dependent and highlight the 






Figure 6-3. High throughput screening of PBAE nanoparticles in confluent D25 RPE monolayers. (A) 
Heat maps showing the percentage transfected RPE cells and (B) percentage survival rate following the 
introduction of a combination of 148 different nanoparticles to confluent RPE monolayers at day 25 post 
seeding using a 60 w/w ratio of polymer to CAG-mCherry plasmid DNA. The color scale bar refers to the 
percentage transfection efficiency and percentage survival that was calculated based on the number of mCherry 








2.4 Validation of 5-3-J12 Nanoparticle Transfection Efficacy 
In order to validate and optimize the top polymer structure identified in our screen, 5-3-J12, polymer 
to DNA w/w ratio and overall polymer dose per well were varied to identify optimal transfection conditions 
(Figure 6-S7). With this optimization, 90 w/w 5-3-J12 nanoparticles were demonstrated to yield the greatest 
transfection efficacy (up to 60% transfection) compared to 30 w/w and 60 w/w nanoparticles of the same 
polymer structure at an equal polymer dose per well of cells. Assessment of a wide range of leading 
commercially available transfection reagents at multiple ratios of reagent to DNA and multiple DNA doses 
further demonstrated the enhanced efficacy of this new chemical compound in transfection of RPE monolayers 
(Figure 6-S8). In direct comparisons, PBAE 5-3-J12 yielded statistically significantly higher transfection 
efficacy (Figure 6-4A) than all tested commercial transfection reagents as well as our previously developed top 
PBAE polymer for transfection of RPE cells (PBAE 557) {Sunshine, 2012 #43}. Viability of RPE monolayers 
with nanoparticle 5-3-J12 was not statistically significantly different from untreated cells, in contrast to most 
commercial reagents, which induced significant cytotoxicity to achieve lower transfection efficacy (Figure 6-
4B). PBAE 5-3-J12 further yielded a greater degree of transgene expression than the top commercial reagent 
ViaFect, as shown by both flow cytometry (Figure 6-4C) and by microscopy (Figure 6-4D). Overall 
transfection efficacy for all transfection reagents varied together across independently prepared iPSC-
derivations of mature RPE monolayers over a 9-month time-span, but the top polymer structure, 5-3-J12, 
always yielded transfection efficiencies (20% to 60%) that were statistically higher than the top commercial 
reagent, ViaFect (Figure 6-S9).  
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Figure 6-4. Transfection of RPE monolayers with top PBAE nanoparticles and with commercially 
available reagents. (A) Transfection efficacy and (B) relative cell count of optimized nanoparticle formulation 
compared to commercial reagents. (One-way ANOVA with Dunnett corrected multiple comparisons) (C) 
Relative expression level of cells transfected with 5-3-J12 and ViaFect demonstrating a greater number of cells 
expressing at all levels of expression. (D) Representative microscope images of RPE cells expressing nuclear 
GFP (green) and transfected with mCherry (red). Scale bar is 100 μm. Bars show mean ± SEM of four wells. 
 
2.5 Biophysical Characterization of 5-3-J12 Nanoparticle 
To further investigate the biophysical properties of 5-3-J12, we characterized these nanoparticles at 
multiple w/w ratios via dynamic light scattering (DLS), electrophoretic light scattering for zeta-potential, and 
nanoparticle tracking analysis (NTA). 5-3-J12 nanoparticles at w/w ratios of 30, 60 and 90 polymer to DNA 
varied significantly in diameter assessed by DLS and NTA with 90 w/w nanoparticles forming significantly 
smaller particles (Figure 6-5A,B). This result is consistent with our previously published findings that forming 
PBAE nanoparticles at high w/w ratios with excess polymer has a tendency to yield a smaller overall population 
of nanoparticles [56, 57]. Zeta-potential of 5-3-J12 did not vary with w/w ratio, with all 5-3-J12 nanoparticles 
measured to have a surface charge of between 25-30 mV (Figure 6-5C). The addition of the J12 end-cap moiety 
to base polymer 5-3-Ac was demonstrated to improve DNA binding capacity via a gel retention assay (Figure 
6-5D), likely due to increased positive charge from the amine-containing J12 end-group. The diameter of PBAE 
5-3-J12 nanoparticles assessed by TEM was similarly consistent with hydrodynamic diameter sizing 






Figure 6-5. PBAE 5-3-J12/DNA Nanoparticle Characterization (A) Nanoparticle hydrodynamic diameter 
measurements assessed via DLS z-average and (B) NTA showed that average diameter decreased as polymer: 
DNA w/w ratio increased. DLS z-average measurements were statistically lower for 90 w/w nanoparticles, 
compared to 30 w/w nanoparticles. (C) Nanoparticle zeta-potential did not statistically differ between the 
nanoparticles at different w/w ratios. (D) End-capping with monomer J12 improved DNA binding compared 
to acrylate-terminated polymers. PBAE 5-3-J12 fully retarded DNA at w/w ratios down to 5 w/w, in contrast 
to the acrylate terminated polymer, which was only effective down to a 10 w/w ratio. (E) TEM showed 5-3-
J12/DNA nanoparticles have a spherical morphology and size of approximately 100 nm. Graphs show the 
mean of three independently prepared samples. *p < 0.01, **p < 0.001, based on one-way ANOVA with 
Tukey's post hoc test. 
 
2.6 Co-transfection and Properties of RPE Monolayer Transfected Cells 
For in vitro mechanistic studies as well as potentially for in vivo ocular gene therapy applications, it could 
be advantageous to transfect cells simultaneously with multiple genes. We therefore tested whether our non-
viral delivery system could provide efficient co-expression of multiple genes. Transfection of mature RPE 
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yielded up to 22% of cells showing co-expression of both genes (Figure 6-6A). Among cells detectably 
expressing either fluorescent protein, most showed expression of both genes (53.5 ± 1.4%), rather than 
expressing just one gene (15.0 ± 2.6% and 31.4 ± 2.7% for CAG-mCherry and CMV-iRFP670 respectively). 
In all transfection experiments, among the transfected cells we observed a wide range of expression levels. We 
also observed that there seemed to be a relationship between expression level and cell viability. With the strong 
synthetic CAG promoter, with both PBAE 5-3-J12 as well as ViaFect-mediated transfection, the cells that 
expressed the exogenous reporter genes at the highest levels were more likely to undergo cell death (see 
Supplementary Video that demonstrate time-lapse microscopy of highly expressing cells undergoing cell death). 
However, the induction of cell death was determined not to be directly attributable to the polymers themselves 
as nanoparticles prepared with non-coding Cy5-labeled plasmid DNA [58] did not induce a significant level of 
cell death, whereas a reduction in the total number of nuclear-GFP positive cells per well for RPE monolayers 
transfected with the same nanoparticles prepared with the CAG-mCherry plasmid was observed (Figure S10). 
Finally, confocal microscopy assessment of RPE monolayers transfected and stained for tight junctions (ZO-






Figure 6-6. Co-transfection of two reporter plasmids with PBAE 5-3-J12/DNA nanoparticles.  (A) 
Nanoparticles formed with pre-mixed plasmids encoding CAG-mCherry and CMV-iRFP enable RPE 
monolayers to co-express two exogenous genes. The majority of the cell population detectable as expressing 
either fluorescent protein, expressed both fluorescent proteins. (B) Representative RPE monolayers co-
transfected with both CAG-mCherry (red) CMV-iRFP670 (blue) reporter constructs.  A purple color indicates 
co-expression of the two exogenous genes. Scale bar is 100 µm. Bars show mean ± SEM of four wells. 
































Figure 6-7. Transfected RPE monolayer tight junction expression. (A) Maximum intensity projection 
confocal microscope image of RPE monolayer transfected with 5-3-J12/DNA nanoparticles at 90 w/w ratio 




Safe and effective non-viral gene delivery of plasmid DNA to post-mitotic cells remains challenging in 
part due to the lack of nuclear membrane breakdown, which is a major barrier to gene delivery. Delivery of 
plasmid DNA to post-mitotic cells is of great utility for the study of retinal biology as well as for the 
development of non-viral therapeutic materials for retinal gene therapy. Here, we designed and utilized a semi-
automated high throughput system to generate and identify candidate biodegradable polymer structures that 
mediate effective delivery to post-mitotic, mature RPE monolayers derived from induced pluripotent stem cells 
[41, 42]. While prior studies have utilized immortalized RPE cell lines such as ARPE-19 or hTERT-RPE1 to 
study gene delivery to RPE monolayers in vitro, these cell lines are provide only a limited model of the cell 
behavior of RPE cells in vivo both in terms of cellular phenotype and gene expression profile. The ES-derived 


















expression of RPE cells in the human retina, enabling them to serve as a useful model for the study RPE biology 
in high throughput formats [42]. 
The approach for high throughput PBAE library generation described here is highly adaptable for 
rapid library generation and screening techniques. In contrast to prior automated and semi-automated synthesis 
libraries that have used pipetting robots such as Tecan [59], our simplified semi-automated technique facilitates 
parallel testing of polymer structures that can be implemented with any parallel pipetting framework, including 
in 96 well plates with a simple multichannel pipet. Our approach also demonstrates the importance of end-cap 
monomer structure for determining the efficacy of linear PBAEs for transfection, an approach which is highly 
amenable to simple parallelization [52]. 
With these validated RPE monolayers and semi-automated polymer library preparation and screening 
technique, we identified multiple candidate polymer structures for transfection of post-mitotic RPE monolayers 
with the most promising candidate, 5-3-J12, yielding up to 60% transfection efficacy with minimal cytotoxicity. 
This polymer structure was further shown to enable co-delivery of two separate plamids coding for two 
fluorescent proteins, and we demonstrated that tight junctions stained with anti-ZO-1 remained largely in-tact 
following transfection. The utilization of this screening approach is notable given that our prior candidate for 
transfection of RPE cells (PBAE 557), identified by screening in ARPE-19 monolayers [21], yields <15% 
transfection efficacy in our current assay with mature RPE monolayers. Similarly, widely-used commercial 
transfection reagents such as Lipofectamine 3000 and JetPRIME polyethylenimine were minimally effective at 
transfecting difficult-to-transfect post-mitotic RPE monolayers. The commercial reagent ViaFect was the most 
effective commercially available reagent tested, but it yielded less than half the level of transfection of our top 
identified polymer, PBAE 5-3-J12.  
Our top identified polymer structure, a new composition that utilizes 3,3′-iminobis(N,N-
dimethylpropylamine) as an end-group, was characterized as a nanoparticle and shown to possess biophysical 
properties very similar to other leading non-viral gene delivery particles (~100 nm in size with a positive surface 
charge). Given the relative ease of synthesis of PBAEs and their overall low cytotoxicty and permanence due 
to their rapid hydrolytic degradation rate [55], they represent a promising biological technology for routine in 
vitro transfections in the laboratory to further research into retinal biology and genetics. 
Despite the promise of PBAEs for transfection of difficult to transfect cells, we do also want to 
mention a note of caution. Previous work has demonstrated that high levels of transgene expression, including 
high levels of fluorescent reporter protein expression, can induce apoptosis and other undesirable cellular 
changes in transfected cells, which may be a challenge for the use of high efficiency non-viral vectors such as 
those described in this manuscript [60]. Presumably related to this phenomenon, we did observe cellular 
changes and cell death in experiments in which RPE cells were induced to express high levels of mCherry here, 





negatives effects of over-expression include utilization of self-limiting expression cassettes and use of weaker 
or regulatable promoters, as well as developing methods to directly reduce the cellular toxicity of over-expressed 
proteins.  
CONCLUSIONS 
In summary, here we report the high-throughput screening and development of PBAE-based, 
biodegradable nanoparticles as efficient vehicles for delivering pDNA to human iPSC-RPE monolayers using 
a combinatorial chemistry approach. By screening a total of 140 synthesized PBAEs with varying chemical 
structures, we identified lead PBAE structures that resulted in markedly increased pDNA delivery efficiency in 
vitro. Our results suggest that PBAE can effectively complex pDNA into nanoparticles, and protect the pDNA 
from being degraded by environmental nucleases and deliver pDNA effectively to RPE monolayers. 
Furthermore, our results support our hypothesis that PBAE-mediated pDNA delivery efficiency can be 
modulated by tuning PBAE end group chemistry. Using human iPSC-RPE monolayers as model cell types, we 
identified several PBAE polymers that allow efficient pDNA delivery at levels that are double that of leading 
commercial transfection reagents, while maintaining high cell viability. The top synthetic polymer, 3,3′-
iminobis(N,N-dimethylpropylamine)-end terminated poly(1,5-pentanediol diacrylate-co-3 amino-1-propanol) 
(5-3-J12), formed ~100 nm nanoparticles when mixed with plasmid DNA, could co-deliver multiple plasmids 
to human iPSC-RPE monolayers, and was capable of transfecting a majority of iPSC-RPE cells with minimal 
cytotoxicity. Together, our results highlight the promise of PBAE-based nanoparticles as novel non-viral gene 
carriers for pDNA delivery into hard-to-transfect cells such as RPE monolayers. 
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1.1 Commercial Transfection Reagent Preparation 
 
All commercial reagents were prepared according to manufacturer recommendations with CAG-mCherry at 
the ratios listed in the table below. After 15-20 minutes for particle formation, nanoparticles were added to day 
25 differentiated RPE monolayer cells in 384 well plates at the specified DNA doses by varying dispensing 
volume. After either 4 or 24 hours, media was entirely replaced with fresh medium and cells were cultured for 
two additional days, at which point transfection efficacy was assessed by image analysis with Cellomics.  Minimal 
transfection (<1%) was generally noted for the tested 4-hour incubation times, so only 24 hour incubation time 
data is presented.  
 
Table S6-1. Commercial reagents 
 





ViaFect Promega E4981 2, 4 24 
Dreamfect Stem OZ Biosciences ST30500 1.5, 3 24 
Dreamfect Gold OZ Biosciences DG80500 2, 4 24 
FuGENE HD Promega E2311 1, 3 24 
FuGENE 6 Promega E2691 2, 6 24 
JetPRIME Polyplus 114-07 0.5, 1 24 
DNA-IN Stem MTI-Global Stem 73750 0.5, 1 24 








Figure 6-S1. Base polymer PBAEs 1H NMR. Following synthesis, polymers were washed with diethyl ether 
twice and characterized by 1H NMR (500 Mhz) to verify that base polymer structures were acrylate 





molecular weight MN of base polymers. Calibration and contamination peaks include CDCl3 7.26; DMSO 




Figure 6-S2. Gel permeation chromatograph polymer size characterization. PBAEs were characterized via gel 
permeation chromatography to assess molecular weight against linear polystyrene standards following 
synthesis and after dissolved in DMSO and washed with diethyl ether twice. Washing with diethyl ether was 
shown to remove unreacted monomers units and small oligomers, (A) increasing polymer number average 








Figure 6-S3. Ineffective endcap monomers. Endcap structures shown were tested and confirmed to 
effectively react with acrylate terminated PBAE polymer 4-4-Ac but the resulting polymers were wholly 
ineffective for delivery of plasmid DNA to HEK293T cells. These E-monomers were excluded from large 














































































































Figure 6-S4. Cell identification using Cellomics Arrayscan software. 20x images acquired using Cellomics 
Arrayscan were computationally analyzed to identify cell nuclei from H2B-GFP (nucGFP) expression (485 
+/- 10 nm excitation), followed by characterization of efficacy transfection from mCherry fluorescence (549 
+/- 7.5 nm excitation) above background. Cells with nucGFP expression below a cutoff threshold, nuclei size 
below a cutoff threshold or overlapping nuclei with nuclei area above cutoff threshold were discarded (orange 








Figure 6-S5. Post-mitotic status of differentiated RPE monolayers. Human iPS cells seeded in 384 plates were 
allowed to differentiate over 25 days in culture in 384 well plates. (A) Cell number per well increases from day 
2 to day 10, at which point cell number peaked and cells began to differentiate. (B) Cells were visibly more 
dense at day 25 post-seeding compared to day 3 post-seeding with smaller nuclei. RPE monolayer at day 25 
additionally possessed textured appearance. Bars show mean ± SEM of eight wells for each condition. Scale 
bar is 100 µm for 20x images. 
 















































Figure 6-S6. In vitro high throughput screening of PBAE nanoparticles in sub-confluent D3 RPE monolayer. 
(A) Representative images showing mCherry transfected RPE cells. Heat maps showing the (B) percentage 





different nanoparticles to confluent RPE monolayer at day 3 post seeding. The color scale bar refers to the 
percentage transfection efficiency and percentage survival that was calculated based on the number of mCherry 
positive cells detected from total number of cell population. Scale bar 100 µm. 
 
Figure 6-S7: PBAE nanoparticle 5-3-J12 dose and w/w ratio optimization. (A) RPE monolayers (D25) 
receiving equivalent DNA doses between 50-125 ng/well demonstrate a w/w ratio of 90 w/w and 75 ng 
DNA dose as optimal for transfection efficacy and (B) relative viability from nucGFP count per well. (C) 
Holding polymer dose constant and varying DNA dose to vary w/w ratio demonstrated that transfection 
efficacy was dependent on the ratio between polymer to DNA and not simply dependent on the amount of 
polymer dosed per well. Nanoparticles formed at 30 w/w were largely ineffective, even when the total 
polymer amount was equivalent to that used for 90 w/w nanoparticles. (D) Relative cell viability of RPE 
monolayer cells treated with equal polymer dose at specified w/w ratios.  


























































































Figure 6-S8. Commercial reagent transfection efficacy optimization. (A) A broad range of commercial 
transfection reagents as well as prior polymer PBAE 557 were tested in transfection of RPE monolayers at a 
range of ratios between polymer to plasmid DNA. (B) Each grouping for transfection and viability show 
multiple DNA doses tested organized from high to low. (C) Relative cell count to untreated wells following 
transfection. (D) Representative microscope images of cells transfected with specific commercial reagents and 
PBAE 557. Bars show mean ± SEM of four wells for each condition. Scale bar is 100 µm for 20x images. 
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Figure 6-S9. Transfection efficacy over multiple preparations of RPE monolayers. RPE monolayers were 
differentiated from human pluripotent stem cells and transfected on four separate occasions to account for 
variability between cell preparations and transfection efficacy. (A) PBAE 5-3-J12/DNA NPs at a 90 w/w 
ratio and dose of 75 ng/well was always more statistically effective for transfection than ViaFect at a 4x ratio 
to plasmid DNA and dose of 200 ng/well (multiple t-tests with Holm-Sidak corrected multiple comparisons). 
(B) Cell viability following treatment was similar between each transfection occasion. (C) Microscope images 
of cells transfected on four different occasions show variation in the level of transfection. (D) Microscope 















































































Bars show mean ± SEM of four wells for each condition. All microscope scale bars 100 µm. 
 
Figure 6-S10. Live cell nuclei count over time and expression time-course. (A) Representative microscopy 
images of nuclear GFP expression of RPE monolayers on days following transfection. Only cells induced to 
express CAG-mCherry show difference in phenotype of nuclei. (B) Reduction in live cell number per well 





treatment with non-coding Cy5 labeled plasmid DNA. (C) mCherry gene expression peaked on day four 
following transfection. Error bars show mean ± SEM of four wells for each condition. Scale bar 100 µm. 
 
Table 6-S2. Base polymer monomers. Monomers used for PBAE library synthesis for screening RPE cells. 












1,3-propanediol diacrylate B3 184.19 24493-53-6 Monomer-
Polymer and 
Dajac Labs 
1,4-Butanediol diacrylate B4 198.22 1070-70-8 Alfa Aesar 




   
  
3-amino-1-propanol S3 75.11 156-87-6 Alfa Aesar 
4-amino-1-butanol S4 89.14 13325-10-05 Fisher Scientific 





Table 6-S3. End-cap monomer library. Acrylate terminated base polymers were end-capped in a high-
throughput manner with the 36 small molecule amine monomers below to yield end-capped linear polymers.  
  




   
  
1,3-diaminopropane J1 74.12 109-76-2 Sigma Aldrich 
2,2-dimethyl-1,3-propanediamine J2 102.18 7328-91-8 Sigma Aldrich 
1,3-diaminopentane J3 102.18 589-37-7 TCI America 
2-methyl-1,5-diaminopentane J4 116.2 15520-10-02 TCI America 
Diethylentriamine J5 103.17 111-40-0 EMD Millipore 
Triethylenetetramine J6 146.23 112-24-3 Sigma Aldrich 
Tetraethylenepentamine J7 189.3 1112-57-2 Sigma Aldrich 
Pentaethylenehexamine J8 232.44 4067-16-7 Santa Cruz 
N,N-Dimethyldipropylenetriamine J9 159.27 10563298 Sigma Aldrich 
3,3′-Diamino-N-
methyldipropylamine 
J10 145.25 105-83-9 MP Biomedicals 
N,N-Diethyldiethylenetriamine J11 159.27 24426-16-2 Sigma Aldrich 
3,3′-Iminobis(N,N-
dimethylpropylamine) 
J12 187.33 6711484 Santa cruz 
Tris(2-aminoethyl)amine J13 146.23 4097-89-6 Sigma Aldrich 
Tris[2-(methylamino)ethyl]amine J14 188.31 65604-89-9 Sigma Aldrich 
1-(2-Aminoethyl)piperidine K1 128.22 27578-60-5 Alfa Aesar 
N-(3-Aminopropyl)piperidine K2 128.22 3529-08-6 Sigma Aldrich 
2-(Aminomethyl)piperidine K3 114.19 22990-77-8 Sigma Aldrich 
4-(Aminomethyl)piperidine K4 114.19 7144-05-0 Fisher Scientific 
1-(3-Aminopropyl)pyrrolidine L1 128.22 23159-07-01 TCI America 
1-(2-Aminoethyl)pyrrolidine L2 114.19 7154-73-6 Santa Cruz 
2-(3-Aminopropylamino)ethanol M1 118.18 4461-39-6 Sigma Aldrich 
N-(3-
Hydroxypropyl)ethylenediamine 
M2 118.18 56344-32-2 TCI America 
N-(2-Hydroxyethyl)ethylenediamine M3 104.15 111-41-1 EMD Millipore 
N,N′-Bis(2-
hydroxyethyl)ethylenediamine 
M4 148.2 4439-20-7 TCI America 
2-(2-Aminoethoxy)ethanol  M5 105.14 929066 Alfa Aesar 
N,N-Bis(2-
hydroxyethyl)ethylenediamine 
M6 148.2 3197-06-6 Alfa Aesar 
1-Amino-4-methylpiperazine N1 115.18 6928-85-4 Sigma Aldrich 
1-(2-Aminoethyl)piperazine N2 129.2 140-31-8 Sigma Aldrich 
1-(3-Aminopropyl)-4-
methylpiperazine 
N3 157.26 4572-031 Alfa Aesar 
1,4-Bis(3-aminopropyl)piperazine N4 200.33 7209-38-3 MP Biomedicals 
2,2'-Oxybis(ethylamine) O1 104.15 2752-17-2 Acros Organics 
2,2′-(Ethylenedioxy)bis(ethylamine) O2 148.2 929-59-9 Sigma Aldrich 
1,11-diamino-3,6,9-trioxaundecane O3 192.26 929-75-9 TCI America 
4,7,10-Trioxa-1,13-tridecanediamine O4 220.31 4246-51-9 Sigma Aldrich 
3-Morpholinopropylamine P1 144.21 123-00-2 Sigma Aldrich 





Table 6-S4. Minimally effective end-cap monomers. Base polymer 4-4-Ac end-capped with the 24 monomers 







Minimally effective endcap monomers         
4-Aminophenyl disulfide E9 248.37 722-27-0 Sigma Aldrich 
Histamine E12 111.15 51-45-6 Sigma Aldrich 
D-Histidine E14 155.15 351-50-8 Sigma Aldrich 
L-Histidine E15 155.15 71-00-1 Sigma Aldrich 
2,4-Diaminotoluene E21 122.17 95-80-7 Sigma Aldrich 
2,6-Diaminotoluene E22 122.17 823-40-5 Sigma Aldrich 
2,4,6-Trimethyl-phenylenediamine E23 150.22 3102-70-3 Sigma Aldrich 
5-(Trifluoromethyl)-1,3-phenylenediamine E24 176.14 368-53-6 Sigma Aldrich 
p-Phenylenediamine E25 108.14 106-50-3 Sigma Aldrich 
2,5-Dimethyl-1,4-phenylenediamine E26 136.19 6393017 Sigma Aldrich 
4,4'-Oxydianiline E28 200.24 101-80-4 Sigma Aldrich 
4-Diaminobenzanilide E29 227.26 785-30-8 Sigma Aldrich 
N,N-Dimethyl-4,4′-azodianiline E34 240.3 539-17-3 Sigma Aldrich 
4-[(E)-(4-
aminophenyl)diazenyl]phenylamine E35 212.256 PH010934 Sigma Aldrich 
1H-pyrrole-2-carbohydrazide E37 125.13 50269-95-9 Sigma Aldrich 
4-Aminoazobenzene E38 197.24 60-09-3 Sigma Aldrich 
Tetrakis(4-aminophenyl)methane E40 380.48 60532-63-0 Sigma Aldrich 
1-(4-Aminophenyl)piperazine E42 177.25 67455-41-8 Sigma Aldrich 
3-Amino-5,6-dimethyl-1,2,4-triazine E43 124.14 17584-12-2 VWR 
2-Amino-4-methoxy-6-methyl-1,3,5-
triazine E44 140.14 1668-54-8 Sigma Aldrich 
3-Amino-1,2,4-triazine E45 96.09 1120-99-6 
Acros 
Organics 
2-Amino-4-chloro-6-methoxypyrimidine E47 130.19 5734-64-5 Sigma Aldrich 
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Foreword: The idea of using branched polymers for nucleic acid delivery is not new, but I felt that no one 
had yet fairly and definitively tested the efficacy of branched poly(beta-amino ester)s against their linear 
counterparts for delivery of plasmid DNA. The resulting paper published in the ACS journal Molecular 
Pharmaceutics is a deep dive into the structural effect of polymer branching on cellular scale delivery of 
plasmids.  
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Abstract: 
Development of highly effective non-viral gene delivery vectors for transfection of diverse cell 
populations remains a challenge despite utilization of both rational and combinatorial driven approaches to 





structures via A2 + B2/B3 + C1 Michael addition reactions from small molecule acrylate and amine 
monomers and then end-capped with amine-containing small molecules to assess the influence of polymer 
branching structure on transfection. These Branched poly(Ester Amine) Quadpolymers (BEAQs) are highly 
effective for delivery of plasmid DNA to retinal pigment epithelial cells and demonstrate multiple 
improvements over previously reported leading linear poly(beta-amino ester)s, particularly for volume-limited 
applications where improved efficiency is required. BEAQs with moderate degrees of branching are 
demonstrated to be optimal for delivery under high serum conditions and low nanoparticle doses further 
relevant for therapeutic gene delivery applications. Defined structural properties of each polymer in the series, 
including tertiary amine content, correlated with cellular transfection efficacy and viability. Trends that can be 
applied to the rational design of future generations of biodegradable polymers are elucidated. 
 
Keywords: non-viral, gene delivery; polymeric nanoparticle; transfection; branched polymer, plasmid DNA  
 
1. Introduction 
  Safe and effective gene delivery to specific cell populations has the potential to revolutionize 
medicine by enabling gene expression to be turned on or off precisely with the delivery of DNA or RNA. 
While viral vectors, particularly adeno-associated virus (AAV), have shown gains in the therapeutic delivery of 
DNA in some diseases, clinical level production of AAV remains an enormous challenge,n nucleic acid 
carrying capacity is limited, and patient existing immunity can limit eligible patient populations.3-4 In contrast, 
non-viral nanoparticle based gene delivery methods have the potential to be both less expensive to produce, 
less immunogenic, and enable greater nucleic acid cargo capacity than AAV. However, non-viral gene delivery 
systems have suffered from low delivery efficacy to many cell types due to both systemic and intracellular 
delivery inefficiencies, which prevent translation to the clinic.5 While non-viral vectors have been 
demonstrated capable for effective delivery in vivo, there remains a need to develop enhanced nanoparticles 
that are more efficient, particularly for applications in which the administration route limits the dose.  
  Polyesters are a class of polymers that have been utilized for non-viral gene delivery with 
high efficacy both in vitro and in vivo to a variety of cell types.6-9 Synthesis of poly(beta-amino ester)s (PBAEs) 
in particular via Michael addition reactions is relatively easy to achieve and vast libraries of linear polymers 
have been synthesized to explore the solution space of possible polymer structures for purposes of gene 
delivery.10-12 Until recently, however, only linear PBAEs have been explored for their ability to deliver nucleic 
acids to mammalian cells, despite the demonstration that branching polymers are often more effective than 
their linear counterparts for delivery of plasmid DNA in a variety of polymer systems such as 
polyethyleneimine (PEI),13 and poly(2-dimethylaminoethyl methacrylate) (PDMAEMA). 14, 15 Recent advances 





polymers highly effective for delivery of nucleic acids to a variety of cell types, including cancer cells14-15, skin 
cells16, neural cells17 and mesenchymal stem cells.17 Much of this prior work in the synthesis of branched 
PBAEs has either failed to assess the efficacy of branched polymers against linear polymers across the entire 
range of possible w/w ratios or has only utilized linear polymer structures of insufficiently high molecular 
weight and cationicity to achieve effective gene delivery.16,19 
  Polyesters with beta-amino groups are rapidly biodegradable and finely tunable for properties such as 
hydrophobicity, molecular weight and cationic charge by selection of constituent monomers. These features 
enable certain structures to be highly effective for gene delivery but often require large empirical screens to 
identify effective structures. The biodegradability of PBAEs in aqueous solution is uncharacteristically short 
for polyesters with typical bond half-lives of 4-6h for the backbone ester bonds,18 enabling the polymers to 
degrade to non-toxic, hydrophilic oligomers within 24 hours. Hydrophobicity can be modulated for 
transfection of different cell types19 and molecular weight can be modulated by tuning the overall vinyl to 
amine ratio.11, 20 Linear acrylate-terminated PBAE polymers can also be end-capped with a variety of small 
molecule primary amines that increase the cationic charge of the polymer by adding secondary as well as 
primary amines to the polymer.21 
 Whereas with polyethylenimine (PEI), branching structure changes the cationic character of the polymer 
(linear polymers contain mostly secondary amines while branched polymers contain a tertiary amine at each 
branch point and a primary amine at each new terminal group), branching in a PBAE synthesis scheme does 
not dramatically change tertiary amines present in polymer structures of the same molecular weight. On the 
other hand, for PBAEs, branching structure can increase the density of end-capping functional groups, and 
these molecules have been shown previously to greatly enhance the transfection efficacy of linear polymers.18, 
21 Branching in other polymeric systems has been further hypothesized to enhance the “needle effect” of 
endosomal escape mediated by polymer swelling, which could help explain this increase in efficacy.22-24 
 Here we present the synthesis and characterization of a new polymer series, Branched poly(Ester 
Amine) Quadpolymers (BEAQs). They are composed of four constituent monomers in ratios that influence 
the cationic character and hydrophobicity of the polymer species in a predictable manner. This work builds 
on the successes of poly(ester amine) materials such as linear PBAEs,12 poly(amine-co-ester) (PACE) 
terpolymers,25 and poly(alkylene maleate mercaptamines) (PAMA)s26 that have demonstrated the utility of 
amines to bind nucleic acids, ester linkages to facilitate nucleic acid release and reduce toxicity as well as the 
ability to modulate cation density and hydrophobicity. We utilized A2+B2/B3 Michael addition reactions to 
synthesize primarily acrylate terminated polymers with well-defined degrees of branching that were then end-
capped with a C monomer to explore the influence of branching structure on transfection efficacy and 
nanoparticle properties. This further enabled us to incorporate fine control of small amine-containing 





specific delivery.18, 27-29 Thus, the four components of the quadpolymers control degradability, 
hydrophobicity, branching, and cationicity which have large effects on delivery efficacy and cytotoxicity.30 We 
assessed each polymer quantitatively for plasmid DNA binding under various conditions to demonstrate that 
increased DNA binding is attributable to increased cationicity resulting from multiple end-caps as well as 
branching structure. Branching was further shown to improve DNA binding and transfection efficacy under 
conditions that normally destabilize polyplex nanoparticles. 
 
2. Experimental 
2.1 Materials: Trimethylolpropane triacrylate (TMPTA/B8, CAS 15625895), Bisphenol A glycerolate (1 
glycerol/phenol) diacrylate (BGDA/B7), CAS 4687-94-9) and 2-(3-Aminopropylamino)ethanol (E6, CAS 
4461-39-6) were purchased from Sigma Aldrich and used without further purification. 4-amino-1-butanol (S4, 
CAS 13325-10-05) was purchased from Alfa Aesar. Acrylate monomers were stored with desiccant at 4°C, 
while amine monomers were stored with desiccant at room temperature. Plasmid peGFP-N1 (Addgene 2491) 
was used for transfection efficacy screens. Cy5-amine (230C0) was purchased from Lumiprobe (Hallandale 
Beach, FL), dissolved in DMSO at a concentration of 10 µg/µL and stored at -20°C in small aliquots. Plasmid 
DNA (eGFP-N1) was labeled as previously described using NHS-Psoralen with the fluorophore Cy5-amine 
at a density of approximately 1 fluorophore/50 base pairs DNA.31 
 
2.2 Polymer synthesis: BEAQs were synthesized according to the ratios in Table S1 at an overall vinyl:amine 
ratio of 2.2:1 and monomer concentration of 200 mg/mL in anhydrous DMF. The diacrylate monomer (B7) 
was first weighed out to a 20 mL scintillation vial, after which triacrylate monomer (B8) was added. 
Anhydrous DMF was added to the vial and monomers were fully vortexed into solution and heated to 90°C 
before adding primary amine monomer S4. Monomer purity was accounted for in synthesis calculations 
based on the vendor characterization of each lot. Monomer B7 was assumed to be 90% pure in the absence 
of any reported purity information. Monomer solutions were then stirred at 90°C for 24h, after which 
polymers were removed from the oven and mixed with a solution of monomer E6 (2-(3-
Aminopropylamino)ethanol) in anhydrous DMF (final concentration 0.2 M) in the dark at room temperature 
for 1h. End-capped polymer solutions were then precipitated twice in diethyl ether (10x volume followed by 
5x volume) and dried under vacuum for three days. Polymers were finally re-dissolved in anhydrous DMSO 
at 100 mg/mL and stored at -20°C in small volume aliquots. Polymers were named according to the 
triacrylate mole fraction; thus B8-50% corresponds to the 50% triacrylate mole fraction polymer formed 
between the diacrylate (B7), triacrylate (B8), amino (S4) and diamino (E6) monomers with the triacrylate (B8) 






2.3 Polymer characterization: Acrylate terminated polymers were sampled from reaction vials prior to end-
capping reactions and precipitated twice in 10x volumes of diethyl ether to recover neat polymer. Acrylate 
terminated polymers were then dried under vacuum for 2h and analyzed via 1H NMR in CDCl3 (Bruker 500 
MHz) to confirm the presence of acrylate peaks and quantify degree of branching. End-capped polymer 
likewise was characterized via 1H NMR in CDCl3 to confirm complete reaction of end-cap monomer with 
acrylate terminated polymers. End-capped polymer was also characterized via gel permeation 
chromatography (GPC) using a Waters system with autosampler, styragel column and refractive index 
detector to determine MN, MW and polydispersity index (PDI) relative to linear polystyrene standards. GPC 
measurements were performed as previously described with minor changes of flow rate (0.5 mL/min) and 
increase in sample run time to 75 minutes per sample.32 
 
2.4 Polymer buffering capacity: End-capped polymer buffering capacity as a function of polymer structure was 
assessed by titrating 10 mg (100 µL at 100 mg/mL) of polymer dissolved in 10 mL of acidified, 100 mM NaCl 
from pH 3.0 to pH 11.18 For titrations, pH was determined using a SevenEasy pH Meter (Mettler Toledo) 
with pH assessed after stepwise addition of 100 mM sodium hydroxide. 
 
2.5 Polymer solubility limit: Polymers were dissolved in pH 7.4, 150 mM PBS or pH 5.0, 25 mM NaAc at the 
specified maximum concentration and aliquoted (50 µL) to a round bottom 96 well plate (n=3 wells). 
Polymers were then diluted stepwise in their respective buffers and absorbance measurements were acquired 
with a plate reader (Biotek Synergy 2) at 600 nm (for opacity indicative of solubility limit). Absorbance 
measurements of 0.5 were defined as the maximum solubility point for purposes of plotting polymer 
solubility (Figure 7-S2). 
 
2.6 DNA binding assays: Yo-Pro-1 iodide binding assays were run similarly to previously published results,33 
where DNA and Yo-Pro-1 iodide (Thermo Fisher) were both diluted to a concentration of 1 µM (3.1 µg/mL 
plasmid) in either 25 mM NaAc, pH 5.0 or 150 mM PBS, pH 7.4 then mixed with polymer to give a 100 µL 
well volume in opaque black well plates. Green channel fluorescence was then measured using a plate reader 
after 30 minutes of incubation (Biotek Synergy 2). Gel electrophoresis binding experiments were run as 
previously described9 with nanoparticles prepared in either 25 mM NaAc buffer, pH 5.0 or 150 mM PBS, pH 
7.4, diluted with 30% glycerol for loading into a 1% agarose gel. 
 
2.7 Nanoparticle characterization: Three samples were independently prepared for each nanoparticle formulation 
at the same concentrations as outlined in the transfection methods section. Nanoparticle hydrodynamic 





micro-cuvettes using a Malvern Zetasizer NanoZS (Malvern Instruments, Marlvern, UK) with a detection 
angle of 173°. Samples were then diluted in 150 mM PBS at a dilution factor of 6 and measured again to 
determine nanoparticle hydrodynamic diameter in neutral, isotonic buffer followed by determination of zeta 
potential by electrophoretic light scattering in disposable zeta cuvettes at 25°C using the same Malvern 
Zetasizer NanoZS. 
Transmission electron microscopy (TEM) images were acquired using a Philips CM120 (Philips 
Research, BriarcliffsManor, New York) on 400 square mesh carbon coated TEM grids. Samples were 
prepared at a DNA concentration of 0.045 µg/µL and polymer 40 w/w ratio in 25 mM NaAc, pH 5.0 after 
which 30 µL were allowed to coat TEM grids for 20 minutes. Grids were then dipped briefly in ultrapure 
water to remove excess dried salt, wicked dry and allowed to fully dry under vacuum before imaging. 
 
2.8 Cell culture: HEK293T and ARPE-19 cells were purchased from ATCC (Manassas, VA) and cultured in 
high glucose DMEM or DMEM/F12 respectively, supplemented with 10% heat inactivated fetal bovine 
serum and 1% penicillin/streptomycin. For noted 96-well plate transfection efficacy experiments, cells were 
plated in CytoOne 96-well tissue culture plates (USA Scientific, Ocala, FL) 24h prior to transfection with 
12,000 cells/well in 100 µL complete media. For noted 384-well plate transfection experiments, cells were 
plated at 2,500 cells/well in 25 µL complete media in 384 well tissue culture plates (Santa Cruz, sc-206081) 
24h prior to transfection. Cells were confirmed periodically to be mycoplasma negative via MycoAlert test 
(Lonza). 
 
2.9 Transfection and cell uptake: For 96 well plate transfections, nanoparticles were formed by dissolving 
synthesized polymers and eGFP-N1 plasmid DNA in 25 mM sodium acetate (NaAc) pH 5.0 then mixing in a 
1:1 volume ratio. Nanoparticles were incubated at room temperature for five minutes, then 20 µL of the 
nanoparticle solution were added to each well of cells containing 100 µL of complete media and allowed to 
incubate for two hours, at which point the media was replaced. Transfection efficacy was assessed for 
percent-transfected cells and geometric mean expression approximately 48h following transfection using flow 
cytometry with a BD Accuri C6 flow cytometer with HyperCyt autosampler and gated in 2D against 
untreated cells in FlowJo (Figure 7-S19). Cell viability was assessed using MTS Celltiter 96 Aqueous One 
(Promega, Madison, WI) cell proliferation assay approximately 24h following transfection. For 384 well plate 
transfection of low doses of nanoparticles, synthesized polymers in DMSO were dissolved in 25 mM NaAc 
buffer to a concentration of 7.5 µg/µL then mixed with DNA dissolved in 25 mM NaAc buffer in a 384 
polypropylene nanoparticle source plate. Nanoparticles were then dispensed to plates of cells at low volumes 
using an Echo 550 liquid handler. After two days to allow for reporter expression, plates were scanned and 





33342. Flow cytometry based cell uptake studies were performed in 96 well plates using 20% Cy5 labeled 
DNA as previously described.32. To remove associated nanoparticles that were extracellular membrane 
associated but had not undergone endocytosis, cells were washed once with 50 µg/mL heparin sulfate in 150 
mM PBS following trypsinization and transfer to round bottom 96 well plates.32 
 
2.10 Confocal microscopy.  Cells were plated on Nunc Lab-Tek 8 chambered borosilicate coverglass well plates 
(155411; Thermo Fisher) at 50,000 cells/well (ARPE-19) or 25,000 cells/well (HEK293T) two days prior to 
transfection in 250 µL phenol red free DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. 
Nanoparticles were prepared as described above at 20 or 40 w/w ratios using Cy5 labeled plasmid DNA and 
eGFP-N1 plasmid DNA at an 0.8/0.2 mass ratio, then added to cells at a total dose of 1500 ng DNA/well 
and incubated for two hours. For imaging, cells were stained for 30 minutes with Hoechst 33342 at a 1:5000 
dilution (H3570; Thermo Fisher) for nuclei visualization, as well as Cell Navigator Lysosome Staining dye 
with pKa 4.6 at a 1:2500 dilution (AAT Bio-quest, 22658) in phenol red free DMEM. Cells were then washed 
twice with phenol red free DMEM and imaged at 37°C in a 5% CO2 atmosphere. Images were acquired using 
a Zeiss LSM 780 microscope with Zen Blue software and 63x oil immersion lens. Specific laser channels used 
were 405 nm diode, 488 nm argon, 561 nm solid-state, and 639 nm diode lasers. Laser intensity and detector 
gain settings were maintained across all image acquisition. All Z-stacks were acquired for entire cell volume 
over scan area of 140 µm at Nyquist limit resolution. 
 
2.11 Data analysis and figures: FlowJo was used for flow cytometry analysis and Cellomics HCS Studio (Thermo 
Fisher) was used for image acquisition based transfection analysis. Polymer structures were characterized in 
ChemDraw (Perkin Elmer, Boston, MA) and Marvin (ChemAxon, Cambridge, MA) to determine logP and 
logD values. Calculation of normalized 50% serum transfection efficacy was performed by dividing the 
percent transfection or geometric mean transfection efficacy achieved in 50% serum media by the same 
nanoparticle (B8% and w/w ratio) formulation percent transfection or geometric mean transfection efficacy 
achieved in 10% serum. Confocal microscopy colocalization of plasmid DNA with lysosomes was assessed as 
intensity weighted colocalization in Zen Blue, then normalized by individual image area of plasmid DNA per 
image for statistical quantification. 
 
2.12 Statistics: Prism 8 (Graphpad, La Jolla, CA) was used for all statistical analyses and curve plotting. Unless 
otherwise specified, statistical tests were performed with a global alpha value of 0.05. Unless otherwise stated, 
absence of statistical significance markings where a test was stated to have been performed signified no 








3.1. Branched poly(Ester Amine) Quadpolymer Synthesis and Characterization 
3.1.1 Synthesis of Acrylate Terminated Polymers 
A series of Branched poly(Ester Amine) Quadpolymers (BEAQ) with differential degrees of 
branching was synthesized via step-growth A2 + B2/B3 Michael addition reactions from a small molecule 
diacrylate (BGDA/B7), triacrylate (TMPTA/B8) and amino-alcohol (S4) monomers (Figure 7-1 and Table 7-
S1). In the synthesis scheme of A2 + B2/B3 + C, A2 corresponds to the primary amine monomer (S4) that 
can react twice, B2 corresponds to the diacrylate monomer (termed B7) that can react twice, B3 corresponds 
to the triacrylate monomer (termed B8) that can react three times and C refers to the end-cap monomer, 
which reacts once due to its presence in excess. We confirmed that each polymer was primarily acrylate 
terminated after 24 hours of synthesis via 1H NMR (Figure S1) by the presence of acrylate peaks between 5.5-
6.5 ppm. Analysis of the acrylate terminated polymer structures with 1H NMR also enabled determination of 
polymer properties including the actual triacrylate mole-fraction of each polymer as well as number of end-
cap moieties per polymer molecule (Table 7-1). By precisely varying the triacrylate monomer mole fraction, 
while maintaining the same 2.2:1 vinyl to amine mole ratio, the degree of branching was able to be carefully 
modulated in the resulting polymers as assessed by 1H NMR. Further, by synthesizing the polymers in each 
series at the same purity-accounted overall vinyl to amine ratio, the number average (MN) molecular weights 
within each series of polymers were all very close to 4 kDa as shown by gel permeation chromatography 






Figure 7-1. Synthesis of Branched poly(Ester Amine) Quadpolymers (BEAQ). A) Diacrylate monomer B7 
and triacrylate monomer B8 were mixed with side-chain monomer S4 to synthesize a series of BEAQs with 
increasing triacrylate mole fraction and degree of branching. B) Linear polymers possess two end-cap 
structures per molecule (red), while each triacrylate monomer in branched polymers results in an additional 
end-cap moiety for every branch point. C) One-pot synthesis of acrylate terminated base polymers was 
performed at 90°C and 200 mg/mL in DMF for 24 hours. Polymers were then end-capped with monomer 
E6 at room temperature for one hour to yield the final product. 
 
3.1.2 End-cap Modification of Polymers 
PBAEs have been “end-capped” with small molecule monomers possessing secondary and tertiary 
amines that increase the overall polymer amine density, resulting in linear polymers with tertiary amines along 
the polymer backbone and greater amine density at just the two ends of the linear polymers.12, 21, 34-35 Most of 
the small molecule end-caps shown previously to increase transfection efficacy with linear PBAE structures21 
increase the cationicity of the polymer at both pH 5 and 7 due to the fact that end-capping with primary 
amine monomers adds at minimum two secondary amines to linear PBAEs. Here, we utilized monomer 2-(3-
aminopropylamino)ethanol (termed E6) for end-capping purposes, as it has been shown to be effective as an 
end-capping group with linear polymers and non-cytotoxic to multiple cell lines.33 38 In contrast to previously 
reported branched polymer schemes, including branched PBAE schemes, this end-capping molecule 
exclusively increases the secondary amine content of the polymer. All BEAQs were confirmed to be 
completely end-capped by 1H NMR and the number average of end-cap moieties per polymer molecule as 
estimated from NMR spectra ranged from two for the linear polymer to seven for the 90% triacrylate mole 
fraction polymer (Table 1). Notably, end-cap molecular mass fraction contribution in these polymers reaches 
near 30% for the high triacrylate mole fraction polymers, whereas linear PBAEs have an end-cap monomer 
mass fraction of approximately 5%, which reduces further for higher molecular weight linear polymers (Table 
1). Polydispersity in moderately branched BEAQs was minimized by synthesizing at a dilute concentration, 
while high polydispersity of hyperbranched BEAQs with triacrylate mole fraction >60% is consistent with 



















Theoretical Actual Molecule Fraction (%) (Da) (Da)  
0 0.0 2.0 5.7 4700 5700 1.203 
10 15.1 3.0 9.1 4700 5700 1.216 
20 22.8 3.4 11.5 4200 5200 1.258 
40 34.8 3.9 15.0 4200 5100 1.223 
50 47.1 4.9 17.1 4200 5800 1.369 
60 58.5 4.5 22.0 4200 5900 1.411 
80 83.3 5.5 27.5 4800 18300 3.849 
90 91.7 6.5 28.2 3100 21600 6.952 
 
3.1.3 Polymer Series Hydrophobicity 
 The chemical properties of each polymer in the series with known Mn and monomer composition 
were predicted in silico to assess the influence of branching with TMPTA on polymer hydrophobicity. 
Hydrophobicity was assessed as predicted partition coefficient (logP) and ionization influenced distribution 
coefficient (logD) at neutral and acidic pH values (Figure 7-2a, 7-S2), demonstrating that branching increases 
BEAQ hydrophilicity for the monomers utilized here, and that pH sensitive ionization plays an important 
role in polymer solubility. Branching was hypothesized to reduce both polymer logP and logD values as a 
greater number of E6 monomer end-cap moieties in branched structures increased the prevalence of 
hydrophilic hydroxyl groups and charged secondary amines; polymers with a high degree of branching were 
further subject to reduction in hydrophobicity due to the fact that the mass fraction of the diacrylate 
monomer B7, which contains a bisphenol group, was likewise reduced. We confirmed this predicted 
reduction in hydrophobicity experimentally via an absorbance based assay, to show that BEAQs with at least 
40% triacrylate mole fraction were over twice as soluble as the linear B8-0% polymer under both low pH and 
physiological pH conditions (Figure 7-S2).  
 
3.1.4 Polymer Series Buffering Capacity 
Titration of the polymers demonstrated buffering capacity in the physiological pH range for 
hypothesized endosomal escape properties (5 to 7.4), as BEAQs with greater triacrylate mole fraction 
possessed a larger buffering capacity in this range (Figure 7-2B). Effective pKa in the pH range from 5 to 8 





curves defined as Δ(-OH)/Δ(pH) (Figure 7-S2B). Effective pKa was demonstrated to increase moderately 
with increased branching from approximately 6.0 to 6.75 (Figure 7-2C). These results are due to the 
combined effects of additional tertiary amine density in the polymer backbone and the presence of additional 
secondary amines in end-groups as the branching increases.18 Tertiary amine density calculated relative to the 
base polymer structures (Table 7-S4) shows that diacrylate B7+S4 polymer repeat units have much lower 
tertiary amine density than triacrylate B8+S4*2 repeat units and physical spacing of the tertiary amines in high 
diacrylate B7 content polymers is greater than for high triacrylate B8 content polymers. But following end-
capping with monomer E6, tertiary amine density is similar amongst all synthesized polymers while secondary 
amine density increased substantially with triacrylate mole fraction from 0.851 to 4.194 mMol per gram 
polymer for B8-0% and B8-90% respectively (Table 7-S5). 
 
3.1.5 Polymer Series DNA Binding 
 Assessment of BEAQ/DNA binding strength interactions via Yo-Pro-1 iodide competition binding 
assays further demonstrated the influence of branching in polymer structure (Figure 7-2D,F). At pH 5, linear 
and branched polymers were equally effective at binding plasmid DNA, while in isotonic, neutral buffer at 
pH 7.4, branched polymers statistically outperformed linear polymers for DNA binding (Table S6). To assess 
if increases in DNA binding strength of the BEAQs were attributable primarily to branched structure or 
changes in amine content, we calculated Yo-Pro-1 iodide quenching as a function of secondary, tertiary, and 
total amine content per base-pair DNA from known structural characteristics of each polymer (Figure 7-S3). 
DNA binding normalized to tertiary amine content effectively condensed the binding assay results at pH 5, 
while normalization of DNA binding in neutral, isotonic buffer to secondary amine content most effectively 
condensed the results to fit one curve (Figure 7-2E,G). Gel electrophoresis DNA retention assays were 
similarly in agreement with these results, demonstrating that branching improved DNA binding particularly in 
neutral, isotonic buffer (Figure 7-S4). These results indicate that BEAQ backbone tertiary amines play an 
important role in polymer complexation with DNA at low pH, but secondary amines in BEAQ end-cap 
structures are primarily responsible for binding plasmid DNA following dilution into neutral solutions.  
Further analysis of the difference between binding at low pH and neutral pH do, however, reveal that 
the increase in end-cap density of branched polymers was not exclusively responsible for increased binding at 
neutral pH. Scaling the difference in binding efficacy as a function of total amines per base pair DNA 
revealed that branched polymers were more effective at maintaining DNA binding in a manner that is 






Figure 7-2. Polymer properties influenced by triacrylate mole fraction. A) Predicted properties of partition 
coefficient (logP) and distribution coefficient (logD) for differentially branched polyesters. B) Titration of 
BEAQs. C) Effective pKa value of maximum buffering point between pH 4.5-8.5 of differentially branched 
PBAEs. D) Competition binding assay of polymer and Yo-Pro-1 iodide at low pH. (n=3 wells, mean ± SEM) 
E) DNA binding in low pH buffer normalized to PBAE tertiary amine content. F) Difference in degree of 
binding between pH 5 and pH 7.4 calculated as a function of total amines per bp DNA. G) Competition 
DNA binding assay in isotonic, neutral buffer. (n=3 wells, mean ± SEM) H) DNA binding in isotonic, 
neutral buffer normalized to secondary amine content. I) TEM image of 20% triacrylate mole fraction 
polymer nanoparticles. 
 
3.2 Nanoparticle Properties 
 Dynamic light scattering (DLS) measurements of polymer/DNA polyplex nanoparticles to assess 
hydrodynamic diameter demonstrated effective independence of nanoparticle properties with regards to 
branching. DLS measurements of polymeric nanoparticles formed in 25 mM NaAc, pH 5.0 at a 40 w/w ratio 









































































































































































































100 nm that maintained a diameter of approximately 100 nm following a 6-fold dilution into 150 mM PBS 
(Figure 7-S5A). All nanoparticle formulations showed similar zeta potential values of approximately +15 mV 
(Figure 7-S5B). Select formulations were analyzed via TEM, which showed dried nanoparticle diameters 
between 30-60 nm (Figure 7-S5C). Notably, the linear 0% triacrylate mole fraction (B8-0%) particles were the 
smallest when assessed by TEM at 32±3 nm, compared to a mean of 54±6 nm for B8-50% nanoparticles, 
which may be attributable to slightly stronger intermolecular polymer interactions driven by increased 
hydrophobic effect for the less branched polymers with higher B7 fraction / lower triacrylate monomer B8 
fraction. 
 
3.3 Cellular Transfection 
3.3.1 Nanoparticle Uptake was Not Influenced by Branching Structure 
We hypothesized that the increased number of end-cap moieties per polymer molecule would result 
in increased cellular uptake, as end-capping linear PBAEs has been demonstrated to improve cellular uptake 
compared to acrylate terminated and side-chain monomer terminated linear PBAEs.21 Further, end-cap 
structures have been shown to convey cell type specificity,21, 27 as well as partially contribute buffering 
capacity of PBAEs in the physiologically relevant pH range.18 To assess whether the increased number of 
end-cap moieties per polymer molecule for BEAQs would yield greater cell uptake relative to linear PBAEs, 
we assessed cellular uptake by flow cytometry of nanoparticles formed with Cy5 labeled plasmid DNA in 
HEK293T and ARPE-19 cells at moderate fluorophore labeling density. All polymers were generally effective 
for mediating cellular uptake of plasmid DNA, with above 95% of cells testing as positive for DNA uptake 
gated against the untreated cells (Figure 7-S6). These branched polymers showed no significant improvement 
in cellular uptake at equivalent w/w ratios to the linear polymer. Thus, an increased number of 2-(3-
Aminopropylamino) ethanol end-cap moieties per polymer molecule did not mediate higher cellular uptake as 
hypothesized. 
 
3.3.2 BEAQ Nanoparticles Mediate High Transfection Efficacy 
 To assess the ability of BEAQs to effectively deliver plasmid DNA to both easier-to-transfect and 
difficult-to-transfect cell types, HEK293T cells and ARPE-19 retinal pigment epithelial cells were chosen for 
transfection studies with the reporter gene eGFP-N1. In these two cell lines, the BEAQs nanoparticles 
achieved up to 99% and 77% transfection efficacy respectively in complete medium as assessed by flow 
cytometry, which is greater than any reported transfection efficacy using non-viral methods in either cell line 
to the best of our knowledge (Figure 7-3). 
Among commercial reagents we fully tested and optimized, including 25 kDa branched 





(Figure 7-S7 and 7-S8), JetPRIME gave the highest level of transfection in ARPE-19 cells at approximately 
40% transfection with tolerable viability. Linear PEI gave slightly higher transfection, but at the cost of 
substantial cytotoxicity. The maximum level of transfection achieved in ARPE-19 cells with the reported 
BEAQ polymers is likewise higher than our previously optimized top linear PBAE 557 formulation, which 
we found transfected only 40-45% of these cells with keeping cytotoxicity <30%.37 This formulation was 
previously shown to lead to transfection in vivo following subretinal injection in mice, making it likely for these 
BEAQ nanoparticles to function in a similar manner in vivo.37 
 




















































































































































Figure 7-3. In vitro transfection with BEAQs in 10% serum media. HEK239T cells A) percent transfection 
efficacy, B) normalized geometric mean expression C) viability and D) fluorescence micrograph of cells 
transfected to express eGFP with the 20 w/w ratio, 50% triacrylate mole-fraction BEAQ. ARPE-19 cells E) 
percent transfection efficacy, F) normalized geometric mean expression, G) viability and H) fluorescence 
micrograph of cells transfected to express eGFP with 20 w/w, B8-20% triacrylate mole-fraction BEAQ. 
(Scale bars 200 µm. n = 4 wells, mean ± SEM). 
 
3.3.3 Moderate Branching in BEAQs Improves Stability in Physiological Serum Conditions 
 Effective delivery under physiological serum conditions remains a challenge for cationic nanoparticle 
based gene delivery, due to the shielding and aggregation effects of serum proteins.38 To assess nanoparticle 
performance under these conditions, the BEAQs were evaluated for transfection in HEK293T and ARPE-19 
cells incubated in 50% serum medium during a two hour nanoparticle incubation (Figure 7-S9). Under these 
challenging transfection conditions, which more closely model an in vivo systemic administration, BEAQs 
demonstrated remarkably statistically improved transfection efficacy compared to their linear counterparts, 
which was particularly pronounced at low w/w ratios in both cell lines (Figure 7-4A,B). The optimal BEAQ-
50 branched polymer was capable of transfecting 98% and 65% of HEK293T and ARPE-19 cells under 50% 
serum conditions. After normalizing transfection efficacy results in 50% serum to matched results in 10% 
serum conditions, BEAQ nanoparticles reported here maintain 80% and 70% geometric mean expression in 
HEK293T cells and ARPE-19 cells with no reduction in percentage of cells transfected (Figure 7-S10). 
  
3.3.4 Moderate Branching Improves Transfection at Low Plasmid Doses 
Transfection at low nanoparticle doses likewise better mimics conditions encountered in vivo 
following administration and dilution into biological fluids. At very low nanoparticle doses, plasmid 
concentrations between 16-256 pM (0.25-4 pg/cell) in 384 well plates, moderately branched triacrylate mole 
fraction BEAQs showed statistically higher transfection compared to the optimized corresponding linear 
PBAE in both cell lines (Figures 7-S11, 7-S12). Overall with statistical assessment at all w/w ratios tested, B8-
40% and B8-50% performed the best in both cell lines. Optimal w/w ratio was notably shifted for low DNA 
dose transfections, such that 60 w/w BEAQ nanoparticles showed better transfection than 20 w/w particles 






Figure 7-4. The effect of transfection conditions on BEAQs. High serum (50%) transfection of A) 
HEK293T and B) ARPE-19 cells with 20 w/w nanoparticles (normal DNA dose of 600 ng/well in 96 well 
plates). Low nanoparticle dose transfection with 40 w/w nanoparticles of C) HEK293T (5 ng) and D) ARPE-
19 (10 ng) doses in 384 well plates. (n = 4 wells, mean ± SEM, statistical markings show results of one-way 
ANOVA with Dunnett corrected multiple comparisons tests to the linear polymer) 
3.4 Branching reduces degree of lysosomal accumulation following uptake 
Transfection of HEK293T and ARPE-19 cells with Cy5-labeled plasmid DNA followed by 
assessment of lysosome colocalization with confocal microscopy at 4 and 24 hours following nanoparticle 
treatment demonstrated that less internalized DNA was colocalized with lysosomes when delivered by B8-
50% BEAQs compared to the linear B8-0% polymer (Figure 7-5A). For accurate quantification of lysosomal 
colocalization throughout the entire cell volume, Z-stacks were acquired at both time-points and nanoparticle 
area per slice was used to scale the respective contribution to calculated z-stack lysosome correlation 
coefficient (Figure 7-S13). Representative uncropped maximum intensity projection images of acquired Z-
stacks for each condition show a high level of Cy5-DNA uptake with limited lysosome colocalization for all 
conditions (Figures 7-S14 and 7-S15). All nanoparticle formulations tested demonstrated a statistically 
significant increase in lysosome colocalization between 4 and 24 hours following nanoparticle treatment 













nanoparticles, specifically for the higher 40 w/w ratio tested, which yielded less than 20% of internalized 
DNA as detectable in lysosomes at 24 hours in either cell type. The degree of lysosome colocalization for the 
linear B8-0% polymer at 24 hours (0.4) was still far below the colocalization we have previously measured for 
PLL (0.78) and BPEI (0.7), despite the ability of BPEI to much more effectively buffer protons on a per-unit 
basis.39 This result supports the notion that amphiphilic polyesters mediate lysosomal in a different manner 
than polyethylenimine, as their degree of lysosomal avoidance is not proportional to their buffering capacity. 
At 24 hours following nanoparticle treatment, cells expressing eGFP from the 20% unlabeled fraction of 
plasmid DNA were visible for all conditions (Figures 7-S16 and 7-S17). Cy5-labeled plasmid DNA was also 
detectable in the nucleus of some cells that typically were also strongly expressing eGFP at the 24-hour time 
point (Figure 7-6). Analysis of single slices from z-stacks did, however, reveal that most plasmid DNA 







Figure 7-5. Lysosome colocalization assessment with confocal microscopy. A) Cells transfected with B8-0% 
and B8-50% at low (20 w/w) and high (40 w/w) nanoparticles and assessed by confocal microscopy show 
statistically significant differences in the degree of lysosome colocalization. Assessed by one-way ANOVA 
with Dunnett corrected multiple comparisons to the B8-50%: 40 w/w conditions. B) Representative 2D 
scattergrams of HEK293T cells at 24 hours post-treatment using 20 w/w nanoparticles. Region 3 represents 
colocalized pixel intensities. C) All conditions in both cell lines showed statistically significant (Holm-Sidak 
corrected multiple t-tests) increases in the degree of lysosome colocalization between 4 hours and 24 hours 
following transfection. (Bars show mean ± SEM of n>100 cells.) D) Representative maximum intensity 
projection images of cells transfected with 20 w/w nanoparticles 24 hours following transfection, showing 
lysosome colocalization in white. 
 
Figure 7-6. Nuclear localization of plasmid 
DNA and expression of eGFP assessed by confocal 
microscopy. HEK293T cells were transfected 24 
hours prior with B8-50%: 20 w/w nanoparticles 
containing 80% non-coding, Cy5-labeled plasmid 
DNA and 20% coding eGFP-N1 plasmid DNA. A) 
Maximum intensity projection demonstrating 
high level of labeled plasmid DNA remaining in 
the cells with minimal lysosome colocalization. B) 
Strong eGFP expression from the 20% of 
unlabeled plasmid DNA. C) A single z-slice 
shows Cy5-labeled plasmid DNA localized to the 
nucleus in select cells (white arrows). 
3.5 Trends in Transfection from Differentially 
Branched BEAQs 
 We analyzed transfection efficacy of each 
polymer over the multiple w/w ratios tested as 
functions of polymer concentration and known 
specific buffering capacity as well as secondary, 
tertiary and total amine content. To account for overall population expression and effects of polymers on 
viability, we scaled geometric mean expression values by viability and normalized to the maximum geometric 
mean expression value of each polymer structure to give viability normalized expression. Viability normalized 





biphasic trends in normalized geometric mean expression. Upon fitting a single quadratic curve to the data 
from all polymers, tertiary amine density as a function of tertiary amines per base pair DNA was revealed to 
be the most important chemical property for predicting optimal w/w ratio for transfection efficacy. 
Particularly, a single curve quadratic fit for all polymer data across all structures for HEK293T and ARPE-19 
cells gave R2 values of 0.761 and 0.615 respectively. 
 
Figure 7-7. Correlation between BEAQ 
properties and viability normalized geometric 
mean expression. Geometric mean 
expression plots were normalized to the 
maximum expression for each polymer and 
scaled by viability at that w/w ratio for A-E) 
HEK293T cells and F-J) ARPE-19 cells. 
Dashed-grey curves show a single quadratic 
fit of all data points for that cell line with 
calculated R2. Plots showing dotted-grey 
curves in addition to dashed-grey curves 
were statistically determined to require two 
fitted quadratic curves to adequately describe 
the data. 
Polyethylenimine did not exhibit the 
same biphasic trends between amine content 
and geometric mean expression as BEAQs, 
but did demonstrate optimal amine content 
of approximately 30 secondary amines which 
may be attributable to the greater 
cytotoxicity encountered with using PEI that 
limits utilization of high w/w ratios (Figure 
7-S18). Interestingly, highly branched 25 kDa 
BPEI had a much higher optimal total 
amines per bp DNA similar to the 
synthesized BEAQs, which may be 
attributable to the level of interaction 








































































































































































































































between amines in linear polymers compared to branched polymers. Spatial accessibility of amines in polymer 





Branching has been demonstrated to yield enhanced transfection in many cationic polymer systems 
and studied in PBAEs through the use of monomers with trifunctional amine monomers40 or trifunctional 
triacrylate monomers for generation of branched polymers.17 Here, we sought to explore the exact nature by 
which branching can improve transfection efficacy of these polymers through a fair comparison of fully 
effective linear PBAEs to equivalent branched species. For this purpose, we synthesized a series of polymers 
with well-defined degrees of branching that was quantified via NMR and GPC. These BEAQs are notable in 
part due to the manner in which end-capping with the chosen E6 monomer affected amine density, 
particularly through adding secondary amines to the polymer structure. We hypothesized that the branching 
structure and high end-cap moiety mass fraction in BEAQs would show improved DNA binding at neutral 
pH and would be more effective for delivery at lower w/w ratios as compared to linear PBAEs due to their 
increased secondary amine cationicity. 
BEAQs were shown via computational and experimental methods to be more water soluble due to 
the increased prevalence of hydrophilic end-cap moieties and more effective at buffering in the physiological 
pH range. We further calculated the effective pKa value of each polymer to demonstrate that branching 
influenced the pH point of maximal buffering capacity. Given the long-standing hypothesis that titration 
capability of polycations in the pH 5-7.4 range is responsible for “proton sponge hypothesis” driven 
endosomal escape,39, 41-44 direct variation of the buffering capacity and effective pKa allowed evaluation of the 
importance of buffering in gene delivery with these polymers. Through quantitative competition DNA 
binding assays we demonstrated that branching improved DNA binding as a function of both increased 
secondary amine content via additional end-cap monomers as well as branching structure by normalized 
binding efficacy to specific amine content of each polymer. Importantly, BEAQs were much more effective 
at binding nucleic acids compared to the linear polymer following dilution into neutral, isotonic buffer.  
Using the two well characterized cell lines human embryonic kidney HEK293T and human retinal 
pigment epithelium ARPE-19, these polymers demonstrated extremely high transfection efficacy (up to 99% 
and 77% respectively) with no notable cytotoxicity at utilized doses. BEAQs did not demonstrate greater 
nanoparticle uptake compared to the linear polymer but did improve transfection efficacy and reduce the 
necessary w/w ratio, effectively improving polymer efficiency of transfection at a given polymer mass. As the 





relevant effective pKa values (nearer to pH 7) but the lowest transfection efficacy, our results further indicate 
that buffering capability and endosomal escape is likely not the rate-limiting step to mediating successful 
transfection in this polymer system. These results reinforce findings from other groups in alternative polymer 
systems that polymer buffering capacity between pH 4-7.4 is a necessary, but not on its own a sufficient 
property for transfection.45 
Under more challenging transfection conditions of extremely low nanoparticle doses or under 
physiological serum conditions, moderately branched BEAQs were statistically shown to outperform the 
equivalent linear PBAE and possess extremely high transfection efficacy for the reported conditions. At ultra-
low plasmid DNA doses, the efficiency of plasmid DNA delivery was rather remarkable compared to 
previously reported optimal nanoparticles, including PBAE terpolymers that include alkyl side chains for 
improved colloidal stability that were shown to require roughly 3x the DNA dose used here to transfect HeLa 
cells with similar efficacy.46 Further, in physiological serum conditions these BEAQ nanoparticles 
demonstrated an impressive degree of transfection compared to what has been reported in the literature. 
Fluorinated PAMAM dendrimers were reported to have their transfection efficacy reduced to 30% of what it 
was in 10% serum when the nanoparticles were added to cells in 50% serum.47 In contrast, BEAQ 
nanoparticles maintained >70% geometric mean expression under matched conditions to 10% serum 
transfections. Other non-viral transfection reagents have similarly been reported to facilitate transfection 
under physiological serum conditions, but often yield only 30-40% the mean expression level of the same 
particles in 10% serum.48 
That being said, even at this relatively high level of efficacy of non-viral transfection, much room is 
left for improvement in non-viral vector efficiency as compared to viral vectors that have evolved for over a 
billion years for efficient transduction. At the low doses tested of 5-10 ng plasmid DNA/well, there were 
approximately 200,000-400,000 plasmids available for every cell in the well (Calculation S1). Based on recent 
estimates of approximately 10 plasmids per polyplex nanoparticle31, 49 there could still be over 20,000 
nanoparticles added per cell at this dose, which is a high multiplicity of infection (MOI). With an estimated 
number of 5,000 plasmids from polyplex nanoparticles being internalized per cell under higher dose 
transfection conditions and an estimated 1/5 of those plasmids reaching the nuclear envelope, uptake of 
nanoparticles appears to be a significant hurdle to effective transfection in vitro.32 In comparison to efficient 
viruses, the low nanoparticle doses tested here are far above the order of magnitude MOI used for adenovirus 
(1-1,000) and various lentiviruses (1-200) to yield similar levels of expression.50-51 In contrast, naturally 
occurring AAVs are often used at a much higher MOI of up to 100,000 to achieve similarly detectable 
reporter gene based levels of transfection in hard-to-transduce cell lines.52-53 Spark Therapeutics recently 
completed a successful phase III clinical trial using subretinal delivery of AAV for the first FDA approved 





therapy.54 Given the similar level of MOI for BEAQ and AAV and coupled with challenges in scaling 
production of AAV for clinical utilization1-2 and the limitations of AAV cargo capacity, non-viral delivery of 
episomal plasmid DNA with this BEAQ system may be a viable strategy for clinical delivery of DNA to RPE 
cells. 
 Escape from endosomes and avoidance of lysosomal degradation remains a significant hurdle to 
nanomaterials aiming to achieve cytosolic delivery. Estimates of endosomal escape of lipid nanoparticles for 
siRNA has revealed that less than 2% of cargo internalized to endosomes typically reaches the cytosol55-56, 
which has been improved by some recent lipid nanoparticle formulations yielding up to 15% escape in HeLa 
cells.57 Polyplex nanoparticles similarly suffer from low endosomal escape efficacy, with the classic materials 
such as polyethylenimine and polylysine almost exclusively remaining in acidified vesicles and undergoing 
lysosomal degradation despite the ability of the former material in particular to buffer hydrogen ions.41 
Transport to acidic lysosomes occurs rapidly following internalization, with nanoparticles typically reaching a 
lysosomal compartment within one hour following internalization.58 In contrast to these findings for most 
other polymeric materials, we demonstrated that BEAQs largely avoid lysosomal degradation with <20% of 
labeled plasmid DNA being detectable in acidified vesicles at 24 hours post-treatment compared to 40-50% 
DNA delivered with the linear polymer detected in acidified vesicles. These results are promising in that they 
demonstrate that branching may improve the ability of these polymers to achieve endosomal escape, which 
remains a primary hurdle to effective gene delivery. 
Finally, we demonstrated how polymer structure, as a function of hydrophobicity and cationicity, 
related directly to optimal polymer/DNA mass ratio and to transfection efficacy as these variables have been 
shown repeatedly to be crucial to yielding robust transfection in other polymer systems.30 To identify 
structure-function relationships between these polymers and transfection efficacy, we analyzed viability and 
geometric mean expression as a function of individual polymer properties including buffering capacity, 
secondary, tertiary and total amine content per bp plasmid DNA. This is the first reported analysis of this 
type reported to our knowledge and yielded insights into the features of polycations that make them effective 
for transfection. In particular, we demonstrated that the optimal number of tertiary amines per bp plasmid 
DNA was near constant across the entire range of branching, while optimal numbers of secondary amines 
increased with degree of branching. With further knowledge of precise desired polymer structures, solid phase 
synthesis of alternating copolymers is an option which has been utilized in the synthesis of precisely defined 
polymers for gene delivery.59 Degradation rate of polymers could also play a role in the differences in 
transfection, as differences in constituent monomers can affect the specific degradation rate.18 
The total possible solution space for BEAQs that may be highly effective for gene delivery is vast, as 
there are many diacrylate monomers, side-chain amino and end-capping amino monomers available that have 





the guidelines outlined here and in previous publications14 will enable the rapid prototyping of diverse 
polymers that may yield further gains to efficient nucleic acid delivery as well as insights into polymeric 
structure/function relationships. The presented method for generating BEAQs can likewise be easily 
expanded to include utilization of branching monomers with other triacrylate monomer use as well as 
quaternary or greater functionality such as pentaerythritol tetraacrylate or dipentaerythritol penta-/hexa-
acrylate to further increase structural diversity. 
 
5. Conclusions 
Branched poly(ester amine) quadpolymers (BEAQs) were successfully synthesized and characterized and were 
demonstrated to have multiple enhancements over leading non-viral gene delivery materials including 
optimized linear PBAEs, BPEI, JetPRIME, and Lipofectamine 2000. BEAQs with a moderate degree of 
branching were shown to more tightly bind plasmid DNA, maintain DNA binding following dilution in 
neutral, isotonic buffer, and possess higher solubility in aqueous media compared to linear analogs. Branched 
polymers formed from diacrylate (B7) and triacrylate (B8) monomers were highly effective for plasmid DNA 
delivery, and moderately branched BEAQs best maintained efficacy at physiologically relevant high serum 
concentrations. Analysis of chemical structure highlighted the importance of the ability to buffer pH at 
approximately 20 nmol H+/ µg DNA as well as the key parameter of tertiary amine content at approximately 
40 tertiary amines per base pair of DNA. Through differential control of polymer branching, BEAQs were 
found to be efficient for non-viral gene delivery to difficult-to-transfect human cells. BEAQs are promising as 
therapeutic gene delivery vehicles and these findings have implications for the design, identification, and 
optimization of next-generation polymeric materials for nucleic acid delivery.  
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Figure 7-S1. BGDA polymer series chemical properties A) BGDA series of acrylate terminated BEAQ 
polymers 1H NMR (500 MHz, CDCl3-d1, 0.05% v/v TMS) spectra. Note that some peaks are from residual 
solvent for diethyl ether (3.48, 1.2 ppm). Relevant peaks for determination of triacrylate mole fraction are as 
follows. BGDA phenyl (4H each) 6.81 and 7.11 ppm in green; TMPTA methyl (3H) 0.83 ppm in red; S4 










Figure 7-S2. BGDA polymer series aqueous properties.  A) Marvin predicted logD values assessing polymer 
hydrophobicity at different pH values. Computed for 140 mM Cl-, Na/K+ conditions with GPC value MN 
matched polymer structures. B) Calculation of normalized buffering capacity was calculated from titration 
data as Δ(-OH)/Δ(pH) at each titration point (between pH 4.5-8). C) Individual polymer titrations enabled 
effective pKa value of each polymer to be determined, defined as pH point of the maximum normalized 
buffering capacity. D) Absorbance spectra of polymer BGDA-20 dissolved into 150 mM PBS, pH 7 at 10 
mg/mL to determine 600 nm wavelength to approximate solubility measurements. Absorbance >0.5 at 600 
nm was defined as insoluble. E) Solubility limit both in acidic buffer and in PBS increased as predicted with 
branching due to the increase in the number of hydrophilic endcap moieties. F) Absorbance measurements of 
BGDA polymers in 25 mM NaAc, pH 5 and G) 150 mM PBS, pH 7.4 to determine solubility. (For error 
bars, n = 3 wells, mean ± SEM) 


























































































150 mM PBS, pH 7.4
















































































































































































































































































Figure 7-S3. DNA binding properties of BGDA polymers. For both buffer conditions the plots show 
fluorescence quenching as a function of polymer concentration, quenching normalized to number of 
secondary amines, normalized to number of tertiary amines and normalized to the total number of amines. A) 
Under acidic conditions at pH 5.0 and low salt, degree of DNA binding is best proportional to the number of 
tertiary amines per base pair (bp) of DNA. B) In contrast, under neutral, isotonic conditions at pH 7.4, the 
degree of DNA binding is best proportional to the number of secondary amines per bp DNA. C) The 









































































































































































































































25 mM NaAc, pH 5









150 mM PBS, pH 7.4









25 mM NaAc, pH 5











(40% triacrylate) and highly branched polymer (90% triacrylate) were compared. (For error bars, n = 3 wells, 
mean ± SEM) 
 
 
Figure 7-S4. BEAQ nanoparticle properties. A) Z-average hydrodynamic diameter measurements of 40 w/w 
ratio nanoparticles in 25 mM NaAc buffer, pH 5.0 and after dilution into 150 mM PBS B) Zeta potential 
measurements assessed in 150 mM PBS, pH 7.4. C) TEM of dried particles. Scale bar 100 nm for all images. 
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Figure 7-S5. BEAQ nanoparticle uptake. Branching did not strongly improve nanoparticle uptake compared 
to the linear BGDA polymer nanoparticles at the same w/w ratios. A) HEK293T low dose nanoparticle 
uptake (300 ng dose, 20% labeled Cy5-DNA) as percent uptake and B) geometric mean. C) ARPE-19 low 
dose nanoparticle uptake (300 ng, 20% labeled Cy5-DNA) percent uptake and D) geometric mean. (Error 
bars show n = 4 wells, mean ± SEM) 
 
















































































































Figure 7-S6. ARPE-19 transfection with control nanoparticle materials. To fairly identify optimal conditions 
for in vitro transfection, both a (A) 600 ng dose of DNA with two-hour incubation and a (B) 100 ng dose with 
24-hour incubation were tested for control reagents. PBAE 557 was shown previously to be generally 
effective for transfection of ARPE-19 cells [1], which we reproduced, showing at most ~40% transfection. 
JetPRIME likewise enabled transfection of up to ~40% of cells, while Lipofectamine-2000 gave a transfection 
efficacy of only 20%. Both JetPRIME and Lipofectamine 2000 were limited due to cytotoxicity. The top 
transfection condition for each reagent with >70% relative viability was included on Figure 4. (Error bars 
show n = 4 wells, mean ± SEM). 






















































































































































Figure 7-S7. Polyethylenimine variants transfections. Linear and branched PEI of various molecular weights 
were tested for optimal w/w ratio in (A-B) HEK293T and (C-D) ARPE-19 cells. Geometric mean expression 
is shown normalized to untreated control cells (value of 1). Normalized viability is shown as a percentage of 
untreated control wells. (Error bars show n = 4 wells, mean ± SEM) 
 
 












































































































Figure 7-S8. BGDA series polymer transfection under high serum (50%) conditions. HEK293T cells A) 
transfection efficacy up to 97% and B) geometric mean expression normalized to untreated cells. ARPE-19 
C) transfection efficacy up to 67% and D) geometric mean expression normalized to untreated cells. 
Moderately branched BEAQs outperformed the linear BGDA polymer when level of expression (geometric 
mean) was taken into account at all w/w ratios. Moderately branched BEAQs were particularly more effective 
at low w/w ratios. (Error bars show n = 4 wells, mean ± SEM) 
 




































































































































Figure 7-S9. Top BGDA series polymers tested under matched conditions in 10% and 50% serum 
conditions transfected effectively the same percentages of cells (A,C) in both HEK293T and ARPE-19 cells. 
B) For level of expression, however, the linear polymer (BGDA-0) suffered a 75% reduction of polymer 
matched max geometric mean expression with increase in serum content, whereas the 60% triacrylate mole 
fraction polymer only suffered a 21% reduction in geometric mean expression in HEK293T cells. D) 
Similarly, in ARPE-19 cells, the linear polymer suffered a 68% reduction in geometric mean expression, 
whereas the 20% triacrylate mole fraction branched polymer geometric mean expression was only reduced by 
30%. (Error bars show n = 4 wells, mean ± SEM) 
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Dunnett's multiple comparisons test Summary Adjusted P Value
0 vs. 10 ns 0.1546
0 vs. 20 ns 0.0765
0 vs. 40 * 0.0161
0 vs. 50 ** 0.0070
0 vs. 60 * 0.0119
0 vs. 80 ns 0.0594

























Figure 7-S10. Low dose BGDA nanoparticle transfection in HEK-293T cells. A) Extremely low volume 
distribution of nanoparticles achieved via Echo 550 acoustic liquid handling with nanoparticle dose titration. 
B) Transfection efficacy and C) cell counts normalized to untreated for varied w/w ratio and overall 
nanoparticle dose (as function of total DNA per well). Branched BGDA polymers with 40-60% triacrylate 
mole-fraction were statistically more effective than the linear BGDA polymer BGDA-0 tested for low dose 
nanoparticle transfection. No nanoparticle formulations showed high cytotoxicity (>30% reduction in 
normalized cell count). Values show mean ± SEM of three wells for each condition. Differences in 
transfection efficacy between polymers were assessed over all tested conditions by One-way ANOVA with 
multiple comparisons to BGDA-0 using matched values for w/w ratio and DNA dose. One-way ANOVA 
was performed with Geisser-Greenhouse corrections for sphericity and Dunnet corrections for multiple 






























































Dunnett's multiple comparisons test Summary Adjusted P Value
0 vs. 10 ns 0.9422
0 vs. 20 ns 0.5227
0 vs. 40 * 0.0276
0 vs. 50 ** 0.0021
0 vs. 60 ns 0.4108
0 vs. 80 ns 0.9996






Figure 7-S11. Low dose BEAQ nanoparticle transfection in ARPE-19 cells. A) Extremely low volume 
distribution of nanoparticles achieved via Echo 550 acoustic liquid handling with nanoparticle dose titration. 
B) Transfection efficacy and C) cell counts normalized to untreated for varied w/w ratio and overall 
nanoparticle dose (as function of total DNA per well). Branched BGDA polymers with 40-50% triacrylate 
mole-fraction were statistically more effective than the linear BGDA polymer BGDA-0 tested for low dose 
nanoparticle transfection. No nanoparticle formulations showed high cytotoxicity (>30% reduction in 
normalized cell count). Values show mean ± SEM of three wells for each condition. Differences in 
transfection efficacy between polymers were assessed over all tested conditions by One-way ANOVA with 
multiple comparisons to BGDA-0 using matched values for w/w ratio and DNA dose. One-way ANOVA 
was performed with Geisser-Greenhouse corrections for sphericity and Dunnet corrections for multiple 












Figure 7-S12. Polyethlyenimine variants transfection correlation. Linear PEI 4 kDa and branched PEI 25 
kDa transfections with varied w/w ratio were assessed for correlation trends between amine content and 
geometric mean transfection in HEK293T and ARPE-19 cells. 
 



















































































































BPEI 25 kDa HEK293T
LPEI 4 kDa HEK293T
BPEI 25 kDa ARPE-19







Figure 7-S13. Flow cytometry gating analysis. FlowJo 10 was used for gating cells analyzed using an Accuri 
C6 flow cytometer. Singlet cell populations were identified and 2D gated for GFP expression or uptake of 








Table 7-S1. Monomer mole ratios for synthesis of BEAQ series  
Theoretical Triacrylate 
Mole Fraction (%) Diacrylate Ratio Triacrylate Ratio Amine Ratio 
0 1.1 0.00 1 
10 0.99 0.07 1 
20 0.88 0.15 1 
40 0.66 0.29 1 
50 0.55 0.37 1 
60 0.44 0.44 1 
80 0.22 0.59 1 





Table 7-S2. 1H NMR integrations for all polymers normalized to acrylate peaks (3H) 
Theoretical BGDA Phenyl B8 methyl S4 
Triacrylate 7.11 & 6.8 ppm 0.83 ppm 2.38 ppm 
Mole Fraction (%) (4H each) (3H) (2H) 
0 9.42 0 4.62 
10 7.16 .91 5.05 
20 6.41 1.25 4.62 
40 6.27 1.87 3.70 
50 4.08 2.58 4.63 
60 2.19 2.02 3.40 
80 .951 3.10 3.19 











Table 7-S3. Number average GPC calculated mass fraction contributions of monomers 
Theoretic Triacrylate 
Mole Fraction (%) BGDA TMPTA S4 E6 
0 0.815 0.000 0.128 0.057 
10 0.686 0.090 0.133 0.091 
20 0.619 0.135 0.132 0.115 
40 0.516 0.204 0.130 0.150 
50 0.418 0.275 0.136 0.171 
60 0.320 0.334 0.127 0.220 
80 0.127 0.468 0.131 0.275 




Table 7-S4. Backbone polymer amine density calculations. The molecular weight for polymer repeat units 
consisting of monomers BGDA+S4, TMPTA+2*S4 and ethylenimine were calculated. Amine density was 
then determined as the number of amines per polymer backbone molecular weight in Da. The branching 
monomer TMPTA gives rise to polymers with the highest tertiary amine density while BGDA monomers 
give rise to polymers with a lower tertiary amine density. 
 
Repeat Unit Molecular Weight Amine density 
 (Da) (Amines/Da) 
BGDA + S4 573 0.00175 
TMPTA + 2*S4 474 0.00422 









Table 7-S5. Yo-Pro-1 iodide competition binding assay. RM one-way ANOVA was performed with Geisser-
Greenhouse corrections and Dunnett test corrected multiple comparisons to the linear, 0 triacrylate mole 
fraction polymer. Results are shown for multiple comparisons assessment at the concentration of 75 µg/mL 
BEAQ concentration tested with an n=3 well replicates for each polymer. 
Triacrylate mole fraction BGDA Series 
pH 5.0, 25 mM 
BGDA Series 
pH 7.4, 150 mM 
10 ns ns 
20 ns ** 
40 ns ** 
50 ns * 
60 ns ** 
80 ns *** 
90 ns * 
 
 
Calculation 7-S1. Plasmids per cell. In 384 well transfection experiments at low nanoparticle doses, 
moderately branched BEAQs yielded 82% transfection efficacy in HEK293T cells at a dose of 5 ng/well and 
42% transfection efficacy in ARPE-19 cells at a dose of 10 ng/well. Cells were seeded at a density of 2500 
cells per well and assumed to divide once to yield 5000 cells per well on the day of transfection. The eGFP-
N1 plasmid has a size of 4733 bp and molecular weight of approximately 3124 kDa, meaning there were 
9.64x108 plasmids/well and 192,800 plasmids per cell available at a 5 ng dose. 
 
 
Calculation 7-S2. BPEI buffering capacity. We have demonstrated previously that 25 kDa branched 
polyethylenimine possesses a buffering capacity of 6.2 mmol H+/g of polymer in the pH range of 7.4 to 5 
[2]. This is the equivalent of 6.2 nmol H+ per mg of polyethylenimine, meaning that polyethylenmine would 
have 6.2 nmol H+ buffering capacity per µg of DNA at a 1 w/w ratio. At the higher than usual optimal w/w 
ratios of 3 and 4 w/w for HEK293T and ARPE-19 (Figure S6), PEI would have an optimal buffering 
capacity of either 24.8 or 37.2 nmol H+/µg DNA depending on cell type. 
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resulting article was selected by editors at NanoMedicine: NBM as the featured cover article and very well 
received by the field, accumulating 50 citations in the first two years since publication. The application of 
endosomal disruptive nanoparticles to facilitate cytosolic delivery of adjuvants for cancer (and other disease) 
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Abstract: Therapeutic cancer vaccines require adjuvants leading to robust type I interferon and 
proinflammatory cytokine responses in the tumor microenvironment to induce an anti-tumor response. 
Cyclic dinucleotides (CDNs), a potent Stimulator of Interferon Receptor (STING)  agonist, are currently in 
phase I trials. However, their efficacy may be limited to micromolar concentrations due to the cytosolic 
residence of STING in the ER membrane. Here we utilized biodegradable, poly(beta-amino ester) (PBAE) 
nanoparticles to deliver CDNs to the cytosol leading to robust immune response at > 100-fold lower 
extracellular CDN concentrations in vitro. The leading CDN PBAE nanoparticle formulation induced a log-





blocking antibody in comparison to free CDN without nanoparticles. This nanoparticle-mediated cytosolic 
delivery method for STING agonists synergizes with checkpoint inhibitors and has strong potential for 
enhanced cancer immunotherapy. 
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The innate arm of the immune system recognizes pathogen-associated molecular patterns (PAMPs) 
through pattern recognition receptors (PRRs) to initiate effective immunological responses, and activation of 
the innate arm of the immune system can be critically important in priming an effective adaptive response. 
Cyclic dinucleotides (CDNs) have been demonstrated to be highly effective PAMP molecules capable of 
robust activation of interferon regulatory factor 3 (IRF3).1 Recently much attention has been focused on 
STING which localizes to the endoplasmic reticulum, a potent inducer of type I IFNs in response to their 
binding of CDNs.2 CDNs are small molecule secondary messengers used by bacteria and produced as 
endogenous products of cytosolic DNA sensing cyclic GMP-AMP synthase (cGAS) that are recognized by 
STING. Both the canonical 2,3 linked bacterial cyclic di-GMP and cyclic di-AMP, as well as the non-
canonical eukaryotic 2,5 linked cGAMP have been shown to directly bind STING and subsequently initiate 
TBK1-IRF3 and NFkB dependent type I IFN proinflammatory immune responses.3 With the recent clinical 
success of immune checkpoint inhibitors4-6 in multiple cancer patients and the overall positive correlations 
between proinflammatory tumor microenvironment and clinical responses to PD-1 blocking antibodies7-10, 
intratumoral stimulation of STING may potentially synergize with immune checkpoint inhibitors. While 
CDNs are currently undergoing clinical trials for safety, there are concerns that simple intratumoral CDN 
injection is a suboptimal means to stimulate the cytosolic STING signaling pathway.  
Since CDN molecules are anionic, we investigated whether cationic polymers that have traditionally 
been used to deliver DNA and siRNA may enable improved cytosolic delivery of CDNs as well. 
Nanoparticles have been engineered for the intracellular delivery of DNA particles to facilitate efficient 
transfection in relevant cells while minimizing toxicity. Poly (beta-amino esters) (PBAEs), a class of synthetic, 
cationic polymers, have been found to be effective as non-viral gene delivery agents for a wide variety of cell 
types both in vitro and in vivo.11-14 Importantly, PBAEs are relatively easy to synthesize with structural 
diversity,15 are effective at binding nucleic acids,16 and hydrolytically degradable under physiological 
conditions, which greatly reduces their cytotoxicity despite being cationic in nature.12,13,17-19 Moreover, they 
can have specific cellular uptake to target cell types20-22 and can also enable effective endosomal escape to the 
cytoplasm, likely due to their buffering capacity.19 With these properties we hypothesized that PBAE 
nanoparticles would improve the cytosolic delivery of anionic CDN molecules, enabling anti-tumor responses 
at lower CDN doses.  We investigated whether PBAEs could enhance CDN delivery to immune cells in vitro, 









All chemicals were of analytical grade and obtained from Sigma Aldrich Chemicals (St Louis, MO, USA). 
RPMI 1640 medium (Gibco BRL, Grand Island, NY, USA), fluorochrome conjugated antibodies (BD 
Biosciences, San Jose, CA, USA), MTT Aqueous One cell viability kit (Promega, Madison, WI, USA). Cyclic 
dinucleotides were provided by Aduro Biotech (Berkeley, CA, USA). QUANTI-blue and THP1-ISG cells 
were purchased from Invivogen (San Diego, CA, USA). Monocyte isolation kit (Miltenyi Biotec, Auburn, CA, 
USA) was used to isolate monocytes from peripheral blood mononuclear cells (PBMC)s and Mouse anti-PD-
1 antibody (clone G4) was generated in-house using mouse hybridoma cells. Monomers for PBAE synthesis 
were purchased as specified in the Supplementary Information Table 1.  
 
Polymer Synthesis 
Poly(beta-amino ester)s (PBAEs) were synthesized in a two-step Michael addition reaction following 
protocols previously published.18 The naming scheme for PBAEs used follows that established by Tzeng et 
al.23 with the first digit denoted by base monomer carbon number, the second digit denoted by sidechain 
monomer carbon number, and the third digit to describe the polymer’s endcapping group. The PBAE chosen 
for CDN delivery was synthesized at a molar ratio of 1.1:1 from monomers 1,4-butanediol diacrylate (B4) and 
4-amino-1-butanol (S4) and then endcapped with a 0.2 M solution of 1-(3-aminopropyl)-4-methylpiperazine 
(E7) in anhydrous tetrahydrofuran. PBAEs were then precipitated twice in a 10x volume of anhydrous diethyl 
ether, isolated via centrifugation at 3,000 rcf and stored under vacuum for two days to remove excess diethyl 
ether. PBAEs were dissolved in anhydrous DMSO at a concentration of 100 µg/µL and stored at -20°C in 
individual use aliquots. PBAE molecular weight was determined via gel permeation chromatography (GPC; 
Waters, Milford, MA) using methods previous published.15,24,25  For 1H NMR, approximately 5 mg of diethyl 




CDNs and polymer were diluted in sodium acetate buffer (25 mM, pH 5.0) to the same concentrations as 
used for the in vitro immunostimulatory treatment. Diluted solutions of CDN and polymer were then mixed 
in a 1:1 volume ratio and allowed to incubate for 10 minutes to formulate nanoparticles. A Nanosight NS500 
(Malvern Instruments, UK) was used to determine number-averaged nanoparticle hydrodynamic diameter. A 
Zetasizer Nano ZS (Malvern Instruments, UK) was used to determine intensity Z-average hydrodynamic 
diameter and zeta potential of particles diluted six-fold in 150 mM PBS (pH 7.4). For nanoparticle tracking 





Camera and analysis settings were maintained for all comparisons between individually prepared samples. All 
data points presented are for mean ± standard error of the mean of value of individually prepared samples 
assessed in triplicate. For transmission electron microscopy (TEM), nanoparticles were formed at a 500 w/w 
ratio between RR-CDG and PBAE 447 at the same concentration as for in vitro immuno-stimulatory 
treatments. Ten microliters were then added to a corona plasma treated carbon film 400 square mesh TEM 
grid and allowed to dry for one hour. TEM images were then acquired using a Philips CM120. Nanoparticles 
without CDN were prepared in an identical manner, constituting polymer only. 
 
Mice and Cell Culture 
Female 6-8 weeks old C57BL/6 mice were obtained from The Jackson Laboratory and maintained according 
to animal care facilities of Johns Hopkins University. THP1-Blue™ ISG (interferon-stimulated genes, 
Invivogen), THP1 human monocytes were grown at concentrations between 0.2-1.0*106 cells/mL in 
suspension in vertical T25/75 flasks.  THP1cells, B16-F1 melanoma cells, and human monocytes were all 
cultured in RPM-1640 medium supplemented with 10% FBS and penicillin (100 U/ mL) and streptomycin 
(100 mg/mL) and maintained in a humidified incubator at 37°C in a 5% CO2 atmosphere. RAW 264.7 
murine macrophages were likewise cultured in DMEM medium supplemented with 10% FBS, penicillin (100 
U/ mL) and streptomycin (100 mg/mL). 
 
Immunostimulatory treatment 
Lipopolysaccharide (LPS) was diluted in fresh media from frozen aliquots of 0.1 μg/μL to the concentration 
required for the specified well dose. CDNs were stored at -20°C in aliquots at 10 µg/µL and were diluted in 
25 mM NaAc, pH 5.0, to the required concentration for the specific well dose to be delivered in 20 μL for all 
treatments. PBAEs were stored at 100 μg/μL in DMSO at -20°C until used.  Nanoparticles were formed by 
diluting PBAEs in 25 mM NaAc buffer, pH 5.0, which was then mixed in a 1:1 v/v ratio with 25 mM NaAc 
buffer containing CDNs at the concentration required for the doses specified. The nanoparticle solution was 
incubated for 10 minutes to allow for particle formation after which for freshly prepared particles, 20 μL were 
added to each well. For lyophilized particles, after particle formation endotoxin free sucrose from a stock of 
600 µg/µL was added to each sample to a concentration of 30 µg/µL. Samples were then frozen at -80°C and 
lyophilized. Lyophilized samples were stored at -20°C with desiccant and resuspended in ultrapure water 
before being added to wells for treatment. After 3-5 hours of incubation, treatment media was removed from 
all wells, cells were washed twice and resuspended in 200 µL fresh media. 
 





THP1-Blue™ ISG cells were specifically designed to monitor the interferon (IFN) signaling pathway in a 
physiologically relevant cell line. They derive from the human THP-1 monocyte cell line by stable integration 
of an IFN regulatory factor (IRF)- inducible SEAP reporter construct. THP1-Blue™ ISG cells express a 
secreted embryonic alkaline phosphatase (SEAP) reporter gene under the control of an ISG54 minimal 
promoter in conjunction with five IFN stimulated response elements. As a result, THP1-Blue™ ISG cells 
allow the monitoring of IRF activation by determining the activity of SEAP. The levels of IRF-induced SEAP 
in the cell culture supernatant are readily assessed with QUANTI-Blue™, a SEAP detection reagent 
(Invivogen). The Quanti-Blue assay was used to measure THP1-Blue cell SEAP activity as a means of 
assessing IRF3 activation. For the assay, Quanti-Blue detection medium was prepared according to 
manufacturer’s instruction. Following 18h treatment, 20 µL of supernatants were added to 180 µL of Quanti-
Blue detection medium in a new 96 well round bottom plate. The Quanti-Blue assay plate was incubated at 
37°C for 1-4h and then the absorbance was read at 630 nm. Mean absorbance of a blank well of Quanti-Blue 
detection media with fresh RPMI media was subtracted to determine raw Quanti-Blue assay values.  
 
Cell viability assay 
Cell viability was assessed using an MTT assay one day following treatment. For the assay, MTT 
reagent was diluted 10-fold into complete medium and incubated with cells in 96 well plates for 2 h. 
Absorbance was then analyzed at 490 nm using a multi-plate reader (Synergy 2, Biotek), blank-subtracted and 
normalized to the untreated cell values to give relative cell viability. 
 
Cellular uptake experiments 
Cells were plated at a density of 150,000 cells/mL in complete medium with 100 µL of media per 
well in 96 well plates. PBAE particles labeled with Cy5 were formed with RR-CDG at a 500 w/w ratio, then 
were added to cells at a dose of 20 µg polymer/well and incubated for 1h at 37°C after which cells were 
washed with PBS twice and analyzed via flow cytometry. A BD Accuri C6 (BD Biosciences) flow cytometer 
with two lasers (488 and 633 nm) with four channels corresponding to green, yellow, red, and far-red 
fluorescence (FL1 at 530 ± 15 nm, FL2 at 565 ± 10nm, FL3 a t610 ± 10 nm and FL4 at 675 ± 12.5 nm, 
respectively) was used for all flow cytometry experiments in combination with a HyperCyt autosampler 
(IntelliCyt). Cell counts per well and nanoparticle concentrations in media were equal between cell types. 
Statistical significance was assessed between the uptake levels of the treated cells by one-way ANOVA with 
multiple comparisons corrected for by Tukey’s method. 
 For confocal microscopy experiments, PBMCs transfected in suspension in 96 well round bottom 
plates as described above were stained with Hoechst 33342 (H3570; Thermo Fisher) to label nuclei. Cells 





borosilicate coverglass well plates (155411; Thermo Fisher) at 37,500 cells/well for imaging. Images were 
acquired using a Zeiss LSM 780 microscope with Zen software and 63 oil immersion lens. Specific laser 
channels used were 405 nm diode, 488 nm argon, 561 nm solid-state, and 639 nm diode lasers.  
 
Tumor growth and Measurement 
For in vivo therapeutic experiments, C57BL/6 mice were injected with B16-F1 melanoma cells at a 
concentration of 2*105 cells/100 µL in the flank. The mice were grouped (n=7) according to the experimental 
plan. Post days 3, 6, 9 and 12 post-tumor inoculation, mice were treated intratumorally with HBSS, CDN in 
HBSS, resuspended empty PBAE nanoparticles or resuspended PBAE + CDN nanoparticles via 50 µL 
intratumoral injection. For anti-PD-1 groups, 100 µg was injected twice weekly on days 3, 7, 10, 14 and 17 
after mice were inoculated with tumors. 
 
Statistical analysis 
Figures present mean ± standard error of the mean calculated from three replicates unless otherwise noted. 
All the above experiments were repeated at least twice whereas for experiments with 96 well plates used either 
three or four well replicates. Statistical significance was designated as follows: ****p<.0001; ***p<.001; 
**p<.01; *p<.05. Statistical analysis was assessed using Graphpad Prism software (La Jolla, CA) at a global 
alpha value of 0.05. 
 
Results 
CDNs are potent activators of IRF3 at micromolar doses 
 Recent publications have shown CDNs to be potent activators of the adaptive immune system via 
activation of type I IFN and proinflammatory cytokine response leading to potent efficacy in multiple models 
of established cancer.1 As a result, we selected the CDNs shown in Figure 8-1A to act as adjuvant molecules 
for studies in vitro. ML-RR-CDA is a modified version of cyclic-di-AMP formulated for increased in vivo 
stability and human STING activation, while RR-CDG was a phosphodiesterase resistant version of cyclic-di-
GMP (Figure 8-1A).1 Since the anti-tumor efficacy of CDN is partly mediated through activity in antigen-
presenting cells (APCs),26 we optimized PBAE formulated CDN nanoparticles in the human monocyte cell 
line, THP1-Blue. The THP1-Blue human monocyte cell line used for in vitro screening expresses the reporter 
gene secreted embryonic alkaline phosphatase (SEAP) driven by the IRF3 promoter activation that is 
activated by ligand binding to the cytosolic protein Stimulator of interferon gene (STING). THP1-Blue cells 
were shown to respond strongly to extracellular concentrations of 10 µM CDN following a four hour 







Figure 8-1. CDNs are potent immune activators at µM concentrations. (A) STING activating CDNs 
ML-RR-CDA and RR-CDG modified for increased stability were used in all studies. (B) ML-RR-CDA was a 
potent activator of immune response down to 10 µM extracellular concentrations, while (C) RR-CDG was 
effective down to 10 µM concentrations when assessed using the THP1-Blue cell line with Quanti-Blue assay 
to detect IRF3 promoter activity. 
 
PBAE nanoparticles improve the efficiency of CDN delivery to human monocytes in vitro 
 An initial array of biodegradable PBAE structures were assessed for their ability to increase STING 
activation in the human monocyte cell line (THP1-Blue) at low extracellular doses of CDN (Supplementary 
Figure 8-1). These structures were selected for having previously been shown to be effective for delivery of 
plasmid DNA or RNA molecules, which are notably larger and more electronegative molecules than 





capable of improving the efficiency of CDN delivery to human monocytes and STING activation at low 
overall CDN doses, they had differential activity. For example, polymers PBAE 446 and PBAE R647 
generally had less than half the activity of the lead polymer PBAE 447. On the other hand, polymer 537 
demonstrated significant cytotoxicity, even at a relatively low dose of 31.25 nM, whereas the other PBAEs 
evaluated did not. Overall, PBAE 447 (Figure 8-2A), a structure containing 4 carbons between acrylate 
groups and 4 carbons between its amine group and its hydroxyl group, was selected for its balance of being 
most effective at IRF3 activation while maintaining high cell viability among the structures evaluated. 
 
Figure 8-2. PBAE 447 synthesis and 
characterization. (A) PBAEs were 
synthesized from small molecule 
monomers B4 and S4 in a Michael 
addition reaction to yield the base 
polymer B4S4. The acrylate terminated 
polymer was then end-capped with small 
molecule E7 to yield PBAE 447.  (B) 
PBAE nanoparticles assessed using NTA 
had a hydrodynamic diameter distribution 
with a mean and SEM of 110 ± 41 nm. 
(C) TEM of PBAE+CDN nanoparticles 
at a w/w ratio of 500 showed dried 
diameters mean and SEM of 77 ± 5 nm . 
Scale bar 100 nm. (D) Nanoparticle 
diameter assessed by dynamic light 
scattering (DLS) Z-average diameter, 
nanoparticle tracking analysis (NTA) and 
transmission electron microscopy (TEM) 
showed varying nanoparticle diameters. 
Error bars show mean + SEM of three 
independently prepared samples (DLS 
and NTA) or 20 nanoparticles (TEM). (E) Zeta potential mean and SEM of 9.1 ± 1.3 mV for nanoparticles 
formed at a 500 w/w ratio with CDN in 150 mM PBS. PBAE nanoparticles with CDN had a statistically 






PBAE 447 polymer and PBAE 447/CDN nanoparticle physical characterization 
 PBAEs were synthesized via Michael addition reaction as our lab has described15 and the synthesis 
scheme is shown in Figure 2A. PBAE 447, selected as optimal for CDN delivery, was measured to have MN 
10,700 g/mol, MW 38,200 g/mol and a polydispersity of 3.58 via gel permeation chromatography against 
polystyrene standards. Analysis via 1H NMR of the synthesized acrylate and endcapped polymers showed that 
endcapping was effective (as demonstrated by the disappearance of the acrylate peaks); the resulting 
endcapped polymers had an MN of 7 kDa (Supplementary Figure 2). Nanoparticles formed from PBAE 447 
fabricated at a w/w ratio of 500:1 with CDN were characterized using Dynamic Light Scattering (DLS), 
Nanoparticle Tracking Analysis (NTA), and transmission electron microscopy (TEM) (Figure 8-2), 
demonstrating that they had a diameter of approximately 100 nm and slightly positive zeta-potential of 
approximately +10 mV. The discrepancy between hydrodynamic diameter reported by DLS and NTA has 
been noted previously for polyplex nanoparticles25 where larger polyplex nanoparticles are over-represented 
in hydrodynamic measurements calculated by an intensity-averaged measurement (DLS) compared to a 
number-averaged measurement (NTA). In addition, the nanoparticles were observed to have smaller 
diameters in dry conditions (TEM) than in hydrated conditions, when hydrodynamic diameters were 
calculated. Notably, unlike some polyplex nanoparticles such as polyethlyenimine, this particular PBAE 
structure forms nanoparticles via the hydrophobic effect even in the absence of any anionic species for 
complexation. Although the observed means appeared slightly higher between the diameters of PBAE 
nanoparticles with the small CDNs compared to those without CDNs as assessed by DLS, NTA, and TEM, 
no statistically significant differences were found between these measurements.  The zeta potential of PBAE 
nanoparticles with the small CDNs was found to be slightly statistically significantly higher than those 
without them, presumably because the CDNs would electrostatically attract additional cationic PBAE 
polymer, which could coat the CDNs and increase cationic surface charge. 
 
PBAE 447/CDN nanoparticle biological optimization 
Following selection of PBAE 447 as the lead structure, we optimized the dose of PBAE added per 
well (Figure 8-3A and 8-3B), resulting in a optimized does of 20 µg for PBAE 447. PBAE 447 was highly 
effective for delivery of ML-RR-CDA, giving equivalent IRF3 activation to free CDN at a 100-fold lower 
dose of dinucleotide (Figure 3C and 3D). ML-RR-CDA was also shown to be a significantly more potent 







Figure 8-3. Optimization of PBAE 447 delivery of CDN in vitro. The dose per well of PBAE polymer 
447 doses was screened for (A) efficacy of CDN delivery and (B) cell viability. A dose of 20 µg/well was 
selected for future in vitro experiments to balance efficacy and cytotoxicity. (C) PBAE 447 was able to 
improve IRF-3 activation at over 100-fold lower extracellular doses compared to free ML-RR-CDA, with 
minimal effect on (D) cell viability. CDN molecules, ML-RR-CDA and RR-CDG were then tested directly 





CDA over RR-CDG in THP1-Blue human monocytes at lower concentrations of CDN when tested with 
Holm-Sidak corrected multiple T-tests between groups. (****P<0.0001, **P<0.01, *P<0.05). Error bars show 
mean +/- SEM of three wells. 
 
PBAE nanoparticles are highly effective for immune cell uptake 
Currently, ML-RR-CDA are being developed for clinical purposes as an intratumoral injectable 
adjuvant. We hypothesized that PBAE-CDN nanoparticles would enhance the potency of CDNs by selective, 
efficient cellular uptake into immune cells in the tumor microenvironment. As a result we first examined the 
efficiency of nanoparticle uptake into monocytes and macrophages as compared to tumor cells in vitro. PBAE 
447/CDN nanoparticles fluorescently labeled with Cy5 were shown to be taken up very effectively by THP1 
human monocytes and RAW 264.7 murine macrophages, showing highly significant uptake over B16-F1 
tumor cells cultured and treated under the same conditions (Figure 8-4A). Nanoparticle uptake into primary 
human myeloid cells was also noted, with over 90% of human donor monocytes showing nanoparticle uptake 
with no significant differences between the degree of uptake between separate donor samples (Figure 8-4B). 
Additionally, fluorescently labeled 447/CDN nanoparticles were clearly internalized following one hour 
incubation with human donor monocytes as evaluated by confocal microscopy (Figure 8-4C). 
 
Figure 8-4. PBAE/CDN 
nanoparticles show selective and 
effective uptake by monocyte and 
macrophage populations. (A) PBAE 
447+RR-CDG nanoparticles were 
internalized by THP-1 human 
monocytes and RAW 264.7 murine 
macrophages more effectively than B16-
F1 murine melanoma cells. Statistics 
performed as One-way ANOVA with 
Dunnett corrected multiple comparisons 
to B16-F1 uptake (****P<0.0001). (B) 
PBMCs from different donors were 
shown to take up CDN nanoparticles 
effectively, with no significant 
differences between donors. Error bars 





CDG+447-Cy5 labeled nanoparticles (green) effectively internalized by PBMCs. Nuclei stained with Hoechst 
(blue). 
 
PBAE+CDN nanoparticles maintain efficacy post-lyophilization and can be stably stored for at least 9 months 
 To facilitate long-term storage of the hydrolysable nanoparticles, lyophilization studies were 
performed following a protocol that we developed for plasmid DNA nanoparticles28 to determine if similar 
stability could be achieved for CDN nanoparticles PBAE+CDN nanoparticles were mixed with sucrose to 
give a final concentration of 30 mg/mL sucrose, then frozen at -80°C and lyophilized. The particles were 
then rehydrated with water and tested to compare their relative efficacy to fresh nanoparticles. Lyophilized 
and stored nanoparticles that showed no detectable changes in efficacy or cell viability compared to the 
freshly prepared nanoparticles (Figure 8-5A and 8-5B). Impressively, the lyophilized nanoparticles remained 
highly effective for IRF3 activation in THP1-Blue cells following 9 months of storage at -20°C in containers 
with desiccant (Figure 8-5C). 
 
Figure 8-5. PBAE/CDN nanoparticles are stable following lyophilization and storage. Lyophilization 
had no effect on the (A) efficacy or (B) cell viability of PBAE+CDN nanoparticles when pre-mixed with 
sucrose as a cryoprotectant. Results analyzed by Holm-Sidak corrected multiple t-tests. (C) Lyophilized 
PBAE+CDN nanoparticles formulated at a dose of 20 µg polymer and 62.5 nM CDN remained highly 
effective at IRF3 activation for at least 9 months following lyophilization when stored at -20°C. 
 
Intratumoral injections of CDN are highly effective at reducing tumor growth in vivo 
 Checkpoint inhibition with anti-PD-1 antibodies has become the standard of care for many cancers, 
but there remains a need to improve upon checkpoint inhibition alone.29 One attractive approach is 
combination immunotherapy.30 To investigate whether PBAE nanoparticle CDN formulations might offer 
value in the setting of combination immunotherapy, we examined whether co-administration of 
PBAE+CDN nanoparticles with PD-1 antibody would offer a survival benefit vs combination 





tumors were established in C57BL/6 mice with subcutaneous flank injections of 200,000 cells. Starting on 
day three, intratumoral injections were performed every three days following the protocol outlined in Figure 
6A, with the final injections on day 12. Administration of 2 µg PBAE+CDN nanoparticles with anti-PD-1 
antibody resulted in significantly reduced tumor growth compared to combination immunotherapy with 
unencapsulated CDN 2 µg dose or empty nanoparticles (Figure 8-6B, P<0.0001 for the comparison). 
Additionally, when combined with PD-1 blockade, there was no statistically significant difference between 
treatment with 2 µg PBAE+CDN nanoparticles with anti-PD-1 antibody vs CDN 20 µg high dose therapy 
(Figure 8-6B) although the high bolus dose of 20 µg CDN was more apparently effective at completely 
eliminating tumors. 
 
Figure 8-6. PBAE+CDN NP therapy 
reduces tumor growth in vivo in the 
presence of anti-PD-1. (A) Tumor growth 
rate study of B16-F1 melanoma tumors 
injected subcutaneously in C57BL/6 mice. 
Intratumoral injections were started on day 
three when tumors were palpable in all 
animals. (B) Twice weekly intraperitoneal 
administration of anti-PD-1 with the 
nanoparticle formulation treatment (NP + 
CDN 2 µg) resulted in statistically reduced 
tumor growth compared to CDN 2 µg 
without nanoparticles when compared with 
Holm-Sidak corrected multiple t-tests. All 
error bars show mean ± SD of five animals. 
 
Discussion 
CDNs are highly potent adjuvants that can impact clinical cancer immunotherapy, leading to robust 
activation of the IRF3 transcription factor through STING, which is capable of triggering tumor regression 
when activated in the right context.1,26,31 With promising pre-clinical results reported to date, CDNs are 
currently under investigation in the FDA Phase I clinical trials for advanced metastatic solid tumors and 
lymphomas (NCT02675439) by Aduro Biotech working with Novartis to determine the tolerable dosing 
window.31 A clinical trial of intratumoral injected CDN as a combination therapy with anti-PD-1 is likewise 





their narrow therapeutic  window.7,10  This can be partly attributed to poor uptake and intracellular delivery of 
the CDNs into the cytosol of the immune cells in the tumor microenvironment and the need to use high 
doses to achieve efficacy. 
Taking this into consideration, we hypothesized that CDN therapy could be improved at lower 
overall doses using a nanomedicine formulation that was biodegradable, enabled enhanced cytosolic delivery, 
and targeted professional APCs. The ER bound STING receptor in APCs does not have access to exogenous 
CDNs until they either reach the cytosol or are internalized to the endosomal space of activated cells.31,32 
Because CDN molecules are both low molecular weight and water soluble due to their anionic charge, they 
are prone to rapid diffusion from the site of the tumor and lack efficient targeting to antigen presenting cells 
at the tumor site; this could potentially lead to off-target effects, resulting in overstimulation or autoimmunity 
side-effects that have been problematic for some patients in the case of other immunotherapies.33  
Here we showed that delivery of CDNs via nanomedicine formulation with cationic and 
biodegradable PBAEs improves their ability to activate IRF3 in vitro at >100 fold lower extracellular 
concentrations. The polymeric PBAE/CDN nanoparticles were shown to have a slightly positive surface 
charge and a particle diameter of approximately 100 nm. Self-assembled PBAE nanoparticles have previously 
been used for delivery of plasmid DNA, minicircle DNA, and siRNA but have not been previously evaluated 
for delivery of smaller molecules, including cyclic dinucleotides to immune cells in the tumor 
microenvironment.11,14,17,34  
While the small size of CDN molecules impedes the ability to measure their direct cellular uptake as 
they cannot be fluorescently labeled without affecting their chemical properties, their net negative charge (2-) 
should enable cationic PBAEs to effectively encapsulate them. We showed that fluorescently labeled PBAE 
nanoparticles were efficiently internalized to the THP1 human monocyte cell line as well as three human 
donor monocyte samples, with greater uptake than tumor cells under the same conditions. This degree of 
selective uptake may be attributable to the endcap utilized for the polymer tested, which has been shown to 
be able to convey both cell type specificity and endosomal uptake mechanism specificity.18,35,36 
 STINGVAX formulations incorporating CDN previously were shown to greatly reduce tumor 
growth and resulted in complete remission of some tumors for CDN doses of 20 µg, but had limited efficacy 
at lower CDN doses.1 Here we showed that a nanoparticle formulation allows for an order of magnitude 
reduction in the necessary dose to eliminate established poorly immunogenic B16-F1 when administered as a 
combination therapy with the checkpoint inhibitor anti-PD-1 antibody. This strategy may have implications 
for pursuing clinical approval of these drug molecules in the future if identification of effective dosing 
regimens proves to be challenging in current clinical trials. Moving towards this goal, we demonstrated the 
application of lyophilization and long-term storage over 9 months without loss of efficacy for this 





nanoparticle formulation consisted of only two components, unlike some previous STING based therapies 
incorporating CDN, attenuated tumor cells, and cytokines that could face significant manufacturing and 
regulatory hurdles and expense.  The manufacturing of these nanoparticles, via mixing of two charged 
components, is amenable to continuous manufacture by a device like the microfluidic device as we have 
recently described for assembly of PBAE/DNA nanoparticles.28 Thus, biodegradable STING agonist 
nanoparticles composed of PBAE 447/CDN are promising for enhanced cancer immunotherapy. 
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Supplementary Table 8-S1: Monomer sources 





B4 1,4-Butanediol diacrylate 1070-70-8 Alfa Aesar 32780 
198.2
2 
B5 1,5-Pentanediol diacrylate 36840-85-4 
Monomer-
Polymer and 





diacrylate Synthesized according to Kozielski et al.1 
262.3
4 
S3 3-amino-1-propanol 156-87-6 Alfa Aesar B23041 75.11 
S4 4-amino-1-butanol 
13325-10-
05 Alfa Aesar A12680 89.14 















Supplementary Figure 8-S1. (A) Monomers used for PBAE synthesis of structures tested for CDN delivery. 
PBAE structures were screened for their ability to (B) induce IRF3 response in THP1-Blue cells with delivery 
of RR-CDG with (C) minimal toxicity assessed by MTT cell metabolic activity assay. CDN dose was titrated, 
while PBAE dose remained constant between conditions at 15 µg/well. PBAE 447 was selected as most 







Supplementary Figure 8-S2. PBAE polymer 447 and PBAE B4S4-Acrylate 1H NMR in CDCl3 was used to 
verify polymer structure and estimate MN to be 7 kDa. The mean repeat unit (MW = 287.36 g/mol) was 
determined to be 23 using the ratio of area between peaks for the endcap secondary amine hydrogen at 0.81 
ppm and the hydrogens of the α-carbons of the B repeat units at 4.08 ppm. The peak and satellites at 2.60 










Supplementary Figure 8-S3. B16 viability following nanoparticle treatment. The nanoparticle 
formulation of RR-CDG+PBAE 447 at a 500 w/w ratio was shown not to have any effect on B16 cells 
viability at doses almost 2.5x greater than those used with THP1-Blue cells for immunostimulatory studies. 
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Chapter 9: Future perspectives in the field of non-viral gene delivery 
  
Foreword: The following is a brief highlight of the most exciting advances in the field of non-viral gene 
delivery I have seen during my PhD (roughly 2014-2020) and where I believe the field is headed next in a few 
key areas. 
 
9.a: Recent advances in gene delivery 
In the twenty-five years since the publication of polyethylenimine as a delivery vector for plasmid 
DNA in 1995, non-viral gene delivery has in some ways barely moved forward, while in others has moved 
forward tremendously.1 The explosion in number of different polymer and lipid systems for delivery of 
genetic cargoes has been enormous and this is not the place for an entire review article (of which there have 
been far too many published in general). What follows is a brief selection of the recent advances in material 
chemistry, approach or application for non-viral technologies.  
On the side of materials engineering, I have been particularly impressed by the inventions of 
CARTs2, use of poly(glutamic acid) conjugated antibodies for specific cell targeting of nanoparticles3 and  the 
innovation of having lipid molecules function both as a carrier molecule and STING agonist.4 Charge altering 
releasable transporters, or CARTs, from Waymouth lab are a very unique recent advancement in that they 
contain self-immolative polymer chemistry that is cytosolically triggered degradation of the entire polymer 
molecule; this is contrast to most polymers that rely on degradation at each individual bond level and has 
great potential for reducing risks of cytotoxicity for highly cationic polymers.2 The paper from Smith et al. in 
2017 for in situ transfection of T-cells in living animals to induce CAR-T cell transfection with a sleeping 
beauty transposon system using PBAE 447 nanoparticles with surface poly(glutamic-acid)-antibody-Fab 
targeting was quite incredible as well.3 Finally, the recent paper from Dan Anderson’s group where 
heterocyclic lipids were engineered for mRNA delivery that function additionally as STING agonists is 
incredibly impressive; this paper demonstrates the ability of the delivery vector to be an active drug molecule 
in and of itself. 4 I also appreciate the work that went into Dan Siegwart’s labs innovation of adding sulfonate 
moieties to lipidoid materials for improving RNA packing in lipidoid nanoparticle formulations.5 Finally, I 
must mention my wife’s recent paper using carboxylic acid ligands for delivery of proteins and 
ribonucleoprotein complexes for CRISPR/Cas9 editing as what I believe will be a rather transformative 
advance in the field of cytosolic protein delivery.6 
Recent advances in assays for development of non-viral gene delivery vectors are also worth 
mentioning, as these innovations are often as important as new materials themselves in driving the field 
forward. I particularly admire the work of my friend Kameron Kilchrist to develop a genetically encoded 





Galectins are proteins that naturally bind to carbohydrates found on glycosylated proteins that are ordinarily 
only found on the outside surfaces of cellular membranes; when an endosome has a disruption event occur it 
exposes those glycosylated proteins to cytosolically expressed Galectin-8-fluorescent-protein construct 
leading to clustering of the fluorescence into discrete puncta. We are using this assay in Green lab and have 
sent plasmids out to other groups to facilitate the adoption of the assay as well. Also worthwhile to mention 
in assay development has been the work of James Dahlman’s lab in barcoding nanoparticles for high-
throughput in vivo testing of hundreds or thousands of nanoparticle formulations within the same animal.8 
This technology has been paramount in demonstrating that the most efficient particles in vitro are rarely the 
most efficient and effective particles in vivo and may limit the utility of in vitro screening.9 
 
9.b: The future of non-viral gene delivery 
 Non-viral delivery for gene therapy and gene editing looks to have a bright future, but that does not 
mean the path will be easy. Much research is focused on strategies that are inherently near impossible to 
translate to the clinic and an enormous amount of academic research is effectively wasted as labs are 
effectively siloed into their own favorite chemical systems. Still, the vast amount of effort poured into 
developing more efficient delivery vectors will very likely lead to the clinical utilization of some nanoparticle 
formulations within the next decade (or two). The most exciting areas of development I see for non-viral 
delivery applications are as follows. 
 Immuno-oncology is an enormous area of development with huge financial potential due to the large 
patient population and as a result is one of the primary areas where non-viral delivery is first being tested. 
Moderna’s recent work (2019) is proof of this, using lipid nanoparticles to deliver mRNA that codes for 
costimulatory molecules, effectively converting tumor cells to become their own professional antigen 
presenting cells.10 Similarly, many companies are interested in using lipid nanoparticles to code for antibodies 
either at site specific locations or via hepatocyte expression. I expect the first approvals for non-viral delivery 
of mRNA cargos will come in the immuno-oncology field as the regulatory framework around cancer allows 
for more rapid approval. The strategy of delivery antibodies as mRNA molecules likely has the ability to 
usurp much of the profit that pharmaceutical companies have enjoyed that has resulted from development of 
biologic antibody drugs, so it will be very interesting to see how the landscape changes as mRNA based 
protein therapeutics reach the clinic. 
 Similarly, nucleic acids are particularly amenable to developing vaccine formulations. I particularly 
admire the work spearheaded by the vaccine development group at Novartis (now owned by GSK) in 
developing the self-amplifying mRNA platform that allows for rapid generation of new protein antigen 
vaccines, in theory allowing humanity to go from identification of a novel pathogen to creation of a 





delivering self-amplifying mRNA faces many delivery challenges but is immensely promising in the robust 
immune responses these molecules can administer. 
 In development of new chemical carriers for gene delivery applications it is difficult to predict the 
future, but I believe in general that the field of translational nanoparticle development will tend to migrate 
more to developing defined sequence carriers that have fewer problems with assembly and polydispersity 
challenges. Some of the materials I utilized during my PhD had molecular weight polydispersity index at or 
above 3 (MW/MN) which can be fine at a pre-clinical level but is simply not suitable for clinical 
development. Utilization of solid-phase synthesis and alternative synthesis pathways to generate better 
defined molecular constructs are needed for true translational potential of many therapies. I believe there is 
likely to be a trend to more biomimicry in development of non-viral therapeutics as well. I personally feel that 
the utilization of extracellular vesicles (or exosomes), cell membrane coated nanoparticles or other poorly 
defined cell derived materials for direct therapeutic applications has little chance of reaching clinical utility 
despite the large application of effort from the field as whole. Learning what features of extracellular vesicles 
makes them effective for delivery and recapitulating those features in a synthetic fashion has huge potential to 
transform the field and yield safer, more effective delivery vectors. Strategies like that taken by Denis 
Discher’s lab whereby CD47 and a minimal peptide mimicking CD4713 improve circulation time of 
nanoparticles by reconstituting the “don’t-eat-me” signal in a synthetic nanoparticle formulation are the way 
of the future. 
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Transfection of Primary and Post-mitotic Differentiated Cells. ASGCT National conference. Washington, 
D.C. 2017. 
10. Wilson DR, Routkevitch D, Mosenia A, Wahlin KJ, Zack DJ, Quinones-Hinojosa A, Green JJ. Development 
of a pH sensor to probe endosomal buffering of polymeric nanoparticles effective for gene delivery. 
American Society for Gene and Cell Therapy (ASGCT) National Conference. Washington, D.C. 2016. 
*Awarded meritorious abstract travel award. 
 
Posters 
1. Wilson DR, Rui Y, Sudhakar D, Conge M, Tzeng Y, Green JJ. A Genetically Encoded Sensor of Endosomal 
Disruption Demonstrates Efficient Entry to the Cytosol Using Polymeric Nanoparticles for mRNA Delivery. 
15th US-Japan Symposium On Drug Delivery Systems. Hawaii, USA. 2019. 
2. Misha B, Wilson DR, Rui Y, Suprenant MP, Hansen BS, Berlinicke C, Green JJ, Zack DJ. Nanoparticle 
based transfection of hard-to-transfect primary photoreceptor cells. ARVO National Conference. Baltimore, 
MD. 2017. 
3. Wilson DR, Siddiq K, Routkevitch DR, Rui Y, Green JJ. Synthesis and Assessment of Highly Branched 
Poly(beta-amino ester)s for Improved Transfection Efficacy. INBT Symposium. Baltimore, MD. 2017. 
4. Wilson DR, Mosenia A, Suprenant MP, Upadhya R, Routkevitch D, Meyer RA, Green JJ. Microfluidic 
Formation of Self-Assembled Poly(beta-amino ester)/DNA Nanoparticles for Enhanced Transfection 
Efficacy. NanoDDS. Baltimore, MD. 2016. 
5. Routkevitch D, Wilson DR, Mosenia A, Wahlin KJ, Zack DJ, Green JJ. The Role of Endosomal Buffering in 
Poly(Beta-amino ester) Nanoparticle Mediated Transfection. INBT Symposium. Baltimore, MD. 2016. 
6. Wilson DR, Mosenia A, Quinones-Hinojosa A, Green JJ. The Role of Endosomal Buffering in Poly(Beta-
amino ester) Nanoparticle Mediated Transfection. BMES National Conference. Tampa, FL. 2015. 
7. Wilson DR, Mosenia A, Quinones-Hinojosa A, Green JJ. The Effect of Poly(Beta-amino ester) Structure on 
Endosomal Buffering and Escape. MedImmune Science Day. Gaithersburg, MD. 2015. 
8. Garner DL, Wilson DR, Bader RA. Immunomodulation by Pseudomonas aeruginosa Quorum Signaling 





9. Wilson DR, Zhang N, Forstner MB, Gahtan V, Bader RA. Statin Delivery by Targeted, Micellar 
Nanocarriers to Treat Peripheral Artery Disease. SUNY-ESF Biotechnology Symposium. Syracuse, NY. 2013. 
10. Wilson DR, Khachan MM, Bhatia SK, Bader RA. Syracuse University Summer Research Symposium. 
Syracuse, NY. 2012.  
Teaching and Mentoring Experience 
• Graduate Research Mentor. Have directly mentored and published research articles with 
nine undergraduate students in the Green lab. Two have won the JHU PURA award under my 
mentorship. 
2015-Present 
• JHU Intersession Course Instructor: Practical Genome Editing and Gene Therapy. 3-week, 
two credit intersession course taught to 14 undergraduate students. 
2019 
• Head Teaching Assistant for Molecules and Cells: Semester long, three credit undergraduate 
core course (136 students) in biomedical engineering under professor Dr. Eileen Haase 
2018 
• JHU Intersession Course Instructor: Advances in Immunoengineering. 3-week, two credit 
intersession course taught 25 Johns Hopkins University undergraduate students. 
2017 
• Johns Hopkins Preparing Future Faculty Teaching Academy. 3 phase teaching program over 
two years including Teaching Institute 3 day course for doctoral students and postdocs  
2017 
• Design project mentor at St. Timothy’s high school through the Medical & Educational 
Perspectives group 
2015 
• Thread mentor to a student at Dunbar High School 2014 – 2016 
• NSF Research Experience and Mentoring (REM) Program. Research project mentor to an 
underrepresented student 
2013 –2014 
• Tutor for engineering, mathematics and physics courses at the Syracuse University 




Arman Mosenia (2015-2016). B.S. Materials Science and Engineering, Johns Hopkins University, 2016. Co-
author on two papers. Recipient of Provosts Undergraduate Research Award and Materials Science 
and Engineering top design project award. Currently pursuing medical degree at University of San 
Francisco. 
Denis Routkevitch (2015-2019). B.S. Biomedical Engineering, Johns Hopkins University, 2018. Co-author on 
three papers. Recipient of Provosts Undergraduate Research Award. Currently entering Johns 
Hopkins University MD/PhD program. 
Mark Suprenant (2016-2018). Co-author on two papers. B.S. Biomedical Engineering, Johns Hopkins 
University, 2018. Currently pursuing PhD in biomedical engineering at Boston University. 
Rahul Upadhya (2016). Co-author on a paper. B.S. Biomedical Engineering, Rutgers University, 2018. 
Currently pursuing PhD in biomedical engineering at Rutgers University. 
Kamran Siddiq (2016-2019). Co-author on a paper. B.S. Biomedical Engineering, Johns Hopkins University, 





Mahita Varanasi (2017-Present) . Co-author on 2 papers in review and 2 papers in preparation. B.S. 
Biomedical Engineering, Johns Hopkins University, 2020 expected. 
Shanelle Mendes (2017-Present). Co-author on 2 papers in review and 2 papers in preparation. B.S. 
Biomedical Engineering, Johns Hopkins University, 2020 expected. 
Ellen B. Wang (2018-Present). Co-author on a paper and two papers in preparation. B.S. Biomedical 
Engineering, Johns Hopkins University, 2021 expected. 
Marranne Conge (2019-Present). B.A. Biology, Berea College, 2022 expected. 
Deepti Sudhakar (2019-Present). Biomedical Engineering, Johns Hopkins University, 2022 expected. 
Intellectual Property: Patents 
1. Polymeric Nanoparticles for CRISPR/Cas9 delivery. Cynthia Berlinicke, Jordan Green, Bibhudatta 
Mishra, Yuan Rui, Srinivasa Rao Sripathi, David Wilson, Donald Zack. 2018. Invention ID: D15178. 
2. Hyperbranched Polyesters with Amphiphilic and pH Sensitive Properties for Effective Nucleic Acid 
Delivery. Jordan Green, Yuan Rui, David Wilson. Provisional 2018. Invention ID: C15182. 
3. Polymeric vectors for gene delivery to retinal cells. Cynthia Berlinicke, Jordan Green, Bibhudatta 
Mishra, Yuan Rui, Srinivasa Rao Sripathi, David Wilson, Donald Zack. Provisional 2018. Invention 
ID: C15188. 
4. Gene Delivery Particles to Induce Tumor-Derived Antigen Presenting Cells. Jordan Green, Randall 
Meyer, Stephany Tzeng, David Wilson. Provisional 2018. Invention ID: C15520. 
5. Polymeric nanoparticles for intracellular protein delivery. Jordan Green, Yuan Rui, David Wilson. 
Provisional 2019. Invention ID: C15781. 
Material Sharing 
• >25 plasmids produced during PhD and deposited to plasmid sharing repository Addgene 
• 25 requests of Addgene deposited plasmids since 2018 
 
 
 
 
 
 
